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Abstract
The identification of the genes underlying the mechanisms of metastasis is of great 
interest, since metastatic disease is the major cause of death in cancer patients. To 
investigate the possible mechanisms of metastasis, I used an inbred rat sarcoma model 
and analysed four related cell populations with significant differences in their ability to 
shed metastases when subcutaneously injected into inbred rats (P < 0.01). I 
characterised the motility and morphology of the four cell populations and found that 
the metastatic cells had a stronger chemotactic response to PDGF/IGF, migrated faster, 
and had fewer stress fibres, than the non-metastastic cells.
Next I performed microarray analysis to investigate the gene expression differences 
underlying the progression to the metastatic phenotype. I examined gene expression in 
the cultured cells, and in the tumours that formed after subcutaneous injection of the 
cells into rats. In this way, I was able to identify genes whose expression was 
significantly changed with metastatic potential, both in cultured cells and in primary 
tumours. Twenty-three genes were differentially expressed more than 2.5-fold in 
metastatic cells (P < 0.05).
The gene encoding protein 4.IB was down-regulated in the metastatic cells. To 
investigate the possible function of 4.IB, I reduced its expression in non-metastatic cells 
by RNA interference (RNAi). Cells with reduced 4. IB expression displayed an altered 
F-actin morphology, with a loss of stress fibres compared to control cells. The stress 
fibre phenotype was rescued by transfection of an RNAi-resistant 4. IB cDNA, showing 
that the effect was specific. I also found that the 4. IB RNAi cells migrated at twice the 
speed of the wild-type cells.
I conclude that the loss of 4.IB in the metastatic cells causes a significant loss of actin 
stress fibres and increase in cell speed, and thus plays a role in progression to metastatic 
phenotype.
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Chapter One
Introduction
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1.1 Metastatic disease
1.1.1 Cancer and metastasis
The uncontrolled division of cells leading to the formation of a tumour is known as 
cancer. Cancer is the result of the deregulation of a certain number of genes by a range 
of environmental and genetic factors (Hahn and Weinberg, 2002). The most life- 
threatening aspect of cancer is the ability of cancer cells to acquire the ability to migrate 
through the body to form one or more secondary tumours. This process is called 
metastasis, and it accounts for the majority of deaths in cancer patients (Ahmad and 
Hart, 1997). The development of metastases is insidious and often underway even 
before the primary tumour has been detected. Therefore it is important to understand 
the cell behaviour and associated gene expression of metastatic tumours, with a view to 
improving treatments and reducing the incidence of metastasis in cancer patients.
15
1.1.2 The metastatic cascade
To metastasise, the tumour cell needs to progress through a series of critical steps 
known as the metastatic cascade (Ahmad and Hart, 1997). The metastatic cascade, 
summarised in Figure 1.1, begins when an embolus of cells or a solitary cell detaches 
from the primary tumour. Detachment may occur in a few ways, such as the inadvertent 
dissemination of cells during surgical resection of the tumour, or a reduction in the 
strength of cell-cell adhesions in the tumour (Bogenrieder and Herlyn, 2003). The 
tumour cell then enters the blood or lymphatic system; this can occur via vessels 
vascularising the tumour itself. Alternatively, the tumour may invade the local tissue 
before entering the circulation. Upon intravasation (entry into the vessel) the tumour 
cell must withstand the shear forces and other mechanical stresses of the circulatory 
system, and continue to evade the immune system. Whilst in the blood stream, it may 
acquire chaperones, for example platelets, which aggregate with the tumour cell and 
provide protection in the circulation (Karpatkin and Pearlstein, 1981). The 
metastasising cell then arrests in the capillary bed of another organ, and begins 
extravasation. This may occur in a passive way, by the tumour cell becoming lodged in 
a capillary bed through which it passes by attrition of the vessel wall. Alternatively, 
intravasation can occur in a more active way, involving the tumour cell degrading the 
ECM, and crossing the wall of the vessel by regulating its shape and motility. Once at 
the secondary site, the cell needs to survive in the new environment, and eventually 
resume cell division to form the secondary tumour. The specific behaviours that 
enhance the metastatic potential of a tumour cell are described in more detail in the 
following section.
16
iFigure 1.1: The metastatic cascade.
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1. The metastatic cascade begins when an embolus of cells or a solitary cell detaches from the primary tumour. The cell degrades the extracellular matrix 
of the surrounding tissue, with matrix-degrading proteases, which may come from the tumour cell or from other cells in the tumour microenvironment.
The cell then enters the blood or lymph system (intravasation).
primary tumour
3. The cell or embolus comes to rest in the capillary bed of another organ, 
rolling and tethering to endothelial cells. Extravasation to the secondary site 
now occur. The cell must now survive in the new environment of the secondary 
site, and eventually resume cell division.
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2. The tumour cell is transported in the 
blood or lymphatic system to a distant site. 
During this time, it must withstand the shear 
forces of the circulatory system and evade 
the immune system. It may aggregate with 
platelets to form an embolus.
1.1.3 The events and cell behaviours required fo r  metastasis
In metastasis, a subpopulation of cells from the primary tumour is selected for its ability 
to negotiate the metastatic cascade (Fidler and Hart, 1982). Cells in the metastatic 
cascade must overcome a series of barriers. Accordingly, if the tumour cell lacks the 
characteristics necessary to progress through any part of the metastatic cascade, it 
cannot cause metastases. Therefore, each of the behaviours required for the metastatic 
cascade can be studied with a view to being made a target for anti-metastatic therapies. 
The events and behaviours that might be needed by the metastasising cell are considered 
here.
1.1.3.1 Tumour vascularisation
Tumours more than 2 mm in diameter must be vascularised in order to survive (Fidler 
and Ellis, 1994). In fact, many adults carry microscopic colonies of cancer cells (in situ 
tumours) but never develop disease because of the failure of these tumours to recruit 
their own new blood supply (Black and Welch, 1993). However, when tumours do 
become vascularised, this provides an opportunity for cells to be transported to the rest 
of the body via the circulation.
1.1.3.2 Degradation o f extracellular matrix
Degradation of extracellular matrix (ECM) can be involved in the local invasion at the 
start of metastasis, and entry and exit of the circulatory system. It is achieved by 
matrix-degrading proteases such as matrix metalloproteases (MMPs) (Ahmad and Hart, 
1997). However, the proteases are not always directly made by the tumour. The 
tumour can influence neighbouring stromal cells, such as mast cells, fibroblasts and 
macrophages, to produce proteolytic enzymes. For example, Sato et al. (2004) have 
shown that contact between cervical carcinoma cells and peripheral stromal fibroblasts 
in vitro causes an increase in MMP production and activation in both cell types, and a 
subsequent increase in invasiveness of the carcinoma cells. Mast cell degranulation 
may also play a role in ECM degradation; the accumulation and degranulation of mast 
cells has been seen at the zone of tumour invasion (Kankkunen et al., 1997). Cells can 
contribute to ECM degradation by mechanical, as well as biochemical means. Tumour- 
associated macrophages have also been seen to form podosomes (Evans et al., 2003) 
which are associated with remodelling of the ECM, and may promote cancer cell 
invasion by remodelling ECM both within the tumour and at the tumour-stroma 
interface. Finally, Lacal et al. (2005) found that the cytokine vascular endothelial
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growth factor-A (VEGF-A), expressed by endothelial cells, can act on human 
melanoma cells and cause them to produce VEGF-A, which increases their ability to 
invade the ECM.
1.1.3.3 Regulation of adhesion
Changes in adhesion are thought to be necessary for tumour cell metastasis at various 
stages of the metastatic cascade (Bogenrieder and Herlyn, 2003). Initially, cell adhesion 
in the solid tumour mass should be weak enough that one or more cells may be freed.
In the blood stream or lymph system, the aggregation of a tumour cell with platelets 
may help it to easily lodge in capillaries and facilitate the tethering and adhesion to 
endothelial cells in order to exit the vessel (Karpatkin and Pearlstein, 1981). Here, it is 
necessary to express molecules that can interact with molecules on the surface of the 
endothelial cells, for example CD44 (Marhaba and Zoller, 2004). The tumour cell may 
arrest on the vessel wall by attaching to an endothelial cell, or to basement membrane 
exposed by endothelial cell retraction. Metastatic cells can also increase their chances 
of achieving transendothelial migration by stimulating endothelial cell retraction. Hart 
et al. (2005) showed that the binding of prostate epithelial cells to endothelial cells can 
cause significant endothelial retraction. The basement membrane exposed upon cell 
retraction is generally a better adhesive substrate for the tumour cells than the 
endothelial cell surface and can allow the tumour cell to move more easily through the 
endothelial barrier.
1.1.3.4 Cell motility
It is widely accepted that cell motility is essential for metastasis. EMT (epithelial to 
mesenchymal transition) is a hallmark of many cancers and results in the acquisition of 
motility (Thiery, 2003). Cell motility is important since the metastasising cell needs to 
move out of the primary tumour, pass between cells in the local tumour environment, 
and eventually transmigrate through vessel walls for entry and exit of the blood or 
lymphatic systems (Condeelis et al., 2005). Heightened motility is a common feature of 
metastatic cells and has been described by several groups. In fact, a recent in vivo study 
has shown that metastatic tumour cells move 4.5 times as frequently as non-metastatic 
tumour cells in the same tumour microenvironment (Sahai, 2005).
Motility of tumour cells may be directional, in the sense that organs and endothelial 
cells might secrete factors that can promote migration of cancer cells into the 
organ/vessel itself. Hujanen and Terranova (1985), for example, have shown that
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melanoma, sarcoma and breast cancer cells can chemotax towards extracts from the 
organs to which they preferentially metastasise. In vivo, tumour cells may migrate to 
the secondary site by travelling along the homing pathways used by other cells, for 
example by exploiting the chemokine-mediated homing of haematopoietic cells to 
specific sites in the body. Muller et al. (2001) report that the chemokines CXCR4 and 
CCR7 are associated with the metastasis of melanoma and breast cancer and propose 
that chemokines and their receptors promote metastasis of cancer cells.
1.2 Cell motility and the cytoskeleton
1.2.1 Cell motility and the cytoskeleton in health and disease
Cell motility underpins a number of physiological processes, as well as metastasis. The 
first cell movements occur during embryogenesis, for example, migration of the neural 
crest cells or the migration of growth cones during the establishment of the nervous 
system (Bray, 2001). Cell migration remains important throughout adult life, for 
example in the migration of fibroblasts during wound healing, and in the circulation of 
immune cells surveying for infection (Bray, 2001). In order to migrate, cells need to 
modulate their shape and their interactions with the substrate. Cells are able to do this 
by altering their cytoskeleton, which is composed of three types of protein filament; 
intermediate filaments, microtubules and actin.
1.2.2 Intermediate filaments and microtubules
Intermediate filaments (IF) provide the cell with mechanical strength and perform a 
variety of structural functions. They are comprised of a number of proteins, for 
example cytokeratins, vimentin, desmin and nuclear lamins (Alberts, 2002), each of 
which is specialised for a different function, for example, the lamins make a meshwork 
underlying the nuclear membrane, called the nuclear lamina, whilst other types of IF 
extend into the cytoplasm from the nuclear lamina or link cells at gap junctions. IF are 
predominantly found in cells that require a lot of mechanical strength, such as epithelial 
cells (Alberts, 2002).
Microtubules are long, thick polymers of tubulin, found in the cytoplasm. One end of 
the filament is usually attached to the centrosome, close to the nucleus, whilst the other 
end (the plus end) is capable of rapid growth, reaching the edge of the cell. 
Microtubules are highly dynamic structures which are also capable of rapid
20
depolymerisation and as such are said to possess dynamic instability (Waterman-Storer 
and Salmon, 1997). Microtubule-associated proteins (MAPs) can stabilise microtubules 
or modify their function, for example, motor proteins such as kinesin and dynein allow 
the movement of organelles along microtubules by binding to and trafficking organelles 
along microtubules (Alberts, 2002). Microtubules can play a role in cancer, and some 
anticancer drugs, for example Taxol, target microtubules (Jordan and Wilson, 2004).
1.2.3 Actin
Whilst intermediate filaments and microtubules have a role to play in cell motility and 
cell shape, actin is of particular importance in this thesis; hence it is described in more 
detail here. Actin is an abundant protein that can exist as a globular protein (G-actin) or 
as Filamentous actin (F-actin). Actin polymerisation can generate forces in the cell 
(Miyata and Hotani, 1992) which are used to create dynamic structures that co- 
ordinately result in cell motility.
1.2.3.1 Actin polymerisation
Actin polymerisation begins with the formation of a stable actin trimer. Two actin 
monomers bind relatively weakly to each other and therefore are rather unstable, but the 
addition of a third actin monomer makes a stable group. This is called nucleation, and it 
is the rate-limiting step in actin polymerisation (Bray, 2001). The monomers add to 
each other in the same orientation, so that filaments are composed of uniformly oriented 
molecules. The ends of the filament have different characteristics; a fast-growing plus 
(barbed) and a slow-growing minus (pointed) end. Each actin monomer is tightly 
associated with an ATP molecule which is hydrolysed after polymerisation occurs. The 
dissociation of the phosphate group reduces the affinity of the actin molecule for its 
neighbour and hence promotes depolymerisation, meaning that actin filaments are 
dynamic structures (Bray, 2001). Actin polymerisation is regulated by actin binding 
proteins, examples of which are cofilin, profilin and thymosin. Profilin binds actin 
monomers (Tilney, 1978) and enables their transfer to the plus end of filaments. Cofilin 
causes the disassembly of actin monomers from the pointed end of the actin filaments 
(Lappalainen and Drubin, 1997). Thymosin acts as a buffer of actin monomers by 
sequestering them and releasing them into the cytosol when the rapid formation of F- 
actin is required (Pollard et al., 2000).
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1.2.3.2 Actin treadmilling
Actin filaments are in a state where the continual addition of subunits at one end of the 
filament is matched by loss of subunits at the other end; this is known as actin 
treadmilling (Alberts, 2002). Treadmilling allows the filament to remain the same 
length as individual actin subunits move along it. Actin treadmilling is not equilibrium 
behaviour, and consequently depends on the energy released by the ATP hydrolysis 
which occurs upon actin polymerisation (Alberts, 2002). The advantage of this 
dynamic behaviour is that the cell can alter its shape rapidly in response to stimuli.
1.2.3.3 Actomyosin contraction
Actomyosin is a complex of actin and myosin. Actomyosin contraction is responsible 
for the movements in muscle fibres as well in non-muscle cells. Myosin filaments can 
interact with actin filaments and generate movement by the hydrolysis of ATP, where 
two actin filaments are pulled past each other in opposite directions, causing contraction 
(Lodish, 1999). This is illustrated in Figure 1.2.
Figure 1.2: Actomyosin contraction in non-muscle cells.
A etiri f ila m e n t  Filam errt s lid in g
filament sliding
In actomyosin contraction, tilting of the head domain of myosin causes contraction as the two 
actin filaments slide past each other. This is taken from a diagram in Molecular Cell Biology 
(Lodish, 1999).
Actomyosin contractions are involved in cytokinesis, where the cytoplasm of a cell 
divides following nuclear division, and in migration. Actomyosin is the basis of stress 
fibres, which will be introduced shortly. Actomyosin contraction is the result of a 
signalling cascade mediated by the small GTPase Rho. Briefly, Rho activates Rho 
kinases (ROCKs) which in turn phosphorylate the myosin light chain, either directly or 
indirectly, causing contraction (Katoh et al., 2001). Myosin light chain phosphorylation 
can also be brought about by the activity of other proteins for example ZIP-like 
kinase/hZIPK (Endo et al., 2004; MacDonald et al., 2001).
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1.2.4 The actin cytoskeleton
Actin can form a variety of specialised cellular structures, with the help of a wide range 
of actin binding proteins. Actin binding proteins can produce actin networks with 
distinct qualities, for example, a-actinin cross-links actin filaments into bundles, and 
spectrin forms gel-like networks (Bray, 2001). Examples of actin-based structures, 
stress fibres, lamellipodia, filopodia and the actin cortex, are displayed in Figure 1.3.
Figure 1.3: Assemblies of actin filaments in a fibroblast.
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Actin can be arranged into different structures specialised for the various requirements of the 
cell. In fibroblasts, actin is arranged into a gel-like network called the actin cortex, which 
supports the cell membrane. It can also occur in tight parallel bundles in plasma membrane 
extensions known as filopodia. At the leading edge of a migrating cell, branched actin filaments 
in the lamellipodium polymerise to push the cell forward. Actin can also be incorporated into 
contractile bundles called actin stress fibres, to give the cell contractility and structural integrity. 
This schematic is adapted from a figure in Molecular Biology of the Cell (Alberts, 2002).
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1.2.4.1 Stress fibres
Stress fibres, shown in the phalloidin-stained fibroblast in Figure 1.4, are bundles of 
actin, myosin and other accessory proteins. Stress fibres are long, plasma membrane- 
bound cables which can stretch from one side of the cell to the other, and exert tension 
by contracting. One of the actin binding proteins involved in stress fibres, a-actinin, 
becomes relevant later in this thesis and so will be briefly described here, a -Actinin 
localises along stress fibres and is thought to play a role in stress fibre bundling as well 
as linking stress fibres with the ECM. It exists as a dimer, and contains two actin 
binding domains which cross-link actin filaments, holding them approximately 40 nm 
apart (Alberts et al., 2002). The reason that the fibres are held apart rather than closely 
apposed is that myosin II, the protein responsible for stress fibre contractility, needs to 
access the bundle, a-Actinin may also be involved in responses to IGF in some cells 
(Guvakova et al., 2002), and it has also been observed in invadopodia (Chen, 1989), 
structures exhibited by cells migrating in a three dimensional matrix, and may therefore 
have an important role in cell motility.
Figure 1.4: Actin stress fibres in a fibroblast.
This fibroblast was 
fixed and stained with a 
fluorescent conjugate of 
the actin binding protein 
phalloidin. This 
confocal image shows 
actin stress fibres 
spanning the rear of the 
cell. Scale bar = 20 pm.
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1.2.4.2 Focal adhesions
Stress fibres are embedded into structures known as focal adhesions, which are clusters 
of proteins forming an attachment between the cell and the substrate. A schematic of a 
stress fibre meeting a focal adhesion is shown in Figure 1.5.
Figure 1.5: Schematic cross-section of a stress fibre meeting a focal adhesion.
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This diagram illustrates a stress fibre attaching to the cell membrane at a focal adhesion. The 
focal adhesion is formed by the clustering of integral membrane proteins which transduce 
signals from the ECM to the cell. The stress fibre indirectly binds the ECM at the focal adhesion 
via transmembrane proteins such as integrins. This diagram is modified from one presented in 
Cell Movements (Bray, 2001).
Focal adhesions are composed of many different proteins. Integrins within the focal 
adhesions bind the ECM, whilst the cytoplasmic domain of the integrin engages with 
other focal adhesion proteins, which include a-actinin, vinculin, paxillin and src. As 
actin filaments can associate with the proteins bound to the integrin’s intracellular 
domain, the integrin enables actin filaments to be linked to the ECM (Bray, 2001). In 
this way, focal adhesions link the cytoplasm with the substrate. As well as 
mechanically attaching cells to the substrate, focal adhesions also participate in 
intracellular communication, transmitting signals for various signalling pathways and 
acting as signalling complexes for the cell. Focal adhesions are required for cell 
motility in many cell types including fibroblasts (see Figure 1.9) which need focal 
adhesions to be formed at the leading edge of the migrating cell. These adhesions then 
remain fixed (relative to the substrate) as the cell moves forward, and are disassembled 
at the rear of the cell.
How do focal adhesions form? Cells grown on an untreated substrate in the absence of 
serum do not naturally form focal adhesions. Focal adhesions form during spreading or 
migration on a tissue culture surface providing the substrate contains the correct ECM
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components (Sastry and Burridge, 2000). Inititally, focal complexes form as the cell 
contacts the substrate and these complexes then mature into focal adhesions which are 
more stable attachment sites which also anchor actin filaments. Another requirement 
for focal adhesion formation is cell contractility or tension, and this is produced by 
myosin activity in the stress fibres. The small GTPase Rho, through its downstream 
effector Rho kinase, stimulates myosin II chain phosphorylation and hence increases 
actomyosin contractility. This results in the formation of stress fibres and the clustering 
of integrins and other proteins to form focal adhesions (Sastry and Burridge, 2000).
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1.2.4.3 The actin cortex
The actin cortex is a dense network of actin filaments tightly associated with the cell 
membrane, as illustrated in Figure 1.6. Actin filaments are attached to the cell 
membrane via adapter proteins (such as a-Actinin) which bind both actin and integral 
membrane proteins (Bray, 2001).
Figure 1.6: Cortical actin visualised by staining with 
rhodamine phalloidin.
Hela cells were fixed and stained with rhodamine phalloidin, 
and imaged on a confocal microscope. This image, of a section 
of the cell near the apical surface, shows the cortical actin 
underlying the cell membrane. Scale bar = 20 pm.
The nucleation and polymerisation of cortical actin produces protrusions on the cell 
surface, such as invadopodia, filopodia and lamellipodia.
1.2.4.4 Lamellipodia
Lamellipodia are broad, flat protrusions of the cell periphery lying parallel to the 
substrate. They typically represent the leading edge of the cell. When lamellipodia 
sweep back over the cell as it migrates forward, they appear as ruffles, examples of 
which can be seen on the migrating cell in Figure 1.8. They are composed of a 
meshwork of branched actin filaments, with the fast-growing ends facing outwards 
(Svitkina and Borisy, 1999). The cell rapidly polymerises actin at its leading edge 
causing a lamellipodium to extend across the substrate in the direction of migration. 
The branching of actin at the lamellipodium generates more force than the simple 
polymerisation of one, unbranched filament, and allows the membrane to be pushed 
forward rapidly. Figure 1.7 shows the branched actin filaments in a fibroblast 
lamellipodium. The branching is mediated by the Arp2/3 complex binding the F-actin 
filament and nucleating a new filament (Svitkina and Borisy, 1999). Actin 
polymerisation at the leading edge and indeed in other actin-based protrusions relies 
upon the continual delivery of actin monomers to the end of the growing filament. The 
speed of actin delivery to the leading edge of the cell was recently calculated after 
FLAP analysis of sarcoma cells (Zicha et al., 2003) and found to be greater than that 
expected due to diffusion alone, meaning that other factors are likely involved in the 
delivery of actin monomers to the growing ends of filaments.
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Figure 1.7: Branched actin networks in a lamellipodium.
This scanning electron micrograph shows the actin 
filaments in the cytoskeieton of a cultured fibroblast (REF- 
52). Binding of the Arp2/3 complex onto actin filaments 
allows nucleation of actin monomers leading to the 
polymerisation o f a branch. Modified from a micrograph by 
T M Svitkina (Svitkina et al., 1997).
1.2.4.5 Filopodia
Filopodia are active membrane protrusions, approximately 0.15 pm in diameter, 
containing unipolar actin filaments (Small et al., 2002). They are found in a variety of 
cell types, including fibroblasts and growth cones, and allow the cell to explore its 
environment. The extensions at the sides of the cell in Figure 1.8 may be filopodia 
being used to sense the environment as it migrates.
1.2.4.6 Podosomes and invadopodia
These are actin-based structures which have only recently started to receive widespread 
attention. Podosomes appear by electron microscopy as small (1-2 pm diameter, 200- 
400 nm deep) plasma membrane extensions, whereas invadopodia are much larger (8 
pm wide, 2 pm deep) (Buccione et al., 2004). Podosomes are actin-rich extensions of 
the cell membrane which may function as dynamic adhesion structures for cell 
migration. They are distinct from focal adhesions as they contain proteins required for 
actin polymerisation, for example WASP (Calle et al., 2004). Invadopodia are actin- 
rich and contain other proteins such as Vinculin and a-Actinin (Chen, 1989). They can 
also degrade the ECM by secreting matrix-degrading enzymes, and they are seen in 
invasive cancer cells cultured on a physiological substrate and may help clear the path 
for a cell as it migrates.
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Figure 1.8: Scanning electron micrograph of a migrating fibroblast.
The cell in this scanning electron micrograph is migrating through the 8 pm diameter pore o f a 
polyethylene terephthalate membrane. This image illustrates the extensive and complex 
structures arising from the cell membrane during migration. The lamellipodium has extended 
and formed attachments with the substrate, allowing the cell to pull itself forward (indicated by 
white arrow). As the cell migrates, the large lamellipodium is swept backwards over the cell, 
forming ruffles (indicated by black arrow). The thin filaments visible on both sides o f the cell are 
filopodia or retraction fibres. Dorsal structures are also clearly present. These membrane 
structures are all due solely to the remodelling of the actin cortex. This micrograph was taken 
by Steve Gschmeissener. Scale bar =10 pm.
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1.2.5 Fibroblast migration
Cell migration involves the coordinated remodelling of the actin cytoskeleton into the 
actin-based structures described in Section 1.2.4. I will introduce fibroblast migration 
since the model used in this study is fibroblast-like, although it should be noted that 
mechanisms of migration vary greatly according to cell type.
1.2.5.1 The multi-step model o f fibroblast migration
Fibroblast migration relies upon a well defined repertoire of movements; extension of a 
lamellipodium, adhesion of the extended membrane to the substrate, contractile forces 
to shift the body of the cell forward in the direction of the lamellipodium, and 
detachment of the adhesions at the rear of the cell (Abercrombie and Heaysman, 1966). 
This is summarised in Figure 1.9.
Figure 1.9: Repertoire of movements needed for fibroblast migration.
The polarised cell extends the membrane at the 
front of the cell to make a lamellipodium (1), 
which is pushed forward over the surface by the 
rapid extension of actin filaments. New 
adhesions form between the lamellipodium and 
the substrate (2). The cell body shifts in the 
direction of the new membrane extension (3) by 
exerting contracting forces to move the 
cytoplasm forwards. The cell also needs to 
retract its tail and move it forward in the direction 
of migration (4). This requires the disassembly 
of the focal adhesions at the rear of the cell to 
allow the membrane to move away from the 
substrate. Note that these movements do not 
necessarily occur in the order depicted in the 
diagram. After Molecular Cell Biology (Lodish, 
1999).
New adhesion
Okl adhesion ' O i
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Having extended a lamellipodium, the cell now forms focal contacts with the substrate. 
Focal contacts are built around integrins, which are transmembrane proteins. The 
extracellular domain of the integrin binds to extracellular molecules such as fibronectin, 
and the cytoplasmic domain binds to proteins localised to the focal adhesion, for 
example a-Actinin or Vinculin (Bray, 2001). Figure 1.5 shows a schematic section 
through a focal adhesion, where a stress fibre contacts the substrate indirectly via 
integral membrane proteins. Contractile forces, generated through stress fibres, move 
the cell body forward to follow its lamellipodium. As essential as the formation of focal 
adhesions is that the cell releases the focal adhesions at the rear of the cell as it moves 
forward. This occurs partly through the exertion of tension on the rear focal adhesions, 
via actomyosin contraction (Katoh et al., 2001).
1.2.5.2 Cell migration in three dimensions
The study of cell migration has predominantly been carried out in two-dimensional (2D) 
models, where cells crawl on a topographically simple substrate such as plastic or glass. 
In vivo, cells are exposed to more challenging environments, where they need to migrate 
through rather dense and complicated tissues. Niggemann et al. (2004) investigated 
how the multi-step, two-dimensional model of cell migration (described in Section 
1.2.5) compares to the motility of tumour cells in a three dimensional collagen matrix. 
They found that the four steps can be observed, although they often merge with each 
other, and do not always occur in the same sequence. Also, the first extension may not 
be carried out only by a lamellipodium but by a number of different pseudopodia, for 
example, a mixture of filopodia, invadopodia and podosomes.
Though the basic mechanisms of cell motility may be the same in two and three 
dimensions, cells likely have to operate slightly different modes of motility in order to 
deal with the challenges presented by the two environments. Indeed, Sahai and 
Marshall (2002) suggest that tumour cells can switch between an elongated and 
amoeboid mode of motility. This and other studies have suggested that two 
dimensional and three dimensional analyses reveal different aspects of cell motility 
(Martins and Kolega, 2006; Sahai and Marshall, 2002).
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1.3 Protein 4. IB
1.3.1 FERM domain proteins
Whilst a large number of proteins are involved in the formation of stress fibres and in 
general cytoskeletal regulation, the FERM (4.1, Ezrin, Radixin, Moesin) 
domain-containing proteins will be discussed here since one member of this protein 
family is relevant to this thesis. The FERM domain has been shown to be involved in 
the linkage of the cytoskeleton to the ECM (Chishti et al., 1998). The best characterised 
FERM domain proteins are Ezrin, Radixin and Moesin. Ezrin was identified as an 
organiser of the cytoskeleton and membrane (Gould et al., 1989), radixin as a barbed 
end actin capping protein at the plasma membrane (Tsukita et al., 1989) and moesin as a 
cytoskeleton and plasma membrane linker (Lankes and Furthmayr, 1991). They are 
required for the induction of stress fibres and lamellipodia by the GTPases Rho and 
Rac, respectively (1997). Other FERM domain-containing proteins include NF2 and 
FAK, both of which are believed to play a role in linking actin to the ECM (McClatchey 
and Giovannini, 2005). Less well characterised are the 4.1 superfamily proteins. The 
first member of the family to be identified was 4.1R, as a major component of 
erythrocyte membranes (Conboy et al., 1986). Since then, the related proteins 4. IN, 
4.1G and 4. IB have been found (Parra et al., 2000; Parra et al., 1998; Walensky et al., 
1999).
1.3.2 DAL-1 and protein 4. IB
4. IB was simultaneously identified in a differential display screen of human primary 
non-small cell lung cancer as the gene DAL-1 which was Downregulated in 
Adenocarcinoma of the Lung (Tran et al., 1999). DAL-1 was later found to be a 
functionally-complete fragment of the full length protein 4. IB (Gutmann et al., 2000; 
Gutmann et al., 2001). DAL-1 is functionally comparable to 4.IB in that it contains all 
the amino acids necessary for the tumour suppressor effect of 4.IB. 4.IB was identified 
in mice by Parra et al. and is so-called because of its membership of the 4.1 protein 
family and its high expression level in the brain (Parra et al., 2000). However it is now 
known to be expressed in a number of other tissues besides brain. In this thesis, the 
name 4. IB will be used since it relates the protein to the 4.1 family. In the description 
of studies where the functionally comparable fragment DAL-1 was used, I will refer to 
the protein as DAL-1/4.1B. Protein 4.IB is encoded by the gene epb41l3, which has
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been found to encode a number of tissue-specific protein isoforms (Gascard et al., 2004; 
McCarty et al., 2005) via alternative splicing.
1.3.2.1 4. IB Junction
Like other members of the 4.1 family, 4. IB is thought to be involved in tethering the 
actin cytoskeleton to membrane glycoproteins. It is reported to be localised to the 
plasma membrane (Gutmann et al., 2000; Parra et al., 2000). It has been shown to have 
tumour suppressor effects by three different groups. Tran et al. (1999) introduced 
DAL-1/4.IB into non-expressing cell lines, and observed a significant reduction in cell 
growth. Charboneau et al. (2002) also found a growth suppressing effect in MCF7 
breast carcinomas transiently transfected with DAL-1/4.IB, and Gutmann et al. (2000) 
found that it was lost in 60% of meningioma samples. However, they found no loss of 
4.IB in sporadic schwannomas (out of 20 samples examined) which indicates that 4.IB 
may act in a tissue-specific manner.
In addition to the association of 4.IB loss with brain, breast and lung tumours, its 
tumour suppressor activity is supported by the fact that the chromosome region on 
which epb41l3 is located, 18pl 1.3, is commonly deleted in tumours (Kittiniyom et al., 
2001; Tran et al., 1998). 4.IB may also be involved in cellular attachment, since the 
expression of DAL-1/4. IB in MCF7 increases their adherence to substrates 
(Charboneau et al., 2002) and the expression of 4.1B/DAL-1 in schwannoma cells 
impaired cell spreading and migration in the Boy den chamber assay (Gutmann et al.,
2001).
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1.3.2.2 4. IB structure and its inter actors
The structure of 4.IB (Parra et al., 2000) is outlined in Figure 1.10.
Figure 1.10: The domain organisation of 4.1 B.
U1 FERM U2 SAB U3 CTD
4.IB has an N-terminal FERM domain, which appears to be a membrane binding 
module common to a number of different proteins. In the cytoplasm, the FERM domain 
is in an inactive, closed conformation (Bretscher et al., 2002) and, upon activation (in 
the case of ezrin, by threonine/tyrosine phosphorylation) assumes an open conformation 
and moves to the membrane. The FERM domain of 4.IB is 74% homologous to the 
prototypical 4.1 family member, 4.1R. The FERM domain of 4.1R has been found to 
interact with various proteins including calmodulin and the integral membrane proteins 
glycophorin C and CD44; 4.IB is also likely to interact with these.
4.IB has been shown experimentally to interact with pll-spectrin (Gutmann et al.,
2001) and the cytoplasmic tail of p8 integrin in primary astrocytes (McCarty et al., 
2005). It was also found to interact with 14-3-3 (Yu et al., 2002) though a later study 
(Robb et al., 2004) showed that disruption of this interaction had no effect on the 
growth-suppressing effect of 4.IB, indicating that either the 4.1B/14-3-3 interaction 
does not occur in vivo, or that other proteins are capable of transducing the growth- 
suppressing signals.
There is a spectrin/actin binding domain (SAB), which, in the prototypical family 
member 4.1R, cross-links spectrin/actin dimers with glycophorin. Despite the sequence 
homology between the SAB of 4.1R and the putative SAB of 4 .IB, the latter has been 
reported to interact very weakly with actin (Gimm et al., 2002) or in fact, not at all 
(Gutmann et al., 2001). The C-terminal domain (CTD) is homologous to the CTD of 
4.1R which has putative binding sites for NuMA (Nuclear Mitotic Apparatus protein) 
and the glycoprotein FKBP13. There are three unique domains, U l, U2 and U3; U l, 
with unknown function, is upstream of the FERM domain, U2 is a spacer between the 
FERM and SAB domain and the function, if any, of U3 is currently unclear.
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1.4 Gene expression profiling o f metastasis
Just as the interplay of tumour suppressor and tumour promoter genes causes a cell to 
become cancerous, a particular combination of genes is required for the cell to progress 
through each step of the metastatic cascade. The development of microarray technology 
has enabled the investigation of the gene expression in tumours, which allows us to 
identify genes that influence metastasis (Rew, 2001). This has important clinical 
implications; microarray analysis of metastasis has the potential to improve diagnostic 
and prognostic tools, tailor adjuvant therapy to each patient, and identify molecular 
targets for drug development.
1.4.1.1 The need fo r gene expression analysis in cancer diagnosis
An important aspect of cancer patient care is the accurate assessment of the stage and 
likely outcome of the disease. A wide range of methods are currently used for this. 
These include the detection of specific molecules (e.g. Prostate Specific Antigen or 
HER2 receptor), lymph node status, histological grade of the tumour MRI imaging, CT 
scanning, and the detection of metastases in the circulation. Whilst these indicators are 
helpful in predicting prognosis, and designing treatment strategies, they are susceptible 
to failure (Dalton and Friend, 2006).
The inability to reliably predict cancer outcomes means that clinicians must err on the 
side of caution when planning treatment strategies for the patient. The result of this is 
that a large proportion of patients are significantly overtreated; patients typically receive 
adjuvant therapy (chemotherapy, radiotherapy or hormone therapy to kill cancer cells 
which may have begun to spread) after surgical resection of the tumour, although, not 
all patients will develop metastases anyway. Adjuvant therapies are exhausting and 
detrimental for the patient, and costly. Clearly it would be preferable to reliably predict 
which patients are at high risk of relapse and treat them accordingly, withholding 
unnecessary treatment from those whose risk of relapse is extremely low, and, in cases 
where more than one treatment option is available, selecting the treatment to which the 
cancer is most likely to respond.
The ideal way to make treatment decisions would be to characterise tumours on the 
basis of their molecular characteristics. For this reason it is hoped that gene expression 
analysis of tumours will reveal gene expression patterns- “predictive gene lists” or
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“gene expression signatures”- that are associated with metastasis (van de Vijver et al.,
2002).
1.4.2 Gene expression microarrays
A gene expression microarray consists of thousands of nucleic acid probes* bound in a 
specific pattern to a silicon or glass slide. Each probe is complementary to a transcribed 
DNA sequence from the organism of interest. Targets (nucleic acids from the sample) 
are produced by extracting RNA from a sample and converting it into cDNA. The 
cDNA target is then labelled and hybridised to the microarray, to which the probes are 
bound. Hybridisation between the sample and a probe indicates that a transcript 
complementary to the probe is being expressed by the cell. In this way, microarrays can 
measure the transcriptional activity in a sample. Gene expression microarrays are 
available as cDNA microarrays and oligonucleotide microarrays; I will focus on the 
latter as they were used in this study.
1.4.2.1 cDNA microarrays
cDNA microarrays are made by generating cDNA oligonucleotides by PCR, and 
printing them onto a solid substrate. cDNA microarray analysis involves the 
preparation of two samples to be hybridised to the same array (reviewed in Duggan et 
al., 1999). The targets are prepared by extracting RNA from the sample of interest, 
reverse transcribing it into cDNA, and labelling it with the fluorescent conjugate Cy3 or 
Cy5. A Cy3-labelled sample and a Cy5-labelled sample are competitively hybridised 
onto the same microarray, and unhybridised cDNA removed by gentle washing. 
Confocal laser scanning is used to detect the Cy3 and Cy5 signals on the microarray.
The signal intensity of the Cy3 and Cy5 indicates the amount of hybridisation and thus 
the relative gene expression in the samples. Since two samples need to be hybridised 
together, selection of appropriate pairs of samples essential. For example, a tumour 
sample would need to be matched carefully to normal tissue or to a pooled tumour 
sample, in order to highlight genes which are up- or down-regulated in the tumour.
1.4.2.2 Oligonucleotide microarrays
Oligonucleotide microarrays are made by synthesising oligonucleotides directly onto 
the substrate by photolithography (light-directed synthesis), which enables accurate
* A note on nomenclature: in microarrays, the “probes” are the nucleic acid bound to the substrate, and 
the “targets” are the nucleic acids from the sample. This terminology may seem illogical given that in 
other hybridisation techniques, the probe is unbound. However it is recommended (Phimister, 1999) to 
define the probes and target not by whether or not they are immobilised but by the fact that the probe is a 
known entity that interrogates, or probes, the target (the unknown entity).
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positioning of groups of oligonucleotides on the array (Lockhart et al., 1996).
Currently, the most reliable and frequently used oligonucleotide microarrays are 
GeneChip® arrays, manufactured by Affymetrix, Inc (de Reynies et al., 2006). Each 
GeneChip array contains hundreds of thousands of different oligonucleotides which are 
present in millions of copies (Barone et al., 2001). The arrangement of features on an 
Affymetrix GeneChip® array is shown in Figure 1.11.
Figure 1.11: Schematic of features on an Affymetrix GeneChip® array.
1.28 cm
28 cm
Actual size* o f  GeneChip
Millions of DNA oligom ers  
built up in each feature DNA
oligom er  
25 b ase pairs
Hundreds o f  thou san d s of
features on  the GeneChip array
Each Affymetrix GeneChip® is 1.28 cm * 1.28 cm and contains hundreds of thousands of 
features. Each feature contains millions of 25 base-pair DNA oligomers probing for a particular 
sequence. Image courtesy of Affymetrix, Inc.
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The Affymetrix system uses cRNA, rather than cDNA, targets to hybridsise to the 
probes. Targets are produced by extracting RNA from the sample, converting it to 
cDNA, and then performing in vitro transcription in the presence of biotinylated 
nucleotides to produce biotin-labelled cRNA. The cRNA is then fragmented and 
hybridised to the array, and unhybridised cRNA removed by gentle washing. The array 
is then incubated with the fluorescent molecule streptavidin-phycoerythrin, which binds 
to the biotin on the cRNA. The signal is amplified by an anti-streptavidin antibody 
followed by a biotin-labelled secondary antibody. The array is then scanned by a 
confocal laser, which excites the fluorescent molecules, causing them to emit light. 
Figure 1.12A shows an example image of a scanned GeneChip® array. The amount of 
fluorescence at each spot indicates the amount of hybridisation and thus the relative 
abundance of the transcript.
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Figure 1.12 Example image of an Affymetrix GeneChip array and schematic explaining 
probe set design.
Images courtesy of Affymetrix, Inc.
(A) Scan image of full chip
The GeneChip array 
contains
-  330,000 Probes 
~15,000 Probe Sets 
~ 16,500 Probe Pairs
(B) Probes, Probe Pairs and Probe Sets
Probe
Probe Pair
■ I I i mi Probe Set
(C) Close-up of scan image showing the PM/MM systemWiHI■■■inni■■■Isss1888!
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This close-up of a scan of a full chip shows 32 probe 
pairs, where the PM is the upper feature and the MM 
the lower feature of each pair.
The probe pair bounded by the pink box has a low 
PM/MM signal ratio, indicating non-specific 
hybridisation.
In contrast, the probe pair in the yellow box has a 
very high PM/MM ratio, indicating very little non­
specific hybridisation.
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1.4.2.3 Affymetrix probe design
Affymetrix GeneChip® arrays enable reliable measurement of transcript abundance 
because each probe on the array is actually paired in a probe set, with another probe that 
differs by one base. Each probe set (illustrated in Figure 1.12B) contains a Perfect 
Match (PM) probe, which has complete base pair complementarity to the transcribed 
sequence, and a Mismatch (MM) probe, which is the same as the PM probe with the 
exception of one mismatched base in the middle of the oligonucleotide. The MM probe 
is an indicator of non-specific hybridisation. After scanning, the fluorescence intensity 
from the MM probe is subtracted from the intensity of the PM probe in order to 
determine the intensity value for the particular probe pair. See Figure 1.12C for an 
example of the fluorescence intensities in the MM and PM of a probe pair. This probe 
design contributes to the accuracy of the gene expression analysis by reducing the 
likelihood of mistaking cross-hybridisation for perfect hybridisaton. A further 
advantage of the Affymetrix probe design is that each transcript is probed by 11 
different probe pairs. Figure 1.12B illustrates the hierarchy of probe features on an 
Affymetrix GeneChip® array.
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1.4.2.4 Overview o f the two gene expression microarray platforms
The main differences between cDNA and oligonucleotide microarrays are summarised
in Table 1.
Table 1: Differences between cDNA and oligonucleotide microarrays.
Probe
Target
Labelling
Number of 
samples hybridised
Hybridisation
specificity
cDNA
microarray
PCH products printed 
onto the substrate
RNA extracted and 
converted Into cDNA
Typically Cy3 ortyS 
2
Moderate
Oligonucleotide
microarray
Oligonucleotides 
synthesised directly 
onto the substrate
RNA extracted, coverted 
Into cDNA and then 
converted to cRNA
Biotin
1
High, owing to PM/MM 
probe design
Affymetrix GeneChip® arrays are a more accurate way of measuring gene expression, 
although cDNA arrays are certainly far more economical. The nomenclature commonly 
used for describing microarray experiments are recapitulated in Table 2.
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Table 2: Summary of microarray nomenclature.
Microarray
cDNA microarray
Oligonucleotide
microarray
Affymetrix GeneChip
Target
Probe
Perfect Match Probe 
(PM)
Mismatch Probe 
(MM)
Probe Pair 
Probe set 
Signal
Expression Ratio (ER) 
or Fold Change (FC)
A glass,filter, or silicon solid substrate, upon which 
oligonucleotides are deposited or synthesized in a defined 
spatial pattern.
A microarray produced by printing cDNA probes onto the 
substrate. Target cDNAs from two different samples are 
labelled with Cy3 or Cy5 and competitively hybridised to 
the microarray.
A microarray produced by synthesising the probes directly 
onto the substrate by photolithography.
A type of oligonucleotide microarray system in which 
multiple probes, including probes to measure non-specific 
hybridisation, measure the abundance of a transcript.
An unknown DNA or RNA sequence in solution, labelled 
with a fluorescent conjugate such as Cy3,Cy5 or biotin.
A known, unlabelled DNA sequence tethered to the 
substrate.
A 25 base oligonucleotide with perfect sequence 
complementarity to the transcribed sequence.
A 25 base oligonucleotide whose sequence is largely 
complementary to  the transcribed sequence, apart from 
one mismatched base in the middle of the 
oligonucleotide. Hybridisation to  the MM is used as a 
reference signal for non-specific hybridisation; a high 
PM/MM signal ratio indicates low levels of non-specific 
hybridisation.
Comprised of a PM and MM probe.
A series of probe pairs probing for the  same transcript.
The fluorescence intensity at a location on the array, 
indicating the abundance of a transcript.
A description of levels of gene expression. E.g., if a signal is 
twice as high in a breast tum our sample as in normal 
breast tissue, then the expression ratio of that gene is 2.
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1.4.2.5 Post-microarray validation of microarray data
Whilst microarray gene expression analysis is a very powerful technology, it is fallible, 
and observed gene expression changes must be backed up by other methods, for 
example RT-PCR or Northern Blotting, and Western Blotting (Chuaqui et al., 2002). 
Also, knowledge of gene expression patterns is of limited use in most situations, unless 
backed up by functional studies which attempt to assign a function to the gene and place 
it in its biological context. To assist with the assignment of gene function, and to enable 
researchers to understand the broad gene expression in the cell, Gene Ontology (GO) is 
used. GO projects, such as that managed by the Gene Ontology Consortium 
(http://www.geneontology.org) attempt to “provide a controlled vocabulary to describe 
gene and gene product attributes in any organism” (Ashbumer et al., 2000). The use of 
GO could, ideally, distinguish genes significantly related to the phenotypes being 
investigated, and secondly, identify groups of genes playing a coordinate role. So, for 
example, if 20% of genes from a candidate gene list were all annotated with the GO 
term “negative regulator of apoptosis” one could postulate that this process must be 
related to the phenotype studied.
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1.4.3 Gene expression signatures for the prediction o f  clinical outcomes
1.4.3.1 The Amsterdam signature
The first gene signature predictive of solid tumour prognosis was proposed by Van't 
Veer et al. (2002), who investigated the gene expression of primary breast carcinomas 
from 98 patients. Of these patients, 34 developed metastases within five years and 44 
remained disease-free after five years. They performed cDNA microarray analysis 
where RNA from each tumour was compared against pooled tumour RNA. Genes were 
considered differentially expressed if the fold-change was greater than 2 (P < 0.01) in 
more than 5 of the 98 tumours (i.e. in 5.1% of the samples). Cluster analysis, the 
grouping of genes according to their gene expression pattern, divided the tumours into 
two clusters. The clinical history of these tumours was then examined. In one cluster, 
the tumours were found to be predominantly from patients with a good prognosis 
(disease-free after five years). The tumours in the second cluster were predominantly 
from patients with a bad prognosis (metastases within five years). The clustering was 
also associated with the ER-alpha receptor status (used as an indicator of prognosis, 
where negative ER receptor staining is associated with bad prognosis). After the 
application of further clustering algorithms, they developed a gene expression signature 
containing 70 genes, believed to be indicative of poor prognosis.
In a subsequent study by the same group, the signature was tested on another cohort of 
breast cancer patients (van de Vijver et al., 2002). Here, 295 tumours were analysed by 
microarray and gene expression compared to the poor prognosis signature. They 
reported a strong correlation between tumours exhibiting the “good prognosis” 
signature, and survival and the absence of metastases. It outperformed all other 
methods currently used to predict clinical outcomes, at predicting the likelihood of 
distant metastases within five years, and thus, would improve the selection of patients 
for adjuvant systemic therapy. The Amsterdam signature was the first demonstration 
that gene expression profiling could be used to guide treatment decisions, and 
potentially result in fewer patients being under- or over-treated.
1.4.3.2 Other predictive gene signatures
Various other groups have derived predictive gene signatures, just two more of which 
are discussed here. Pawitan et al. (2005) used a similar approach to Van't Veer et al. to 
obtain a subset of genes (the Swedish signature) that could distinguish between good
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and bad prognosis. They extracted RNA from 150 breast tumours (38 of which were 
from patients with a poor prognosis, 121 from patients with a good prognosis) and 
compared gene expression using Affymetrix oligonucleotide arrays. Only three out of 
the 64 genes in their dataset also appear in the Amsterdam signature. A third signature, 
the Rotterdam signature, was developed from a similar study on primary breast cancers 
by Wang et al. (2005). Likewise, there is only a three-gene overlap between the 
Amsterdam and Rotterdam signatures, and the three genes are not the same for all three 
signatures. A possible reason for the lack of cross-over was that different microarray 
technologies were used; cDNA microarrays in the development of the Amsterdam 
signature and oligonucleotide arrays in the development of the Rotterdam and Swedish 
signatures. Moreover, different genes were represented on each type of microarray.
This indicates that conclusions drawn by microarray analysis are heavily influenced by 
the technology used. Secondly, the genetic variability of the cohorts of patients 
probably made it difficult to establish a common signature.
1.4.3.3 Current clinical value of predictive gene lists
There is a curious lack of overlap between the gene expression signatures of metastasis 
that have been described so far. Furthermore, the Amsterdam and Swedish signatures 
were unable to correctly predict outcomes when tested on each other’s patient cohorts 
(Ein-Dor et al., 2006), and a more comprehensive re-analysis of seven major predictive 
gene lists by Michiels et al. (2005) was unable to produce gene lists that were any better 
at classifying patients than chance. Ein-Dor et al. (2006) performed mathematical 
modelling to investigate the extent to which patient genetic variability contributes to the 
data. They concluded that the problem underlying the unreliability of the recent reports 
is that there are not enough patients, and propose that thousands, rather than hundreds, 
of patient samples are needed to generate a reliable, robust predictive gene list.
To summarise, a significant body of work demonstrates the use of microarray analysis 
in the search for gene expression signatures that can be used to predict clinical outcomes 
and highlight potential drug targets. However, more work is needed in order to develop 
a gene expression signature with an acceptably low rate of misclassification of 
metastatic risk. Ideas emerging from the recent reports are that there is infrequent 
overlap between predictive gene lists developed by different groups, and that 
patient-based microarray analyses theoretically require thousands of well-curated 
samples to yield clinically useful gene expression signatures.
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1.4.4 Gene expression analysis of animal models of metastasis
Animal models of metastasis can be used in conjunction with microarray analysis to 
search for genes that support the metastatic phenotype. The main advantages of animal 
models of metastasis are that they are tractable, and that the effects of certain genes can 
be tested by an in vivo metastasis assay, or by in vitro assays designed to test the ability 
of cells to perform metastasis-related behaviours such as migration or adhesion. The 
use of animal models can also avoid some of the challenges posed by patient-based 
analysis of metastasis. For example, the variability arising from using cohorts of 
patients with different genetic background can be avoided by using the same animal 
strain or, ideally inbred rats to reduce genetic variation in the host. Furthermore, in 
animals, it is possible to investigate the expression changes which mediate the 
progression from a benign to a metastasising tumour, by comparing primary and 
secondary tumours, whereas in patients, usually only one sample per patient is 
available.
1.4.4.1 Rho C as a metastasis promoter in melanoma cells
The first major report of gene expression analysis of an animal model of metastasis 
came from Clark et al (2000), who used in vitro selection to obtain highly metastatic 
variants of a poorly metastatic tumour cell line. They performed microarray analysis of 
the parental tumours and metastases, and found a number of genes with enhanced 
expression in metastases. Some of these genes, such as the cytoskeletal proteins 
Thymosin p4, Rho C, a-Catenin, a-Actinin and IQGAP, had potential roles in aspects of 
metastasis. The investigators tested Rho C by overexpression, or expression of a 
dominant negative Rho C, in the cells. The cells were subjected to a metastasis assay, 
where cells were injected into the tail vein of a mouse; this tested the stages of the 
metastatic cascade from the survival of the cells in the blood stream followed by 
extravasation and proliferation. The metastases were counted after some weeks. They 
found that Rho C overexpression increased the number of metastases and that 
expression of dominant-negative Rho C markedly decreased the number of metastases, 
indicating that Rho C activity contributes to the development of metastases in this 
model. This interesting finding demonstrates the value of microarray analysis in 
metastasis models.
1.4.4.2 Ezrin as a metastasis promoter in osteosarcoma
Khanna et al (2001) used a mouse osteosarcoma model to investigate genes involved in 
metastasis. The model was comprised of two clonally-related cell lines, with different
metastatic potentials. They found that 53 genes were significantly differentially 
expressed between the two cell lines. One of these, the ERM protein ezrin, was 
upregulated in the more aggressive cell line. They investigated the role of ezrin in 
metastasis (Khanna et al., 2004) by suppressing its expression in the more aggressive 
osteosarcoma cells and subjecting them to an in vivo metastasis assay, performed by 
intravenous tail injection of the cells. They found that the reduction in ezrin 
significantly reduced the development of pulmonary metastases.
1.4.4.3 Metastasis assays involving subcutaneous injection
Other studies describe the gene expression of metastasis using a model where the cells 
were delivered to the animal by subcutaneous implantation. This approach, unlike 
intravenous injection, tests all parts of the metastatic cascade, including intravasation. 
Margalit et al. (2003) investigated the gene expression in pulmonary metastases that 
developed after subcutaneous injection with D122 lung carcinoma cells or B16-F10.9 
melanoma cells into inbred mice. They found WISP-1 overexpression in the pulmonary 
metastases of both the cell lines, suggesting that WISP-1 overexpression may be 
important for metastasis. Li et al. (2003) also used the subcutaneous implantation 
approach, to develop highly metastatic hepatocellular carcinoma (HCC) cell lines by 
serial tumour progression in nude mice. The cell lines shed metastases throughout the 
animal at rates of between 70 and 100%. They performed microarray analysis of the 
newly developed and highly metastatic cell line in comparison to the parental cell line 
and found 25 differentially expressed genes. These genes were thought to potentially 
confer the ability to shed metastases. Another model using subcutaneous implantation 
into the mammary gland was used by Yang et al. (2004) to identify the transcription 
factor Twist as being a regulator of EMT, which is a common feature of metastatic 
cells. Finally, Wang et al. (2002b) suggested that the mRNA transporter ZBP-1 is 
important to the localisation of p-actin and hence motility, from gene expression 
profiling of a similar model.
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1.4.5 Investigation of metastasis using a rat sarcoma model
I decided to investigate the gene expression of metastasis using a rat sarcoma model 
developed by Vesely et al. (Vesely, 1989; Vesely et al., 1987; Vesely and Weiss, 1973). 
The model was developed in inbred LEWIS rats and is comprised of four related cell 
populations (see Figure 1.13). K2 cells were derived by spontaneous transformation of 
embryonic fibroblasts in vitro (Vesely and Weiss, 1973). T15 cells were obtained from 
K2 cells by in vivo passaging. T15 cells were implanted subcutaneously into a rat and 
metastasis was allowed to occur; A297 cells were recovered from the metastatic lesions. 
Similarly, A297 cells were implanted subcutaneously into a rat and A311 cells were 
recovered from a resulting metastasis.
Similar models have proved useful for studies of metastasis in the past (Fidler, 1973) 
and are valuable because they are testable, have a clear history, and originate from the 
same parent tumour (thus enabling assessment of the features that caused cancer cells to 
progress through the metastatic cascade with different efficiencies). Further advantages 
of this model are that it is derived from inbred rats, and therefore the genetic 
background is similar and differences observed between the cells are likely due to 
differences in metastatic potential rather than differences between subjects. Also, our 
approach includes the effects of the immune system, which is known to play a role in 
metastasis, for example, tumour associated macrophages can contribute to ECM 
degradation. Furthermore, our chosen model involves subcutaneous implantation rather 
than tail vein injection of the tumours cells during the metastasis assay. This approach 
tests all of the steps of the metastatic cascade.
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Figure 1.13: Development of the rat sarcoma model.
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The rat sarcoma model of metastasis is the result of a combination of in vitro and in vivo 
passaging of K2 cells, which are spontaneously transformed rat embryonic fibroblasts. T15 are 
a subpopulation of a K2 culture, and A297 and A311 were obtained from the metastatic lesions 
arising after implantation of T15 and A297 cells.
The cancer in this model is sarcoma, which is a class of tumour arising from 
mesenchymal tissue, for example, fibroblasts, muscle and bone. Tumours arising from 
epithelial tissues, such as skin and mammary gland, are called carcinomas. Whilst 
sarcomas are less prevalent than carcinomas, sarcoma models of metastasis can offer 
insights into both sarcomas and carcinomas, because of the tendencies of epithelial 
cancers to undergo EMT (see Section 1.1.3.4).
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All four rat sarcoma cell populations of the model are oncogenic, but have different 
metastatic potentials (defined as the percentage of primary tumours that shed 
metastases). To assess the metastatic potential of the four cell populations, 1 million 
cells were injected subcutaneously into inbred Lewis rats (Pokoma et al., 1994). In 
every case, primary tumours developed. After 4-6 weeks, the rats were sacrificed and 
inspected for metastases. The metastases localised primarily to the lung but were 
observed elsewhere. The metastatic potentials of the cells are shown in Figure 1.14.
The K2 cells have no metastatic potential. However the T15, A297 and A311 cells have 
metastatic potentials of 40, 90 and 100% respectively.
Figure 1.14: Rat sarcoma cells with differences in metastatic potential.
Cell Population
The cell populations K2, T15, A297 and A311 were subcutaneously implanted, in doses o f 1 
million cells, into inbred LEWIS rats. The metastatic potentials (the percentage of subjects 
which developed secondary tumours) are significantly different between the K2 cells and the 
T15, A297 and A311. The K2 cells have no metastatic potential, whereas the other three cell 
populations have metastatic potentials of 40, 90 and 100% respectively; **P < 0.01. The 
number of rats tested with the K2, T15, A297 and A311 cells were 20, 24, 10 and 10 
respectively. This experiment was performed by Eva Pokorna (Institute of Molecular Genetics, 
Academy of Sciences of the Czech Republic).
The following chapters describe the characterisation of the rat sarcoma cells, and the 
analysis of gene expression in the model. Following this, candidate genes indicated by 
the microarray were systematically tested for their role in behaviours which relate to 
metastasis.
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Chapter Two
Materials and methods
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Unless otherwise stated, all reagents were supplied by Sigma-Aldrich.
2.1 Cell culture
2.1.1 Sarcoma cells
Rat sarcoma cell populations K2, T15, A297 and A311 were a gift from Pavel Vesely 
(Institute of Molecular Genetics, Academy of Sciences of the Czech Republic). K2, full 
name LW13K2, are spontaneous neoplastic transformants from inbred LEWIS rats 
(Vesely and Weiss, 1973). T15, full name RPSL4T15, were developed from K2 by 
neoplastic progression in vivo and in vitro (Vesely et al., 1987). A297, full name 
A297Nb, were developed from T15 cells by in vivo selection, where cells were 
collected from a tumour in the rat with the highest number of metastases. A311, full 
name A337/311RP, were obtained from a retroperitoneal metastasis that arose when the 
A297 cells were applied to the rats. The cells were maintained in MEM with Hanks’ 
salts supplemented with 10% bovine serum (SML, Germany), 0.09% sodium 
bicarbonate, 1 mM glutamine and phenol red indicator, at 37°C with 5% CO2 in a 
humidified incubator, and passaged every 2-3 days. Passaging of cells involved a brief 
wash in 0.02% trypsin/5 mM EDTA followed by incubation in 0.02% trypsin/5 mM 
EDTA for 0.5-1 minute to detach cells. Further trypsin/EDTA activity was inhibited by 
the addition of fresh culture medium to the suspension. The cell suspension was used to 
prepare new cultures. For motility and chemotaxis assays, cells were seeded onto 
coverslips at a density of ~3500 cells per cm . For transfections, cells were seeded at a 
density of -7000 cells per cm2. For routine subculture, cells were seeded at a density of 
-4000 cells per cm2.
2.1.2 HeLa cells
HeLa cells were cultured in E4 medium supplemented with 10% foetal bovine serum 
and phenol red indicator, and maintained at 37°C with 10% CO2 in a humidified 
incubator. Cells were passaged every 2-3 days as described for the sarcoma cells, and 
seeded for transfections at -25,000 per cm2 and for routine subculture at -16,000 cells 
per cm2
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2.2 Immunocytochemistry and confocal microscopy
2.2.1 Immunocytochemistry
Cells growing on 13 mm diameter, 170 pm thick glass coverslips were fixed in 4% 
FA/PBS for 10 minutes, washed and permeabilised by incubation in cold 0.1% 
Triton/PBS for 10 minutes. Cells were incubated with 1% bovine serum/PBS to block 
non-specific sites prior to a 45 minute incubation with mouse a-Actinin antibody (Santa 
Cruz) or mouse CASK antibody (Chemicon International) diluted 1:400 in PBS. Cells 
were then washed three times with PBS over the course of 10 minutes, then incubated 
with Alexa 488-conjugated anti-mouse IgG diluted 1:400 in PBS, and rhodamine 
phalloidin diluted 1:2000 (both from Molecular Probes) for 30 minutes, and washed 
three times with PBS for 10 minutes. Coverslips were mounted by inversion onto 8 pi 
Mowiol on a microscope slide, and allowed to dry overnight and then stored at 4°C. 
Mountant was prepared by shaking 12 ml Citifluor AF1 (Citifluor Ltd.) and 2.4 g 
Mowiol 4-88 (Calbiochem) for 2 hours. Tris-HCl was then added to a final 
concentration of 100 mM and incubated at 50°C with mixing until dissolved. The 
solution was then filtered through a 0.45 pM filter and stored at -80°C.
2.2.2 Confocal microscopy o f  fixed cells
Confocal microscopy was performed using a Zeiss LSM 510 microscope using a 63 x, 
NA1.4, phase-contrast objective lens. Z-stacks were acquired using Zeiss software, 
taking an optical section every 0.2 pm from the adhesion plane to the top of the cell. 
Images were optimised by averaging 8 scans. The final stack size was approximately
146.2 pm x 146.2 pm x ~2 pm; 1024 x 1024 x 11 pixels.
2.2.3 Analysis o f  actin arrangements in phalloidin-stained cells
2.2.3.1 Acquisition
Images of the sarcoma cells were randomly selected. An area of the coverslip 
approximately 2 mm x 2 mm was scanned at low magnification and the images placed 
together in a tile scan, which gave a low magnification image of the region. Groups of 
cells were visible but at too low a magnification to be able to tell whether or not stress 
fibres were present. This eliminated biased acquisition. Groups of cells in the tile scan 
were marked and fields acquired at x 25 magnification.
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Images of the HeLa cells were acquired in a semi-random way where groups of cells 
were found by looking at the wide-field phase contrast image, from which it was not 
possible to tell whether or not stress fibres were present.
2.2.3.2 Image analysis
Images of phalloidin-stained cells were subjected to a double-blind analysis of F-actin 
structures using Metamorph® software (Molecular Devices Corporation). 
Randomly-named images were opened in Metamorph, and each cell was inspected and 
classified to an F-actin category by manually selecting the cell with the mouse. All 
Z-sections of the image, from the adhesion plane to the top of the cell, were inspected 
for actin structures. HeLa cells were categorised as containing either “stress fibres”, 
where at least one stress fibre was observed, or “disordered actin”, where filaments but 
no stress fibres were observed, or “cortical actin”, where actin was restricted solely to 
the cell cortex. Sarcoma cells were categorized as containing either “stress fibres” or 
“no stress fibres”. Using a dynamic data exchange all cell assignments made were 
directed logged into an Excel spreadsheet (Microsoft). The correct descriptions of the 
images were then revealed and the percentage of control and treated cells falling into 
each actin category was calculated.
2.3 Cell motility assays
2.3.1 Dunn chemotaxis assay
Chemotaxis was assessed using the Dunn chemotaxis chamber (Zicha et al., 1991). The 
assembly of the Dunn chemotaxis chamber is summarised in Figure 2.1, and described 
in detail here. 18 mm x 18 mm, 170 pm thick glass coverslips were prepared for use in 
the Dunn chemotaxis chamber by immersion in a mixture of 60% HC1 and 40% ethanol 
for at least 20 minutes, followed by immersion in distilled water for 20 minutes, and a 
final immersion in 70% ethanol for sterilisation. Coverslips were dried with 
compressed air filtered through a 0.45 pM filter (Millipore). Cells were seeded on 
coverslips three days before the experiment, and grown to 5-10% confluence. They 
were then serum-starved by incubation for five hours in medium containing 0.5% BS.
A sterile Dunn chamber was placed on a flat clean surface and 200 pi phenol red-free 
starvation medium was placed into the wells of the chamber. The coverslip of cells was 
picked up with fine sterile forceps and inverted gently onto the pool of medium flooding 
the wells. Using a tissue, the coverslip was positioned so that there was a gap of 
approximately 1 mm on one side of the coverslip allowing access to the outer well. The
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other three sides of the coverslip were dried by applying gentle pressure with a tissue, 
and sealed with a molten wax mixture. The wax was comprised of equal volumes of 
bleached white beeswax (Acros Organics), paraffin wax (Fisher Scientific) and soft 
yellow paraffin (Fisher Scientific), mixed and heated to 60°C. The outer well was 
drained of starvation medium by drawing the liquid out of the chamber with a tissue. 
The central well of the chamber still contained starvation medium. The outer well was 
then washed once with fresh medium to remove debris or factors released by cells 
crushed during the assembly of the chamber. Then starvation medium supplemented 
with 60 ng/ml human PDGF-p (Peprotech EC) and 80 ng/ml human IGF-I (Peprotech 
EC) was added to the outer well. The open side of the chamber was dried and sealed 
with the wax mixture. The assembled Dunn chambers were rinsed gently with distilled 
water and dried with compressed air to remove debris and crystals from the coverslip.
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Figure 2.1: Assembly of the Dunn chemotaxis chamber.
The Dunn chemotaxis chamber is a modified bacteriological counting chamber with two 
concentric cells separated by an annular bridge, the top of which is 0.02 pm lower than the rest 
of the slide.
(A) The wells are  flooded with 
approximately 200 pi starvation 
medium
(B) A coverglass with cells is 
inverted onto the medium, 
covering both wells, leaving a 
filling gap of about 1 mm on one 
side.
(C) The other three sides of the 
cham ber are  dried, and sealed  
with wax.
(D) The outer well is drained 
and filled with medium 
containing chem oattractant. 
Finally the open side of the 
cham ber is dried, and sealed  
with wax.
(A) The wells are flooded with approximately 200 pi starvation medium and (B) a coverslip with 
cells is inverted onto the medium and positioned so that it covers both wells, leaving a filling 
gap of about 1 mm on one side. (C) The three edges of the coverglass without the filling gap 
are dried and sealed with wax. (D) The medium is removed from the outer well; the starvation 
medium remains in the inner well since it has been sealed in by the coverglass. The outer well 
is then rinsed with starvation medium to remove any cell debris, and refilled with medium 
containing chemoattractant. Finally the open side of the chamber is dried and sealed with 
wax.
Within 30 minutes a concentration gradient develops at the bridge region, due to the presence 
of growth factor-supplemented medium on one side of the bridge and starvation medium on 
the other. Cells overlying the bridge region are exposed to this concentration gradient and will 
migrate the other well, if they are chemotactic to the growth factors therein. All media for 
these experiments were used at 37°C, and equilibrated to 5% CO2 in the incubator.
Annular Inner well
bridge / / ^
d iv id in g --------------U f  (
inner and J)outer wells
-------  • uu ter wen
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2.3.2 Random walk assay
When investigating general cell motility rather than chemotaxis, the random walk 
chamber (Figure 2.2) was used. The random walk chamber is composed of a 
microscope slide out of which a 10 mm diameter circle has been cut. A coverslip 
(thickness -230 pm) was glued to the slide. This results in a slide containing a 10 mm 
diameter well that can be filled with medium. Coverslips of cells can be inverted over 
the well and fixed into position using wax to create a hermetically sealed environment. 
Cells were grown to approximately 5-10% confluence on square 18 mm, 170 pm thick 
coverslips (prepared as described for the Dunn chamber) for three days. They were 
starved by five hour incubation in medium containing 0.5% BS. A sterile random walk 
chamber was placed on a flat clean surface and 200 pi phenol red-free medium, 
containing 10% BS, was placed into the well. The coverslip of cells was picked up with 
sterile fine forceps and inverted gently onto the well. Each side of the coverslip was 
dried by applying gentle pressure with a tissue, and then sealed with the molten wax 
mixture described before. Random walk chambers were rinsed gently with distilled 
water and dried with compressed air to remove debris and crystals from the coverslip.
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Figure 2.2: Assembly of the random walk chamber.
The random walk chamber Is comprised of a microscope slide with a 10 mm 
diameter hole drilled in the centre. A coverglass is glued to the slide to create a 10 
mm diameter well.
(A) The well is flooded 
with approximately 
200 pi medium.
(B) A coverglass of 
cells is inverted onto 
the well.
(C) The ed g es of the 
coverslip are dried, 
and sealed  with wax.
(A) The well is flooded with approximately 200 \il medium (warmed and gassed to 
37°C, 5% C02) and (B) a coverglass with cells is inverted over the well. (C) The 
edges of the coverglass are dried with a tissue and sealed with wax.
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2.4 Low light level digital microscopy
2.4.1 Equipment and acquisition
Movies were acquired with a lOx NA 0.3 phase contrast objective on an Axiovert 
135TV inverted microscope (Zeiss) or a 1 Ox NA 0.17 phase contrast objective on a 
Diaphot or an E1000 upright microscope (Nikon). The microscopes were equipped with 
sensitive CCD cameras (Orca ER, Hamamatsu Photonics UK Limited). A motorized 
stage (Marzhauser Wetzlar GmbH & Co) and piezo focus (Physic Instrumente) on the 
E l000 microscope, and a motorized stage (Prior Scientific Instruments Ltd.) and piezo 
focus (Physic Instrumente) on one of the 135TV inverted microscopes, allowed multiple 
fields to be acquired. The microscopes were housed in Perspex chambers developed to 
accurately maintain a temperature of 37°C. The Dunn or random walk chamber was 
placed on the microscope stage and suitable fields found. For motility studies, a suitable 
field contained relatively sparsely seeded cells, distant from any cells crushed during the 
assembly of the chamber. AQM software (Kinetic Imaging) was used to collect images 
every 5 minutes, of either phase contrast only, or sequential phase contrast and GFP/Cy3 
images. A total of 200 time-points were collected resulting in films that were 16.6 hours 
in duration.
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2.4.2 Evaluation offilms of migrating cells
Figure 2.3 summarises the method used to assess cell motility. Films were reviewed in 
Motion Analysis software (Kinetic Imaging) and cell trajectories were produced by 
interactive tracking of cell translocations. The speed and chemotaxis of the cells were 
evaluated using an algorithm (Zicha and Dunn, 1995) implemented in Mathematica® 
(Wolfram Research, Inc.). In this algorithm, cell trajectories were aligned to a common 
origin. For each film, the direction of the increasing concentration of the growth factors 
in the gradient was determined according to the position of the outer well in the images. 
Trajectories from individual films were normalized by rotation using the direction angle. 
In multiple field acquisition it was impossible to position the outer well at the top of the 
computer screen for each field. After rotation, the angle of the direction of cell 
movement was calculated. Calculation of the angle depended upon the cell migrating a 
distance of at least 70 pm. The distributions of the tracks were represented by circular 
histograms, where the red arrow indicates the mean direction of the cell migration, and 
the green wedge indicates its 95% confidence interval. The statistical comparison 
between chemotactic responses of the cell populations was based on ANOVA applied to 
normalised displacement in the direction of the gradient. Occasionally, due to slight 
differences in cell culture conditions, the speed of the control cells varied from one 
culture to another. In such cases, the speeds were normalized using the average speed of 
uninjected cells from the same field. The Mathematica® Notebook used for the 
processing of cell tracks can be found in Appendix 1.
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Figure 2.3: The evaluation of cell motility.
To assess cell motility, cells were filmed overnight on a low light level digital microscope. Cell translocations 
were tracked using Motion Analysis software (Kinetic Imaging), and their trajectories analysed using an 
algorithm developed in Mathematica to evaluate cell speed and the distribution o f the directions of cell 
trajectories.
(A) A field ofA297 cells in the Dunn Chamber. Here, the outer well (containing growth factors) is visible a t the 
top of the field and the inner well (containing starvation medium) is a t the bottom.
(B) Cell trajectories, where the green dot represents the position o f the cell a t the first frame of the film and the 
red dot represents its position a t the end o f the film.
(C) Data are imported into Mathematica and the origins o f the trajectories are aligned.
(D) The data are processed in Mathematica and the distributions represented by circular histograms, where 
the red arrow indicates the mean direction o f cell migration, and the green wedge indicates its 95% 
confidence interval.
61
2.5 Gene expression analysis
2.5.1 Overview o f  Affymetrix GeneChip® system
Microarrays measure the expression of thousands of genes in parallel. In this study, the 
microarray experiments were performed using Affymetrix Rat 230A GeneChips®. The 
GeneChip® contains an array of oligonucleotide probes bound to the glass of the chip. 
Each probe is designed to hybridise to a transcribed sequence of the rat genome. The 
Rat 230A GeneChip® is about 1.3 cm2 and contains approximately 300,000 
oligonucleotide probes, which together measure the expression of approximately 15,000 
transcribed sequences. Briefly, RNA is extracted from the sample, fragmented, labelled 
with biotin and allowed to hybridise to the microarray overnight. This RNA hybridises 
to its complementary probes sequences on the GeneChip® array. The biotin reacts with 
streptavidin-phycoerythrin, use to stain the arrays, and the amount of fluorescence, 
which corresponds to the amount of hybridisation, is recorded by a camera. The extent 
of hybridisation is an indication of the amount of transcript in the sample.
2.5.2 Experimental design
The first microarray experiment was two dimensional. I analysed (1) gene expression 
between a metastatic and a non-metastatic sarcoma cell population and (2) their gene 
expression responses to the chemotactic growth factors PDGF and IGF. The project 
was then extended to include two more cell populations, plus the primary tumours that 
developed when the cells were subcutaneously implanted into rats. Three biological 
replicates were performed for each condition throughout.
2.5.3 Sample collection
2.5.3.1 Cultured cells
Sub-confluent, early passage cells were harvested by detachment with trypsin after 
being made quiescent in medium containing reduced (0.5%) serum for five hours, 
followed by 1) no further treatment, 2) stimulation for 30 minutes with 30 ng/ml PDGF 
and 40 ng/ml IGF, or 3) stimulation for 180 minutes with 30 ng/ml PDGF and 40 ng/ml 
IGF. Samples were checked for mycoplasma by agar colony growth, and found to be 
free of contamination.
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2.5.3.2 Tumours
One million cells were injected subcutaneously into rats and primary tumoursbegan to 
develop. The animals were sacrificed 4-6 weeks later, and 1 cm3 of primary tumour 
was excised and stored at -20°C in RNAlater (Qiagen).
2.5.4 Preparation ofRNase-free reagents
2.5.4.1 DEPC water
Diethylpyrocarbonate (DEPC) treatment inactivates RNases. DEPC was added to 
distilled water at 0.1%. The bottles were shaken thoroughly, incubated overnight at 
room temperature, and then autoclaved.
2.5.4.2 Preparation of RNase-free reagents and the RNase-free environment
All reagents, for example buffers, were treated with DEPC after being prepared, or 
made up with DEPC-treated water. Equipment, instruments and surfaces used in the 
preparation of RNA were cleaned with 0.3% hydrogen peroxide or RNase Zap Wipes 
(Ambion), followed by rinsing in DEPC-treated water.
2.5.5 RNA extraction
The cultured cells were homogenised in Qiashredder columns. Tumour samples were 
tough and accordingly received a different homogenization; after being removed from 
the RNA stabilization solution and weighed, they were placed in 750 pi RLT lysis 
buffer (provided with the Qiagen kit) per 100 mg of tissue. They were homogenized for 
40 seconds with a rotor-stator homogeniser, sonicated for 20 seconds, and the resulting 
lysates then cleared of cell debris by centrifugation. Total RNA was extracted with the 
RNeasy Mini-Kit (Qiagen) according to the manufacturer’s instructions. The 
concentration and purity of the RNA was determined using readings taken at 260 nm 
and 280 nm on a Nanodrop spectrophotometer.
2.5.6 RNA agarose gel electrophoresis
Before the RNA was further manipulated, its quality was verified by visualization of 
28S and 18S ribosomal RNA bands by gel electrophoresis. 1 pg RNA was loaded on a 
1% TBE agarose gel supplemented with 1 pg/ml ethidium bromide. The gel was run at 
60 volts for one hour, and the DNA visualized using a UV transilluminator. When 
clear, undegraded bands of 28S and 18S ribosomal RNA were seen at an intensity ratio 
of approximately 2:1, the RNA was considered to be of high quality. Smeared bands
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indicated that the RNA had been degraded at some stage, and was not acceptable for use 
in further experiments.
2.5.7 Preparation o f  biotin-labelled, fragmented cRNA
The extracted RNA was reverse transcribed to obtain cDNA. This was then subjected 
to in vitro transcription to obtain cRNA, which was labelled with biotin and fragmented 
ready for hybridisation to the Affymetrix GeneChip® array.
2.5.7.1 First strand synthesis
10 pg of total RNA and 5 pM T7-01igo(dT)24 primer (Affymetrix) were denatured by 
incubation at 65°C for 10 minutes, and then allowed to anneal by cooling on ice for 5 
minutes. The RNA was then reverse-transcribed into cDNA using Superscript II 
Reverse Transcriptase (Invitrogen) and incubated at 42°C for an hour.
2.5.7.2 Second strand synthesis
The first-strand reaction was incubated at 16°C for 2 hours with 1 mM dNTPs, Second 
Strand Buffer, 10 units E.coli DNA Ligase, 40 units DNA Polymerase I and 2 units 
E.coli RNase H (all supplied by Invitrogen). Following this, 10 units T4 DNA 
polymerase were added, and after a further 5 minutes at 16°C, the reaction was 
terminated by the addition of 10 pi 0.5M EDTA. The cDNA was cleaned-up using the 
GeneChip® Sample Cleanup Module (Affymetrix) according to the manufacturer’s 
instructions.
2.5.7.3 Synthesis o f fragmented cRNA
In vitro transcription (IVT) was performed using the Enzo BioArray High Yield 
Transcript Labelling Kit (Enzo Diagnostics) according to the manufacturer’s 
instructions. The cDNA was incubated at 37°C for 5 hours with feaction buffer, biotin- 
labelled ribonucleotides, DTT, RNase inhibitor mix and T7 RNA Polymerase, resulting 
in an approximately 100-fold amplification of RNA. Unincorporated dNTP were 
removed with the GeneChip® Sample Cleanup Module (Affymetrix) according to the 
manufacturer’s instructions. The concentration and purity of the cRNA was determined 
using readings taken at 260nm and 280nm on a Nanodrop Spectrophotometer. 25 pg 
cRNA was incubated in fragmentation buffer (Affymetrix) at 94°C for 35 minutes.
2.5.7.4 Confirmation of sample quality
The purity of the cRNA was determined by the ratio of absorbance at 260/280 nm. 
Samples with 260/280 ratios between 1.9 and 2.1 were acceptable. A 1.2%
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formaldehyde agarose gel was run to check the quality of the starting total RNA, cRNA 
and fragmented cRNA of all the samples, alongside a 0.24-9.5 Kb RNA ladder 
(Invitrogen) and RNA Century Size Markers (Ambion).
2.5.8 Hybridisation and scanning
Hybridisation of cRNA targets to the array and scanning were carried out at the 
Paterson Institute in Manchester, UK. Briefly, the cRNA was processed using an 
Affymetrix GeneChip® Instrument System according to the manufacturer’s 
instructions. Briefly, spike controls were added to 20 pg fragmented cRNA and then 
allowed to hybridize to the GeneChip® arrays overnight. Arrays were then washed and 
stained with streptavidin-phycoerythrin, and scanned on an Affymetrix GeneChip® 
scanner to generate an image of the entire GeneChip® array. Each spot (containing a 
probe set) on the GeneChip® array is 20 pm2 and was scanned at a resolution of 3 pm, 
giving an average of 49 pixels per spot. After scanning, array images were assessed by 
eye to check that the scanner was aligned correctly and to check that there were no 
significant bubbles or scratches on the chip surface.
2.6 Analysis o f  microarray data
Data were analysed with Affymetrix Microarray Suite (MAS 5.0) and with an algorithm 
developed in Mathematica® (shown in Appendix 2).
2.6.1 Analysis o f  microarray images in MAS 5.0
Analysis of microarray images was carried out at the Paterson Institute. The raw 
scanned images were analysed with Affymetrix Microarray Suite (MAS 5.0) software. 
Individual features on the GeneChip® were identified and a grid was overlayed, to 
separate each spot from its neighbours. The average intensity of each spot was 
calculated using the pixels at the centre of each grid-square and not the pixels at the 
outer edge. The actual signal intensity was calculated from the difference in brightness 
between the PM and MM probes in each probe set (see Section 1.4.2.3 for a detailed 
explanation of the PM/MM probe design). Once signal intensity had been calculated, 
the transcript was assigned as absent, marginal or present.
2.6.1.1 Spike controls and housekeeping gene controls
The array included a set of control probes to facilitate normalization and scaling of the 
experiments. Control probe hybrisations were assessed kindly by Yvonne Hey at the 
Paterson Institute. 375’ ratios for GAPDH and beta-actin were found to be within
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acceptable limits (from 0.97 to 1.72), and spike controls were present on all chips, at the 
expected intensities. When scaled to a target intensity of 100 (using Affymetrix MAS 
5.0 array analysis software), scaling factors for all arrays were within acceptable limits 
(0.19-0.405), as were background, Q values and mean intensities.
2.6.2 Data analysis in Mathematica®
Signal intensity data were subjected to a number of processes leading to the production 
of lists of candidate genes. The algorithm is displayed in full in Appendix 2 and is 
described briefly here.
2.6.2.1 Exclusion o f unexpressed genes from the data analysis
Signal intensity data were imported into a Mathematica® Notebook developed in the 
laboratory (Appendix 2). Transcripts which had been scored as absent by MAS 5.0 on 
all three replicates were excluded from the gene expression analysis.
2.6.2.2 Normalisation
Normalisation was needed to correct for systematic differences in intensity between 
arrays that did not represent true biological variation. We used the median intensity of 
each array to normalise the arrays to each other.
2.6.2.3 Calculation of expression ratios
Expression ratios (ER) were used to consider the difference in gene expression between 
two samples. For example, ER > 2 means that expression of a gene is twice as high in 
one sample compared to another. The mean expression value of the three replicates was 
used in the calculation of ER. In the first experiment, we determined the ER between 
the different cell populations, and between the responses of the populations to 
PDGF/1GF. In the extended microarray experiment, we also looked at the ER between 
the cell populations and their corresponding primary tumours.
2.6.2.4 Calculation of statistical significance
To determine the statistical significance of each ER, the t test was applied to the 
expression ratio data (not the raw intensity data) using the formula
,  Xi  -  x 2
t  =  — — ~
SX \ - X t
where s is the standard deviation, the numerators are the sum of the means of each 
group and the denominator is the standard error of the difference between the two 
means. The resulting t value was used to find the P-value from a table of values.
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Because of the large number of samples being tested, the P-value was corrected with the 
Benjamini-Hochberg algorithm (Benjamini and Hochberg, 1995) to avoid an 
unacceptably high number of false positive calls.
2.6.2.5 Generation o f candidate gene list from the initial microarray experiment 
Here we made two comparisons, (1) between the K2 and A297 cell populations and 
(2) between starved cells and cells treated with the growth factors. Different ER and 
significance criteria were applied to each dimension. Changes in gene expression 
between the populations were defined by ER > 1.6 (P < 0.05). Changes in gene 
expression in the growth factor response were defined by the less stringent parameters 
of ER > 1.3 (P < 0.1). Cluster analysis was performed to group genes according to 
shared expression patterns. The gene expression ratios were represented by a 
naturalistic colour scale indicating the size of the ER. In this colour scale, black 
represented the lowest values, and increasing ER values are in cyan followed by blue. 
ER = 1 (no change) are represented by green, and expression ratios higher than 1 (where 
the gene was overexpressed in the A297) were represented by yellow, orange and then 
red. The statistical significance is indicated as follows; *P < 0.1, **P < 0.05,
*** p < 0.01. Larger expression ratios were not believed to necessarily indicate a more
significant result; hence the inclusion of statistical significance when compiling the 
candidate gene lists. Genes were selected for further study on the basis of their 
expression pattern, statistical significance, and any information available in the 
literature.
2.6.2.6 Generation of candidate gene list from the extended microarray experiment 
Expression ratios of the response to growth factors were calculated and the t-test 
applied. It became clear that there were no significant differences in gene expression in 
response to PDGF/IGF. Therefore, the three time-points were averaged and used to 
calculate the ER between the four cell populations, with ANOVA applied to calculate 
the statistical significance with the Benjamini-Hochberg algorithm. ER between 
metastatic and non-metastatic cells were then calculated by dividing the value for the 
T15, A297 and A311 populations by the value for the non-metastatic, K2 cell 
population. The criteria used for the final selection of candidate genes were ER > 2.5 
(P < 0.05), with no significant difference in gene expression pattern between the 
cultured cells and the primary tumours. This generated a list of twenty-three genes. To 
produce a list of eighty differentially expressed genes, less stringent parameters, ER > 2 
(P < 0.05) were applied to the data. To display the patterns of gene expression,
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normalised absolute gene expression values were calculated, logged, and plotted to 
show the cell and tumour data for the same gene in one graph.
2.7 RT-PCR
2.7.1 Preparation o f  cDNA by reverse transcription
RNA was extracted from the cells of interest as described for the microarray. 10 pg of 
total RNA and 5 pM oligo(dT) primer (Affymetrix) were denatured by incubation at 
65°C for 10 minutes, and then allowed to anneal by cooling on ice for 5 minutes. The 
RNA was then reverse-transcribed into cDNA using Superscript II Reverse 
Transcriptase (Invitrogen) and incubated at 42°C for 60 minutes. The cDNA was then 
treated with 2 units of RNase H (Ambion) for 20 minutes at 37°C.
2.7.2 PCR
Fragments of each gene of interest were amplified from the template cDNA by PCR 
using Taq polymerase (produced by Cancer Research UK) or Qiagen’s Taq polymerase. 
10% of the reverse-transcription product, 1 x Taq buffer, 0.2 mM dNTPs, 20 pmol 
forward primer, 20 pmol reverse primer, and 1 unit of polymerase were used in each 
reaction. PCR reactions were performed using a PTC-200 Peltier thermocycler (MJ 
Research) using the following protocol; an initial denaturation at 94°C for 2 min, 
followed by 30 cycles of 1 minute of denaturation at 94°C, 1 minute of annealing at 
60°C, primer extension at 72°C for 1 minute per kilobase of product. A final extension 
step was performed at 72°C for 5 minutes to complete any unfinished polymerisation. 
PCR products were resolved on a 1% TBE agarose gel supplemented with ethidium 
bromide, and visualized by UV transillumination.
2.7.3 R T-PCR primers
2.7.3.1 Primers usedfor the validation of microarray data
The sequences of the primers used for RT-PCR for validation of microarray data are as 
follows, alpha actinin-1 forward 5’- ACCAACTCAGCCACCTGC-3’, 
alpha actinin-1 reverse 5’- CTCGGCTTGGTCAGGTGG-3’;
Bmp2 forward 5’- TCAAGCCAAACACAAACAGCC-3’,
Bmp2 reverse 5’- ACGTCTGAACAATGGCATGA-3’; 
crmp4 forward 5’- GTGAGTGGAAGGGGTGTTGT-3’, 
crmp4 reverse 5’- GGTTGGGTCTTGGCATTTTA-3’;
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GAPDH forward 5’- TGCTGAGTATGTCGTGGAGTCT-3’, 
GAPDHreverse 5’- CCCTGTTGCTGTAGCCATATTC-3’; 
mmp2 forward 5’- CAAGCCCAAGTGGGACAAGAACC-3’, 
mmp2 reverse 5’- CAGGTCCCAATGTCGGTGTG-3 ’; 
mmp3 forward 5’- ATGAAAGGGCTCCCAGTCC -3’, 
mmp3 reverse 5’- AAACTCCAACTGTGAAGATCCGC -3’; 
mtap6 forward 5’- ATAAACTGGCTGAGGCGAAA-3’, 
mtap6 5’- ACT ACAGGGGCTTGGTCCTT-3 ’; 
robo forward 5’- AGGGGAGAGAAGCTCTGGAC-3’, 
robo reverse 5’- TTGACGTTGGGAAAGTAGGC-3’; 
tpm forward 5’- AGGAAGCCTCACGAAAACAA-3’, 
tpm reverse 5’- TCCTCTCGCAGTGCTACTCA-3’;
Adamtsl forward 5’-GATGGTTTACAGGCTGCCTTC-3’, 
Adamtsl reverse 5 ’ -TTGTTTGGCAC ACCAGTAAGC-3 ’; 
Ankyrin 3 forward 5’- CCGACTCCCTCAGACACTACA-3’, 
Ankyrin reverse 5’- GTGTTCCTTCCAGGTCTCTCC-3’;
Bk forward 5’- GACCTGATCGCCATAAGGAAG-3’,
Bk reverse 5 ’-GGTTTTGAAGTGGGGAATCAA-3 ’;
Cask forward 5 ’-ACCATTCGGAAAATCCATGAG-3 
Cask reverse 5’- CTGACACAAGGCCGATAACAA-3 ’; 
Cspg4 forward 5’- ACCATCCAGAGAGCCACAGTA-3’, 
Cspg4 reverse 5’- AGCAGGACGTTAGTGAGGACA-3 ’; 
Epb41l3 forward 5’- CATCCAGCAGCAAACTCTCAC-3 
Epb41l3 reverse 5’- GTCACGAAGGAACAGGGTAGG-3’; 
GAPDH forward 5’- TGCTGAGTATGTCGTGGAGTCT-3’, 
GAPDH reverse 5’- CCCTGTTGCTGTAGCCATATTC-3 ’; 
Greml forward 5’- GATGACTGAGAGCGTTGTTCG-3’, 
Greml reverse 5’- GACCCAGTCACCTTTCTCTGG-3’;
Plk2 forward 5’- AACTTGGCCAATGCTCTGTTT-3’,
Plk2 reverse 5’- AAGAGCATGTTCAGGGCGTAT-3 ’;
Ril forward 5’- AGCAGGCCTGAGAACAAGAAC-3’,
Ril reverse 5’- TAGCGGAAGGATCCAGACTGT-3 ’;
Trax forward 5’- AACGCTTGCTATGCCCTT AAA-3 ’,
Trax reverse 5’-CCTTCCACCCAAAATGTCACT-3\
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2.7.3.2 Primers usedfor the detection of epb41l3 isoforms 
The sequences of the primers used for the detection of isoforms of epb41l3 in the 
sarcoma cells are, forward 5’-ATGTCTCGCAGCTTGGATGGA-3’, and reverse 5’- 
GCTTCTCCCCAGAAGATTGTTTAGTCT-3 ’.
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2.8 Immunoblotting
Immunoblotting (Western blotting) was performed to verify protein expression.
2.8.1 Preparation o f  cell lysates
Subconfluent, early passage cells were detached by incubation with trypsin and 
centrifuged at 2000 rpm for 10 minutes. Supernatant was removed and the cell pellets 
were washed with PBS and lysed for 15 minutes in cold RIPA buffer (lx PBS, 1% 
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitors 
(100 pg/ml PMSF, 50 KIU aprotinin and 1 mM sodium orthovanadate). Cell lysates 
were cleared by centrifugation at 10,000 g for 10 minutes. Total protein concentration 
was measured using the Coomassie Assay (Pierce) according to the manufacturer’s 
instructions.
2.8.2 SDS-Polyacrylamide gel electrophoresis and transfer
Electrophoresis and transfer were carried out using an XCell SureLock apparatus 
(Invitrogen). Equal amounts of protein, typically 20 pg, were loaded onto a 4-12% 
Nupage Bis-Tris polyacrylamide mini-gel (Invitrogen) and electrophoresed at 125 V for 
approximately 90 minutes. Proteins were transferred onto a PVDF membrane 
(Immobilon P, Millipore) by the application o f200 V for at least 60 minutes. 
Membranes were stained briefly with Ponceau-S solution to verify that the protein 
transfer had been successful.
2.8.3 Visualisation o f  proteins
Membranes were blocked overnight in 5% non-fat dried milk (Marvel). They were then 
incubated with primary antibody for 1 hour. Antibodies to a-Actinin (Santa Cruz), 
CASK (Chemicon International) and 4. IB (kindly provided by Narla Mohandas, New 
York Blood Center) were used at a dilution of 1:2000. Antibodies to actin and GAPDH 
(both from Abeam) were used at a dilution of 1:10,000). Primary antibodies were 
washed three times in TBST over 30 minutes. Blots were then incubated with 
HRP-conjugated secondary antibody (all from Amersham Biosciences) diluted 1:5000 
for 30 minutes followed by TBST washes as before. Protein bands were visualised 
using an Enhanced Chemi-Luminescence (ECL) system (Amersham Biosciences).
Blots were stripped with 5% acetic acid for 5 minutes, and re-probed with mouse anti- 
GAPDH or actin (both Abeam) to confirm that equal amounts of protein had been
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loaded. Blots were stripped up to three times for re-probing for other proteins of 
interest, or for optimisation of a new antibody.
2.9 cDNA constructs
CFP-actin and YFP-actin constructs were made by James Monypenny (Dunn et al., 
2002). GFP-a-Actinin was a gift from Marina Guvakova (University of Pennsylvania). 
GFP-V14 Rho was a gift from Ferran Valderrama (UCL). All other constructs were 
produced as follows.
2.9.1 Candidate gene cloning
2.9.1.1 Strategy
The coding sequence (CDS) of each candidate gene was obtained from Genbank 
(http://www.ncbi.nlm.nih.gov/Genbank). Primers were designed to anneal to the ends 
of the CDS and to incorporate restriction sites to be used for directional cloning into a 
pEGFP vector (Clontech). C-terminally tagged GFP fusions of BK and 4. IB, and N- 
terminally tagged GFP fusions of CASK, 4. IB and RIL were generated.
2.9.1.2 Generation o f template cDNA
RNA was extracted from the cells of interest as described for the microarray (Section 
2.5.7.1). 10 pg of total RNA and 5 pM oligo(dT) primer (Affymetrix) were denatured 
by incubation at 65°C for 10 minutes, and then allowed to anneal by cooling on ice for 5 
minutes. The RNA was then reverse-transcribed into cDNA using Superscript II 
Reverse Transcriptase (Invitrogen) and incubated at 42°C for 60 minutes. The cDNA 
was then treated with 2 units of RNase H (Ambion) for 20 minutes at 37°C. The cDNA 
was then cleaned-up using a Qiaquick PCR Purification Spin Column (Qiagen) 
according to the manufacturer’s instructions, and eluted in 10 mM TrisCl, pH 8.5. The 
amount and purity of the cDNA were determined using readings taken at 260 nm and 
280 nm on a Nanodrop spectrophotometer.
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2.9.1.3 Primers
The sequences of the primers used for cloning into pEGFP-based vectors are shown 
below. The base pairs complementary to the mRNA sequence are shown in blue, and 
the enzyme recognition sequences are shown in red.
Primers used for C-terminal tagging with GFP 
BK forward including Xho I  site,
5’-AATTAACTCGAGGCAGCAATGGCGTACATCCAGTTGGAACCACTGAACG-3’; 
BK reverse including Kpn I  site,
5’-ATTAAGGTACCATGCAGCATCAGGTCACCTCCAGCGAGGCCGGAGACAC-3’.
Primers used for N-terminal tagging with GFP 
CASK forward including Xho I  site,
5-A ATTA ACTCG AGGG AGC A ATGGCCG ACG ACG ACGTGCTGTTCG AGG AT-3 ’; 
CASK reverse including Kpn I  site,
5’-TTAATTGGTACCTGCTGCCTAATAGACCCAGGAGACCGGGACCCACTG-3’;
4.1B forward including Hind III site,
5’-TAAATCAAGCTTGCAGCAATGACAACCGAATCAGGATCAGACTCAGAA-3’;
4. IB reverse including Kpn I  site,
5’-TTAATTGGTACCTGCTGCTCAATCCTCTCCATCTTCTGGTGTGATTTC-3’;
RIL forward including Hind III site,
5’-ATATATAAGCTTGCAGCAATGACCCACGCGGTGACCCTGCGCGGCCCT-3’;
RIL forward including Kpn /  site,
5’-GTGACTGGTACCTGCTGCTCAGACAAGTTCCACCTTGGCATTGGGATA-3’.
2.9.1.4 Polymerase Chain Reaction
For amplification of cDNA, KOD Hot Start DNA Polymerase (Novagen) was used. 
The components of each PCR reaction were as follows; 1 x PCR Buffer for KOD Hot 
Start DNA Polymerase, 1 mM MgS04, 0.2 mM dNTPs, 100 ng cDNA, 0.6 pM primer 
pair and 10% DMSO. Thermal cycling was performed on a PTC-200 Peltier 
thermocycler (MJ Research) with the following conditions; 2 minutes denaturation at 
94°C, followed by 30 cycles of 15 seconds at 94°C, 30 seconds at 65°C, 2 minutes at 
72°C, and a final extension step at 72°C for 5 minutes. The PCR product was 
electrophoresed on an agarose gel alongside a 1 kb DNA ladder (Invitrogen) and the 
correctly-sized band excised and purified using a Qiaquick PCR Purification Spin 
Column as before.
73
2.9.1.5 Restriction digestion and ligation of cDNA
The cDNA was double-digested overnight at 37°C, with the restriction enzymes whose 
recognition sequences had been included in the primers. The reaction was terminated 
by incubation at 75°C for 10 minutes and cleaned-up using a Qiaquick PCR Purification 
Spin Column. The digested CASK, RIL and 4.IB cDNAs were ligated into a similarly- 
cut pEGFP-C3 vector (Clontech) and BK cDNA was ligated into similarly-cut pEGFP- 
N1 vector (Clontech) overnight at 16°C using T4 DNA Ligase (NEB), with a 
vectorrinsert molar ratio of 1:4.
2.9.1.6 Transformation of E. coli and plasmid preparation
An aliquot of One Shot TOP 10 Chemically Competent E.coli (Invitrogen) was 
transformed with the ligation reaction according to the manufacturer’s instructions and 
plated onto LB Agar plates supplemented with 50 pg/ml Kanamycin A. Plates were 
incubated overnight at 37°C. The following morning, colonies were picked and 
inoculated into 3 ml LB supplemented with 50 pg/ml Kanamycin A, and incubated with 
shaking at 37°C for at least six hours. The samples were then centrifuged at 5000 rpm 
for 10 minutes and plasmid DNA was prepared from the resulting bacterial pellets using 
Qiagen’s Miniprep system according to the manufacturer’s instructions. Miniprepping 
was carried out by staff at the Cancer Research UK London Research Institute 
Equipment Park. Once the sequence of the clone had been verified, large plasmid 
stocks were purified using the QIAfilter Plasmid Maxi Kit (Qiagen) according to the 
manufacturer’s instructions.
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2.9.1.7 DNA sequencing
The sequences of the inserts were checked by performing PCR-cycle sequencing using 
the BigDye Terminator v3.1 system (ABI) and an ABI 377 automated sequencer (PE 
Applied Biosystems). Sequencing was carried out by staff at the Cancer Research UK 
London Research Institute Equipment Park. Typically the insert was sequenced with 
forward and reverse primers flanking the multiple cloning site of the GFP vector, as 
well as with internal, gene specific primers for reading sequences further away from the 
ends of the insert. Primers used for the sequencing of cDNA fragments inserted into the 
multiple cloning site of pEGFP-C3 were designed by James Monypenny (2003) and are; 
forward, 5’-CGGCATGGACGAGC-3’, and reverse, 5’-GCTGCCATGGCGCCC-3\ 
Sequences of the gene specific primers used to read sequences far from the ends of the 
insert are, GFP-BK (downstream of base 771), 5 ’-GGAACGCTACACCTTCGAGA-3 ’; 
GFP-CASK (downstream of base 1125), 5 ’-CCAGGATCAGCATCTTCACA-3 ’; 
GFP-CASK (downstream of base 1500), 5’-TGAGCCAATGGGAATCACT-3 ’; 
GFP-4.1B (downstream of base 800), 5 ’ -AACC AC ACGAAAGAACTGGA-3 ’; 
GFP-4.1B (downstream of base 724), 5 ’ -GGGGACTATGATCCT-3 ’; GFP-4.1B 
(downstream of base 1327), 5 ’-ATGTCTCGCAGCTTGGATGGA-3 ’.
2.9.2 Subcloning
2.9.2.1 Generation of untagged cDNAs
Where GFP-fusion proteins were not required, the GFP gene was excised from the 
construct by digestion with Agel and BsrGI. The digested vector was then treated with 
Mung Bean Exonuclease (NEB) for 30 minutes at 30°C to remove 5’ overhangs. The 
product was cleaned-up and ligated overnight at 16°C, transformed into E.coli and mini- 
prepped as usual. Plasmids were analysed by agarose gel electrophoresis to check that 
the GFP had been removed, and then resequenced to ensure that the cDNA of interest 
was still present and in the correct reading frame.
2.9.2.2 Generation of C-terminally GFP-tagged 4.IB
A C-terminally tagged 4. IB construct was generated by amplifying 4. IB from the 
original N-terminally tagged construct (see Section 2.9.1) by PCR using the following 
primers, 4. IB forward including Hind III site,
5 ’ - AAATC A A G  CTTGGAGGAATG AC AACCG A ATCAGG ATC AG ACTC AG AA-3 ’;
4. IB reverse including Kpn I  site,
5 ’-TTAATTGGTACCAATCCTCGTCCATCCTCTCCATCTTCTGGTGTGATTTC-3 ’.
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The DNA was then digested with Hindlll and Kpnl and ligated into a similarly-cut 
pAcGFP-Nl vector.
2.10Sequence analysis
2.10.1 DNA sequence analysis
In the primer design process, DNA sequences were manipulated using the Sequence 
Manipulation Site (http://www.bioinformatics.org/sms/). Sequence trace data obtained 
by BigDye Terminator PCR-cycle sequencing were viewed with FinchTV (Geospiza, 
Inc). DNA sequences were aligned using the Clustal W program (Chenna et al., 2003). 
DNA sequences were translated into protein sequences using the Sequence 
Manipulation Site.
2.10.2Protein sequence analysis
Protein sequences of the epb4H3 splice variants were superficially investigated by 
searching for protein domains with Pfam (Bateman et al., 2004). Predicted domains 
with E-values < 0.05 were accepted.
2.11RNA interference
RNA interference was achieved using siRNA oligos (Ambion) introduced to the cells 
by lipofection or microinjection, depending on the requirements of the particular 
experiment. Annealed purified siRNA oligos were from Ambion, Inc. and were 
resuspended according to their protocol. The siRNA sense sequences are as follows, 
Rat actnl, GGAUGGUCUUGGUUUCUGU;
Rat cask, GCGGGAAGCCAGUAUCUGU;
Rat epb4H3, GCAUGCAGUGCAAAGUGAC;
Human epb4H3 oligo 1, GCAUCACUAAACCGAUAAU;
Human epb41l3 oligo 2, GCUCGAAUAUCAGCAAUUA;
Human epb4U3 oligo 3, GCGAUUACAUUAGUGAGUU.
The control was Silencer Negative Control #1 siRNA (sequence not made available by 
Ambion, Inc.). Oligos were labelled with Cy3 using Silencer siRNA Labelling Kit 
(Ambion, Inc.) for studies where it was important to be certain of exactly which cells 
contained siRNA. The efficacy of the siRNA at reducing expression of the target 
protein after 48 hours was first checked by immunoblotting, and sometimes
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immunocytochemistry. A negative control siRNA was performed in all RNAi-based 
experiments. Cells were used in experiments 48 hours after transfection.
For RNAi rescue experiments, Hela cells were transfected with rat 4.IB cDNA 48 hours 
after siRNA transfection, and the effects of the rescue assessed after 24 hours (72 hours 
after the first transfection). The persistence of RNAi after 72 hours was also checked by 
immunoblotting. RNAi rescue was achieved because the three Human epb41l3 siRNA 
oligos targeted sequences that were not present in the cDNA for rat epb4H3.
2.12 Transfection o f nucleic acids into cultured cells
2.12.1 Microinjection
Cells seeded on 22 mm x 22 mm, No. 1.5, coverslips were microinjected with an 
Eppendorf transjector and micromanipulator system mounted on a Zeiss Axiovert 35 
equipped with a tungsten lamp, a long-working distance condenser and a x20, NA 0.3, 
long-working distance objective. Microinjection needles were made from glass 
capillaries (Fisher Scientific) using an electronic microfilament puller (P-97, Sutter 
Instrument Co.). Solutions were prepared for microinjection by centrifugation at 14,000 
rpm for at least 20 minutes in order to sediment particles that would have blocked the 
microinjection needle. siRNA oligos were microinjected into the cytoplasm at a 
concentration of 2 pM, and cDNA constructs were microinjected into the nucleus at a 
concentration of 0.05 pg/pl.
2.12.2 Lipofection
Cells were seeded at 40-50% confluence the day before transfection. Chemical 
transfection was performed using Effectene (Qiagen) according to the manufacturer’s 
instructions. For cDNA transfection, 0.3 pg/ml DNA was used and for siRNA 
transfection, 100 nM siRNA oligos were used. Briefly, for one well of a 12-well plate, 
~30,000 cells were seeded and the following day the cells were washed and 800 pi fresh 
medium added. The nucleic acids were then added to 72 pi of EC buffer (provided with 
the Effectene reagent), and 2.5 pi Enhancer solution was added. The tube was then 
vortexed briefly and incubated at room temperature for 2 minutes. 6 pi of Effectene was 
then added and the tube was vortexed for 10 seconds and incubated at room temperature 
for 5 minutes. 400 pi medium was then added and mixed by pipetting up and down 
gently, and the mixture then added to the cells. The day after transfection the cells were
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washed and fresh medium was added to the cells. Expression of cDNA was usually seen 
after 12 hours, and a reduction in protein expression caused by siRNA transfection 
usually occurred after 48 hours.
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Chapter Three
Characterisation o f the rat 
sarcoma model of metastasis
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Metastasis, the dissemination of cancerous cells from a primary tumour leading to the 
growth of a secondary tumour at a distant site, is the most life-threatening aspect of 
cancer. Therefore, the mechanisms of metastasis are of great interest. My approach to 
studying the mechanisms of metastasis was based upon a rat sarcoma model composed 
of four cell lines with different abilities to metastasise.
I began by characterising the cell populations comprising the model. I focussed on cell 
motility and the cytoskeleton, since previous work (Pokoma et al., 1994) had indicated 
that other cell populations from this model have distinct F-actin cytoskeletal 
arrangements. Moreover, remodelling of the actin cytoskeleton is essential for cell 
migration and invasion, which play a role in metastasis. I also looked at the 
arrangement of F-actin by imaging fixed cells stained with rhodamine phalloidin.
Finally, I investigated cell motility, in terms of the chemotactic responses of the cells to 
a gradient of PDGF and IGF. These growth factors were chosen since a related sarcoma 
cell population was already known to chemotax towards PDGF/IGF, furthermore, 
chemotaxis towards blood vessels and organs may be important in the metastatic 
cascade.
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3.1 The actin cytoskeleton
3.1.1 Differences in F-actin organisation between the sarcoma cell 
populations
Differences in F-actin organisation between the non-metastatic and metastatic cells were 
observed after staining fixed cells with rhodamine phalloidin, and imaging cells on a 
confocal microscope. The images in Figure 3.1 show the differences in F-actin 
organisation. The non-metastatic K2 cells tend to have F-actin arranged into thick actin 
stress fibres, which sometimes traverse the cell. These cells are generally well spread.
In the metastatic T15, A297 and A311 cells, on the other hand, stress fibres occur less 
frequently. They are usually polarised and their actin is concentrated into ruffles at the 
leading edge, and elsewhere arranged into a network of disordered filaments.
The non-metastatic K2 cells have significantly more stress fibres than their metastatic 
counterparts T15, A297 and A311. Quantification of randomly-acquired fields revealed 
that 68% of K2 cells contain at least one stress fibre, in comparison to only 7-10% of 
the metastatic cells (Figure 3.2).
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Figure 3.1: F-actin organisation in the four cell populations.
These confocal images of rhodamine phalloidin-stained cells show the distinct 
arrangements of F-actin in the non-metastatic and metastatic cells. F-actin in the K2 
(non-metastatic) cells is generally arranged into stress fibres, which sometimes 
traverse the cell. The K2 cells tend to be larger than the other three populations, and 
well spread. F-actin in the metastatic cell populations (T15, A297 andA311) is 
typically arranged into ruffles at the leading edge of the cell, and elsewhere, into a 
disordered network of thin filaments. These cells spread less than the K2 cells and 
are usually polarised. Images in the right panel were taken at high magnification for 
optimal observation of F-actin structures. Images in the left panel were taken at a 
lower magnification to demonstrate that the phenotypes are representative across a 
larger field of cells. Scale bar = 20 pm.
82
Figure 3.2: Distribution of stress fibres in the four cell populations.
100
SO
-m
0 m
1 40 
1
20
IQ T1S A297 A311
This graph shows the percentage of actin stress fibre-containing cells in each population of the 
metastasis model. These data were obtained from randomly selected fields of rhodamine 
phallodin-stained cells acquired on a confocal microscope. Images were subjected to a blind 
analysis, in which a cell was classified as having stress fibres if  it contained at least one actin 
fibre that could be seen at a magnification of *25. The numbers of cells scored for K2, T15, 
A297 and A311 are 50, 55, 40 and 55 respectively. The difference in stress fibre distribution 
between the K2 and the T15, A297 andA311 is significant (x2 P < 0.005).
3.2 C ell m otility
3.2.1 Chemotactic responses of the cells to PDGF/IGF
Responses of the cells to a gradient of PDGF/IGF were tested in the Dunn chemotaxis 
chamber and are illustrated in Figure 3.3. The circular histograms present the 
distributions of the directions of the cell tracks and illustrate the differences in the 
chemotactic responses. The K2 cells are not chemotactic; in contrast, the T15, A297 
and A311 cells have strong and significantly greater chemotactic responses. These data 
represent at least five independent experiments for each cell population. Only cells that 
had migrated further than 70 pm were included in the evaluation of chemotaxis.
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Figure 3.3: Chemotactic responses of the sarcoma cell populations to PDGF/IGF.
A297
The circular histograms represent the chemotactic responses of the cell populations to a 
concentration gradient of 60 ng/ml PDGF and 80 ng/ml IGF in the Dunn chemotaxis chamber 
over 16 hours. Here, the well containing the growth factors is at the top of the histogram, and 
the growth factors diffuse towards the well containing the starvation serum, at the bottom of the 
histogram. The red arrow indicates the mean direction of cell migration, and the green wedge 
indicates its 95% confidence interval. The non-metastatic K2 cells are not chemotactic to the 
gradient of PDGF/IGF, but the metastatic T15, A297 and A311 cells have a strong chemotactic 
response. The chemotactic responses of the K2 and T15/A297/A311 cells are significantly 
different (ANOVA P < 0.05). These data represent at least five independent experiments, and 
the total numbers of cells analysed for the K2, T15, A297 and A311 cell populations are 61, 81, 
86 and 32 respectively.
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3.2.2 Differences in the speed o f migration between the cell populations
The cell populations migrate at different speeds in the Dunn chemotaxis chamber (Figure 
3.4). The speeds were calculated from the same data used for the evaluation of 
chemotaxis, without applying any restriction on the distance moved, meaning that all the 
cells recorded were included in the analysis. The non-metastatic K2 cells move at a 
mean speed of 11 pm/hour, and the T15, A297 and A311 cells move at 17, 19 and 14 
pm/hour respectively. The increased speed in the T15 and A297 cells compared to the 
K2 cells is statistically significant. However, there is no significant difference in speed 
between the non-metastatic K2 cells and the most metastatic, A311 cells, in fact, the 
A311 cells show a reduced migration compared to the T15 and A297 cells.
Figure 3.4: Speeds of in vitro migration of the sarcoma cell populations.
Cells were exposed to a concentration gradient of PDGF/IGF in the Dunn chemotaxis chamber. 
A low light level digital microscope was used to acquire one phase contrast image every 5 
minutes for 16 hours. Cells were tracked and the speeds evaluated using a Mathematica®
30
K2 115 A297 A311
Cell Population
Notebook developed in the laboratory. 
The mean speed of migration of the 
non-metastatic K2 cells is 11 pm/hour, 
whereas the metastatic T15 and A29V 
cells migrate significantly faster, at 17 
and 19 pm/hour. The difference in 
speed between K2 and A311 is not 
significant. The total numbers of cells 
analysed for the K2, T15, A297 and 
A311 cell populations are 171, 116, 177 
and 74 respectively. Error bars 
represent the SEM. Statistical
significance is indicated as follows; **P < 0.05; n.s = not significant.
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A more detailed analysis revealed that the cells within each population are 
heterogeneous and that subpopulations of fast-migrating cells exist. For example, in the 
A311 population, of which the average speed of migration is 14 pm/hour, there is great 
heterogeneity and some cells migrate at a speed of up to 40 pm/hour (see bottom 
histogram in Figure 3.5A). In comparison, the K2 cells, which have an average speed 
of 11 pm/hour, are less heterogeneous and contain fewer fast-migrating cells. When the 
fractions of cells migrating faster than 20 pm/hour are compared, it becomes clear that 
the metastatic cells have a significantly larger fast-migrating fraction of cells (Figure 
3.5B). The fast-migrating subpopulation of the non-metastatic cells K2 comprises 8% 
of the total K2 cell population, whilst the fast-migrating fractions of the T15, A297 and 
A311 cells make up 32, 34 and 20% respectively of the total cell populations.
Figure 3.5: Distribution of cell speeds within the four populations.
A. The histograms illustrate the different distributions of speed between the four cell 
populations, and that within each, there are subpopulations of cells.
B. The proportion of fast-migrating cells (cells migrating faster than 20 pm/hour) is significantly 
increased in the metastatic compared to the non-metastatic populations (X* P < 0.01).
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Figure 3.5: Distribution of cell speeds within the four populations.
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Chapter Four
Gene expression profiling o f  
the model o f metastasis
The previous chapter described differences between the cell populations in the 
metastasis model, which are summarised in the following table.
Table 3: Summary o f differences between the sarcoma cell populations. 
€«il type K2 T1S A297 A311
Characteristic
Metastatic potential 0% 40%
F-actin cytoskeleton
Rich in Mainly arranged into a network of
stress thin filaments; contains fewer and
fibres finer stress fibres
Actin dynamics
Slow Faster Not
tested
Not
tested
Response to 
IGF/P0GF
Not
chemotactic: Strongly chemotactic
Speed of migration 
mm/hour
If 17 19 14
Some of these characteristics may correspond to the differences in metastatic potential.
I compared the gene expression between the sarcoma cell populations with a view to 
identifying the genes responsible for these differences. Gene expression was measured 
using Affymetrix GeneChip® Rat 230A microarrays, which contain probes to measure 
the expression of most of the genes in the rat genome.
Two related microarray experiments were performed. The first experiment compared 
gene expression in K2 and A297 cells and their responses to PDGF/IGF. The second 
experiment included the cell populations T15 and A311, as well as tumours generated 
by implanting the cells subcutaneously into rats. Using the data obtained from both 
experiments, I looked for differences in gene expression between the non-metastatic and 
metastatic cell populations, filtering out genes whose expression did not correlate 
between cultured cells and primary tumours, and obtained a list of twenty-three 
candidate genes.
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4.1 Initial microarray experiment
4.1.1 List o f  candidate genes
Asymetrix Rat 230A GeneChips® were used to compare the gene expression of the K2 
and A297 cell populations, when subjected to (1) starvation in 0.5% serum for five 
hours, (2) starvation followed by 30 minutes treatment with PDGF/IGF (3) starvation 
followed by 3 hours treatment with PDGF/IGF. These responses will be referred to as 
control, early and late, respectively.
About two thirds of the genes on the Affymetrix GeneChip® had detectable expression 
levels in the cells. 294 genes (out o f-15,000 probed transcripts) were significantly 
differentially expressed between A297 and K2 cells, where a significant difference in 
gene expression was defined as an expression ratio > 1.6 (P < 0.05). The expression of 
these genes was different between populations, but unchanged by stimulation of the 
cells with PDGF/IGF. This is because the gene expression responses to the growth 
factors were relatively small, and were being masked by the relatively high number of 
differences between the cell populations.
I was interested in both the metastatic potential and the response to PDGF/IGF, since 
the cells are chemotactic to these growth factors. Therefore I applied different 
expression ratio (ER) and significance criteria to each dimension of the experiment. 
Changes in gene expression between the populations were defined by stringent 
parameters (ER > 1.6, P < 0.05) and changes in gene expression in the growth factor 
response were defined by less stringent parameters (ER > 1.3, P < 0.1), and a list of 298 
candidate genes was produced (Appendix 3).
In this list, 95 genes had increased expression in metastasising cells and 157 genes had 
decreased expression in the metastatic cells. In the response of the metastatic cells to 
growth factors, 39 genes had differential expression. In the response of the 
non-metastatic cells to the growth factors, 25 were changed. A total of 16 genes 
exhibited differential expression both between the cell populations and in response to 
growth factors. These observations are expressed in Figure 4.1.
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□ Increased expression in A297
□ Increased expression in K2
□ A297 responding to PDGF/IGF
□ K2 responding to PDGF/IGF
□ Differentially expressed in both 
dimensions
Figure 4.1: Summary of the gene expression patterns observed in the initial microarray 
experiment
The candidate genes were mainly differentially expressed between the two cell populations, 
with almost half the genes being downregulated with metastasis. Some genes changed in 
response to growth factors, 16 of which were also differentially expressed between the two cell 
populations (represented by the red segment).
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4.1.2 Candidate genes selected after manual inspection of the data
The list of 298 genes was too long to investigate fully, so I manually inspected the data 
in order to obtain a manageable list of candidate genes for further study. I was 
particularly interested in genes whose early or late responses were different between cell 
populations. An example of such a gene is microtubule-associated protein 6 (<mtap6), 
which is not only increased in metastasising cells, but is also increased when 
metastasising cells are responding to PDGF/IGF. Such patterns may indicate genes that 
can mediate motile responses that would be of benefit to a metastasising cell. I also 
considered the genes in terms of the novelty of their connection with metastasis, and 
possible relationships to the mechanisms of metastasis, inferred from the literature. In 
this way, eight genes were chosen for further analysis and are presented, with their 
expression ratios, in Table 4.
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Gene (Gene symbol)
Alpha actinin 1 (actnl)
Gene ontology: Biological process Expression ratio
AE/ACAL/AE KE/KC KL/KE AC/KC AE/KE AL/KL
M
Bone Morphogenetic Protein (bmp2)
Translocating chain-associating membrane protein 
(RGD: 1359100)
Actin binding 
Cytoskeleton 
Calcium binding
Skeletal development 
Epithelial to mesenchymal transition 
Transforming growth factor beta receptor 
None assigned
Matrix metalloproteinase 2 (mmp2)
Matrix metalloproteinase 3 (mmp3)
: ■ : : : \  ■ m
Microtubule-associated protein 6 (mtap6) 
Roundabout homolog 1 (robol) 
Tropomyosin 1 alpha (tpm)
Proteolysis 
Collagen catabolism 
Peptidoglycan metabolism 
Proteolysis 
Collagen catabolism 
Peptidoglycan metabolism
Microtubule-based process
Chemotaxis 
Cell adhesion 
Homophilic cell adhesion 
Muscle contraction 
Regulation of muscle contraction 
Muscle development
1.5** 1.5 1.31.1 0.9 1.1 1 i o....... i.o i.o
1.1 1.4 1.6 0.6 2.8* 1.9* 4.3**
1 1.4 0.9 1.1 0.2** 0.2 0.2** mmi
0.9 1 1 0* 0 0*
1.1 1 1.1 1.1 5* 5.1 4.4**
1 1.4* 0.9 1.4 1.2 1.4 1.4*
0.5 1.6 1 1 2.1 3.5**
0.9 0.9 1.1 1.1 0.5* 0.4** 0.3
Table 4: Initial microarray experiment: Candidate genes selected after manual inspection of the data.
Expression ratios represent expression compared between two samples. A=A297; K-K2; C=Control (5 hour starvation); E-Early response (starvation 
followed by 30 minutes IGF/PDGF); L= Late response (starvation followed by 30 minutes IGF/PDGF). The statistical significance of each expression 
ratio was calculated using the t-test and corrected with the Benjamini-Hochberg algorithm; * P -0 .1, ** P=0.05, *** P=0.01. The principle three gene  
ontology terms specified for the biological process of the gene byAffymetrix are listed here.
4.1.3 Validation o f candidate genes by R T-PCR
Microarray data requires validation by at least one other method (Chuaqui et al., 2002). 
Therefore, some of the candidate genes were tested by RT-PCR to confirm the 
expression indicated by the microarray analysis. Figure 4.2 shows the RT-PCR products 
of actnl, mtap6 and tpml. The expression patterns of actnl and tpml reflect those 
detected by the microarray. However, mtap6 appears to be up-regulated in K2 cells,
although the microarray data suggetsed that it is down-regulated in these cells. The
microarray data were not always consistent with the RT-PCR data and microarray data 
were therefore only trusted when supported by RT-PCR.
Figure 4.2: Initial microarray experiment: Validation of gene expression by RT-PCR
RT-PCR was performed to check the expression of selected 
candidate genes. Total RNA was extracted from each cell
population and reverse-transcribed into cDNA, and regions of
each gene of interest were amplified by PCR. PCR products 
were resolved on a 1% TBE agarose gel supplemented with 
ethidium bromide, and visualized by UV transillumination. Tpml 
and actnl are upregulated in A297 and K2 respectively, which 
reflects the gene expression pattern detected by the microarray. However, RT-PCR showed 
that mtap6 is upregulated in K2 cells, although the microarray data indicated that it is 
downregulated in these cells. RT-PCR for GAPDH was performed as a control.
K2 A297
actnl ■ ■ B nS mmI  
mtap6
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4.2 Extended microarray experiment
4.2.1 Genes differentially expressed between metastatic/non-metastatic 
sarcoma cells and tumours
This experiment included all four cell populations as well as the primary tumours which 
arose after subcutaneous injection of these cells into the inbred rats. The extended 
dataset was processed in the same way as the initial experiment. Metastatic cells were 
compared to non-metastatic cells with six comparisons being made; T15 cells vs. K2 
cells, A297 cells vs. K2 cells, A311 cells vs. K2 cells, T15 tumours vs. K2 tumours, 
A297 tumours vs. K2 tumours, and A311 tumours vs. K2 tumours. The criteria applied 
to generate a list of genes were firstly, that each of the six expression ratios should be 
greater than 2, and secondly, that five out of the six expression ratios should be 
significant (P < 0.05). The resulting list of eighty genes is shown in Table 5.
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Table 5: Extended microarray experiment: The eighty most differentially expressed 
genes between non-metastatic and metastatic cells and tumours.
In this table, the Affymetrix Identifiers, expression ratios and symbols for each differentially 
expressed transcript are displayed. The Affymetrix Identifier is the unique identification for each 
transcript that is probed by the array. Not all transcripts are yet characterised, which is why only 
forty-four of the Affymetrix Identifiers in this table have accompanying gene symbols. Where 
the gene’s identity has been inferred from sequence similarity to another gene, the gene symbol 
is enclosed in parentheses. The middle columns describe the expression ratio of two 
experimental groups, where t - T 1 5  cells, a = A297 cells, k - K 2  cells, m -  A311 cells, tt = T15 
tumour; at = A297 tumour, kt = K2 tumour, mt = A 311 tumour. High expression ratios (ER > 1) 
indicate that the gene is over-expressed in metastatic cells. Low expression ratios (ER < 1) 
indicate that the gene is under-expressed in metastatic cells. Statistical significance is indicated 
as follows; *P < 0.1, **P  < 0.05, ***P < 0.01.
Affymetrix
Identifier
t/k a/k m/k tt/kt at/kt mt/kt Gene
symbol
1369113 a t 0.*** 0.*** Q Irk* 0.** 0.** 0** Cktsflbl
1372820 at 0.*** 0.*** 0.*** 0.1* 0.** 0.**
1370696 at 0.*** Q *** Q kkk 0.** 0.* 0.** LOC207121
1372539 at 0.*** Q *** Q irk* 0.** 0.1* 0.**
1377029 at 0.*** Q kirk Q kkk Q *** 0.** 0.**
1370503 s  at o*** 0.*** 0.** 0.1** Q i^rtrk 0.*** Epb4.1l3
1368955 at 0.** Q kirk Q kkk 0.1** Q 0.1** Cask
1372809 at 0.1*** Q kkk Q kkk Q *** q  m 0.*** (AF152002)
1376071 at 0.1*** Q kkk 0.1*** 0.3** 0.2** 0.2**
1374318 at 0.2*** Q kkk Q kkk 0.5** 0.2*** 0.2**
1368106 at 0.1** Q kkk 0.1*** 0.2*** 0.2*** 0.2** Plk2
1369972 at 0.2** Q kkk 0.1** 0.3 0.1** 0.1** Serpinb5
1382117 at 0.3** Q kkk Q kkk 0.4 0.1** Q *** (FLJ21148)
1369126 at 0.3* 0.1** 0.1** 0.** 0.** 0.** Ptgfr
1376708 at 0.2*** 0.1** 0.1** 0.3** 0.4** 0.4*
1375986 at 0.2*** 0.1*** 0.1*** 0.1*** 0.1** Q y ***
1371475 at 0.2*** 0.1*** 0.1*** 0.4*** 0.2*** 0.1** Rnase4
1387653 at 0.3*** 0.1*** 0.1** 0.4** 0.3** 0.2*** Tsnax
1374953 at 0.2*** 0.2*** 0.1*** 0.2** 0.2** Q f  *** IMAGE:7110106
1368533 at 0.4** Q kkk 0.1*** 0.3** 0.2*** Q 7 *** Heph
1398823 at 0.3** 0.1** Q 1 *** 0.4*** 0.4*** 0.3** Tsnax
1388821 at 0.3** 0.1*** 0.1*** 0.6** 0.1*** 0.1*** (AW319517)
1368943 at 0.3** 0.2*** 0.1*** 0.5** 0.2*** 0.2** Rnase4
1377181 at 0.2** 0.2* 0.3** 0.3** 0.2*** 0.3**
1368223 at 0.2** 0.3** 0.2** 0.3** 0.1*** 0.1** Adamtsl
1369652 at 0.2*** 0.2*** 0.3*** 0.5* 0.4** 0.4** Thy1
1390638 at 0.5** 0.*** 0.1** 0.3** 0.1** 0.1*
1372310 at 0.2*** 0.2** 0.2*** 0.5** 0.6** 0.4** (trp)
1376047 at 0.4*** 0.1*** 0.1*** 0.4* 0.1** 0.1**
1389712 at 0.5** 0.1*** 0.2*** 0.1** Q *** q  y ***
1368021 at 0.4** 0.2*** 0.2** 0.3** 0.3** 0.4** Adh1
1377506 at 0.3** 0.2** 0.2** 0.1** 0.1** 0.1** (GDF-1)
1391428 at 0.1*** 0.3** 0.4** 0.1** 0.1** 0.1**
1374652 at 0.4** Q jkk k 0.3*** 0.2** 0.2** 0.4
1375729 at 0.5** 0.1** 0.2** 0.4* 0.2** 0.2**
1372655 a t 0.3*** 0.2*** 0.3*** 0.4** 0.4** 0.4**
1374728 at 0.3** 0.2** 0.3** 0.3** 0.3** 0.4*
1376786 a at 0.3*** 0.2*** 0.3*** 0.3*** 0.3*** 0.3**
1398363 at 0.4** 0.2** 0.2*** 0.8 0.3** 0.3**
1390468 at 0.4*** 0.2*** 0.4*** 0.5** 0.5** 0.5**
1373198 at 0.5** 0.3** 0.3** 0.4*** 0.3** 0.2** (2810451A06)
1374817 at 0.4** 0.4* 0.3** 0.1*** q  y*** Q
1370642 s  at 0.4** 0.4** 0.3*** 0.7 0.4** 0.5*** Pdgfrb
1374743 at 0.5*** 0.2*** 0.5*** 0.4** 0.4** 0.5*
1374448 at 0.4*** 0.4** 0.4** 0.4** 0.5* 0.5** (invasion & met)
1374685 at 0.5** 0.4** 0.3*** 0.3** 0.1** 0.2**
1372870 at 0.5** 0.4*** 0.4*** 0.5**
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0.4** 0.3***
Affymetrix
Identifier
t/k a/k m/k
1381012 at 0.4** 0.4** 0.4**
1388628 at 0.4*** 0.4*** 0.5***
1367967 at 0.4** 0.5** 0.5**
1372469 at 0.6* 0.4*** 0.4**
1386969 a t 2 ** 2.2** 1.3
1374066 at 2.1** 2.3** 2.3**
1372650 at 2.2** 2.3** 2.2**
1372069 at 2.1** 2.6** 2.1**
1370398 at 2.2** 2.4** 2.2**
1372935 at 1.7* 3.** 2.1**
1387750 at 1.9** 2.6** 2.4**
1375855 at 3.1*** 2 7*** 2.2**
1375767 at 2.3** 3.4*** 3.1***
1390474 a t 2.9*** 2.9*** 3.2***
1373494 at 2.5** 4.*** 2.6**
1370942 at 2.7*** 3.9** 2.7***
1388718 at 2.8** 4.9** 2.4*
1398305 at 2.7** 3.1** 4.5**
1369249 at 4.1** 4.7** 3.6**
1387153 at 4.1*** 4.5*** 4.9***
1373617 at 4.3*** 5.2*** 4.2***
1370418 s  at 3.6*** 4'2*** 5.9***
1376304 a t 3.8** 5.4** 4.7**
1373642 at 5.7*** 3.7*** 6.1***
1370638 at 6.1*** 4.3** 6.***
1377065 at 5.8** 6.4*** 5.3**
1371363 at 5.2*** 9.3*** 8.7***
1368342 at 5.2** 13.6*** 10.2***
1368713 at 8.2** 26.1** 3.9
1371679 at 18.7*** 15.2*** 17.4***
1371132 a a t 18.1*** 17.3*** 21.3***
1370987 a t 59.1*** 42.6*** 49.6***
1368685 at 54.*** 76.6*** 64.9***
tt/kt at/kt mt/kt Gene
symbol
0.5** 0.5** 0.4**
0.5** 0.4** 0.3*** MGC94283
0.4** 0.3*** 0.3** Leprel
0.4*** 0.3*** 0.4***
4.4** 3.4** 3.5** Nrn1
2.1** 1.9 2.2**
1.8** 2.5** 2.**
3.** 3.2*** 3.7*** (bA130C19.2)
2.2** 2.2** 1.9* Wmp1
2.5** 3.4*** 3.4**
2.6** 2.7** 2.4** Twist
5.6*** 2.9** 2.1
1.6* 2.4**
3.6** 2.8*** 3.5*** (9330161F08)
2.5** 2.2** 3.** (bcr)
2.4** 2.6** 2.9* (Rasa3)
6.5** 7.5** 7.4** Tmodl
2.3** 3.4** 2.9** Bk
3.7** 3.9* 3.7** Ank
3.1** 3.5** 3.9** Ril
3.1** 2.7** 2.6*
3.5*** 4.6*** Bk
2.5** 3.1** 2.2**
3.6** 4.3*** 4.1**
11.8** 11.6** 16.3** Ank3
10.1** 12.7** 12.7**
1. 2.3** 2.6**
3.5*** 4.1** 5.7* Ampd3
17.** 18.8** 42.*** Mmp10
9.3*** 8.2** 8.3***
13.6** 21.7** 24.1** Ank3
2.2** 2.6** 2.3** Spn
12.8*** 14.6*** 15.3*** Cspg4
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4.2.2 Functions o f the differentially expressed genes
Forty-four of the top eighty genes had been assigned a gene ontology (GO) term 
describing their biological process. The genes were grouped into categories according to 
their GO term. The main categories of these genes were signal transduction, motility, 
protein phosphorylation, cell growth, adhesion and proteolysis. Some GO terms did not 
readily fit into a category, or form a new category, and were grouped together as 
“miscellaneous”. These data are displayed to give an impression of the functions of 
some of the most differentially expressed genes (Figure 4.3).
Figure 4.3: Extended microarray experiment: Functions of the eighty most differentially 
expressed genes.
Forty-four of the eighty most differentially expressed 
genes had been assigned GO terms describing their 
biological process. These were grouped into seven 
categories, which are displayed to give an impression of 
the functions of the most differentially expressed genes. 
Terms featuring in the list of the top eighty genes are 
adhesion, cell growth, cell motility, protein 
phosphorylation, proteolysis and signal transduction. 
Some terms (such as organ morphogenesis or mRNA 
cleavage) did not readily fit into a category or form a 
category of their own, and were grouped together as "miscellaneous".
Arfhesm
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4.2.3 Shortlist of candidate genes
Genes differentially expressed between non-metastatic and metastatic cell populations 
were shortlisted if they had an expression ratio > 2.5 (P < 0.05). In order to ensure that 
the gene expression differences observed were not solely due to the effects of cell 
culture, we compared gene expression in the cultured cells with expression in the 
corresponding primary tumours. We filtered out genes whose in vitro and in vivo 
patterns of expression were significantly different. This generated a list of twenty-three 
genes (Table 6). Of these genes, fifteen are down-regulated in metastasising cells and 
eight are up-regulated in metastasising cells. Graphs of gene expression were produced 
for each candidate gene and are shown in Appendix 4. Figure 4.4 shows the gene 
expression graphs for bk, cask, epb41l3 and r/7, which are analysed in more detail in the 
next chapter, since they were thought to be suitable candidates for functional assays. 
The graphs illustrate that only genes whose expression correlated between cells and 
tumours were selected for the shortlist, and that there are differences in gene expression 
between non-metastatic and metastatic cells.
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Table 6: Extended microarray experiment: Genes with greatest differential expression between non-metastatic and metastatic sarcoma cells and tumours.
G en e dow n regu la ted  in m eta sta tic  cells  
Gene (gene symbol) Gene ontology (biological process) Expression ratio
Gremlin 1 homolog (Greml) Cell-cell signalling; embryonic patterning; organ morphogenesis 0.006
RAR-related orphan receptor alpha (Rora_predicted) Transcriptional regulation; DNA-dependent signal transduction 0.027
Erythrocyte protein band 4.1-like 3 (Epb41l3) Cell proliferation; cortical actin cytoskeleton; actin organisation 0.028
Ca/CaM-dependent serine protein kinase (cask) Protein complex assembly; protein phosphorylation; transport 0.031
Hypothetical gene AF152002 (LOC290595) 0.063
EST; Affymetrix Identififer 1376071_at 0.069
Polo-like Kinase 2 (Plk2) Protein phosphorylation; cell cycle 0.080
EST; Affymetrix Identifier 1375986_at 0.14
RNase A family 4 (Rnase4) mRNA cleavage 0.15
Similar to CG12279-PA (LOC500420) 0.17
Translin-associated factor X (Tsnax) 0.18
A disintegrin-like and metalloproteinase (Adamtsl) Proteolysis; integrin signalling; cell proliferation 0.22
Growth differentiation factor 1(Gdf1_predicted) 0.25
EST; Affymetrix Identifier 1391428_at 0.25
Neogenin (Neo1) Protein phosphorylation; cell motility; cell adhesion 0.29
Expression ratio
Signal transduction; positive regulation of apoptosis 
MAPK activation; cell motility; cell adhesionChondroitin sulfate proteoglycan 4 (cspg4)
Table 6 (continued): Extended microarray experiment: Genes with greatest differential expression between non-metastatic and metastatic sarcoma cells and
tumours.
Candidate genes have an expression ratio of more than 2.5 (P < 0.05). GO terms for the biological process of the gene are those assigned by Affymetrix, and the first 
three annotations are listed here. The expression ratio indicates the mean expression value of the three metastatic cell populations compared to the non-metastatic 
cell population.
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Figure 4.4: Expression patterns of the genes bk, cask, epb41l3 and ril.
Gene expression values are shown for the cultured cells and primary tumours, 
where the green line represents expression levels in the cultured cells, and the 
red line represents expression levels in the primary tumours. In these graphs, 
the expression patterns of the cells and tumours are closely matched since this 
was one of the criteria used to define a candidate gene.
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4.2.3.1 Confirmation o f candidates by R T-PCR
RT-PCR for ten of the candidate genes confirmed the expression patterns found by the 
microarray analysis (Figure 4.5). Replication of the expression patterns for all of the 
genes tested confirmed that the microarray data are reliable.
Figure 4.5: Extended microarray experiment: validation of candidate gene expression.
RT-PCR was performed for ten of the candidate genes 
from the extended microarray experiment. Total RNA 
was extracted from each cell population and reverse- 
transcribed into cDNA, and regions of each gene of 
interest were amplified by PCR. PCR products were 
resolved on a 1% TBE agarose gel supplemented with 
ethidium bromide, and visualized by UV 
transillumination. The expression patterns observed in 
RT-PCR are the same as those indicated by the 
microarray, confirming that the microarray data are 
reliable. RT-PCR for GAPDH was performed as a 
control.
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4.2.4 Investigation o f  candidate genes using the literature and gene 
ontology
To assess the value of pursuing each of the candidate genes further, I investigated the 
functions of the genes using their GO (gene ontology) terms and by searching the 
literature. Unfortunately, not all transcripts probed by the Affymetrix RAE230A 
GeneChip® array had been assigned annotation (i.e. they were unknown genes), since 
characterisation of the rat genome is incomplete. In fact, nine out of the twenty-three 
entries in the candidate gene list were not annotated (see Table 6). Five of these are 
Expressed Sequence Tags (ESTs). Four others were unknown, but had been named 
“Hypothetical gene AF152002”, “Similar to CGI2279-PA”, “Similar to Riken cDNA 
9330161F08” and “Similar to Synaptopodin-2” on the basis of their sequence homology 
to other genes. Due to the scarcity of information on such transcripts, the nine 
unannotated genes were not investigated further.
Each of the remaining 14 candidate genes was briefly investigated by a search of the 
literature, to establish whether it had already been associated with metastasis or 
behaviours related to metastasis. This yielded useful information, for example that 
Ankyrin 3 is a putative metastasis promoter (Bourguignon et al., 2000), and that 
Epb41l3 had been identified as a tumour suppressor (Tran et al., 1999). After 
considering the genes in terms of their novelty, degree of characterisation, and 
annotation, four were selected for further study; bk, cask, epb4H3 and ril.
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4.2.5 Integration of microarray data with an interaction database
The construction of gene or protein networks from microarray data is important since it 
may enable the functional annotation of large datasets (Brazhnik et al., 2002). The 
microarray data described here was used in a collaborative study (Jonsson et al., 2006) to 
identify protein communities involved in cancer metastasis. Though the results of the 
collaboration did not ultimately contribute to the choice of candidate genes, the 
methodology that was developed represents an improvement to microarray analysis and 
therefore is mentioned briefly here and fully described in Appendix 5.
A collaborator, Pall Jonsson, produced a protein network (or “interactome”) of putative 
protein-protein interactions in the rat proteome. This was achieved by performing 
BLAST searches of the rat genome against all proteins in the DIP and MIPS protein 
interaction databases (Pagel et al., 2005; Salwinski et al., 2004). The microarray data 
was then overlaid onto the resulting interactome, and the differentially expressed genes 
used as starting nodes to produce interaction networks. Further analysis was then 
performed on the networks, in order to identify relevant protein communities. A protein 
community was defined by members of the community being linked to many other 
members. 37 such communities were identified and are displayed in Figure 4.6. Protein 
communities found by this method include TGF-0 and MMP communities.
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Figure 4.6: Protein communities identified by cluster analysis.
In a collaborative project with Pall Jonsson and Paul Bates, protein communities in 
metastasis were identified after developing a rat interactome and integrating it with 
the microarray data. The communities are labelled according to the main function of 
the proteins within the community and colours used to distinguish one community 
from another. This figure, prepared by Pall Jonsson, illustrates that differentially 
expressed genes can be clustered according to function, to reveal potentially 
important interactions.
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Chapter Five
Functional studies of 
selected candidate genes
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The biological functions of the candidate genes were investigated with emphasis on cell 
motility and the cytoskeleton. My strategy was to alter the candidate gene expression by 
RNAi or the expression of cDNA. RNAi was achieved by the use of sequence-specific, 
double-stranded RNA molecules to artificially interfere with the activity of targeted 
endogenous genes. For the expression of cDNA, the gene was cloned into a mammalian 
expression vector and then transfected into cells. The motility and F-actin cytoskeleton 
of the cells expressing altered levels of the gene were then assessed. HeLa cells were 
sometimes used in the functional studies as they are more amenable to transfection than 
the sarcoma cells.
This chapter describes work on a-Actinin, BK, CASK and RIL. a-Actinin was a 
candidate from the first microarray experiment (Table 4) and did not feature in the final 
gene list obtained from the extended microarray experiment. However, the functional 
studies on a-Actinin are included here, since they were underway before the extended 
microarray experiment had been started.
110
5.1 a-Actinin
a-Actinin is an actin-binding protein that is upregulated in the metastatic A297 cells. 
The large pool of a-Actinin in A297 cells may enable them to perform the 
motility-related components of metastasis more efficiently than the K2 cells. A role for 
a-Actinin in the chemotaxis of A297 to PDGF/IGF is supported by the fact that it is 
thought to be involved in responses to IGF in other cells (Guvakova et al., 2002). 
a-Actinin has also been observed in invadopodia (Chen, 1989) and if the invadopodia 
of A297 cells are rich in a-Actinin this would be an advantage for invasion.
5.1.1 Expression o f a-Actinin in the sarcoma cells
5.1.1.1 Protein expression
Immunoblotting was performed to check that there was differential expression of the 
protein, as well as the mRNA, between K2 and A297 cells. The immunoblot in Figure
5.1 shows that a-Actinin is overexpressed in the metastatic cells.
Figure 5.1: Expression o f a-Actinin shown by immunoblotting.
Cell lysates of K2 and A297 were produced and equal amounts
_ of protein were resolved by SDS-PAGE, transferred onto aa-Actinin *  ***** ^ 7
PVDF membrane, and probed with an antibody against
GAPDH
a-Actinin according to standard ECL protocols. The 
immunoblot shows that a-Actinin is overexpressed in metastatic A297 cells. The blot was 
reprobed for GAPDH to confirm equal loading.
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5.1.1.2 Cellular localisation o f a-Actinin
The cellular localisation of a-Actinin was investigated by immunocytochemistry and 
confocal microscopy. Figure 5.2 shows representative images of both cell types. 
a-Actinin staining can be seen along stress fibres in the K2 cells, and in the ruffles of 
the A297 cells. The reason for the discrepancy in localisation is likely that the two cells 
types have their actin arranged in different ways (see Section 3.1.1), rather than that 
there is a cell type-dependent localization of a-Actinin to specific regions of the F-actin 
cytoskeleton. The reduced a-Actinin staining in K2 compared to A297 supports data 
from the microarray, RT-PCR and immunoblotting.
Figure 5.2: Localisation of a-Actinin in K2 and A297 cells.
Cells were fixed and stained with rhodamine phalloidin and an antibody to a-Actinin; single 
confocal images are shown. a-Actinin colocalises primarily with actin in ruffles in A297 cells and 
actin stress fibres in K2 cells. There is slightly less a-Actinin staining in K2 than in A297 cells, 
as would be expected from the microarray and immunoblot data. Scale bar = 20 pm.
F-actin uactinin-1 Merged
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<
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5.1.2 Migration ofK2 cells ectopically expressing a-Actinin
There is a potential link between a-Actinin expression and cell migration, since 
a-Actinin is an actin binding protein. I introduced GFP-a-Actinin into the K2 cells, 
which do not endogenously express a-Actinin, and observed their motility. Figure 5.3 
shows that control (GFP-expressing K2 cells) migrate at 14.3 ± 1 pm/hour. Since this is 
not significantly different from the typical K2 cell speed of 11 ± 0.5 pm/hour, it seems 
that microinjection and expression of GFP does not itself affect cell migration. K2 cells 
expressing GFP-a-Actinin migrate at 11.9 ± 2.1 pm/hour, which is not significantly 
different from the speed of the control cells. Therefore, the expression of a-Actinin in 
K2 does not increase cell speed.
Figure 5.3: Effect of a-Actmm expression on K2 cell migration.
GFP-acttnin
•cDNA construct
GFP-a-Actinin or GFP alone were ectopically 
expressed in K2 cells and the effect on cell 
migration measured. K2 cells expressing GFP 
migrated at 14.3 ± 1 pm/hour, which is a 
typical K2 cell speed. a-Actinin-expressing 
cells migrated at 11.9 ±2.1 pm/hour. The 
speeds of cells expressing GFP or a-Actinin 
are not significantly different. This bar chart 
represents data collected from 3 movies from 
J which 24 GFP-expressing and 52 
GFP-a-Actinin-expressing K2 cells were 
analysed. Error bars indicate the SEM.
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5.1.3 Migration of A297 cells with reduced a-Actinin expression
5.1.3.1 Depletion of a-Actinin by RNA interference
To complement the overexpression experiments in the K2 cells, a-Actinin expression in 
A297 cells was reduced by RNAi. RNAi was achieved by introducing short interfering 
ribonucleotides (siRNA) into the cells by lipofection or microinjection. The 
immunoblot in Figure 5.4A shows that a-Actinin expression is reduced 48 hours after 
transfection of 100 nM siRNA into A297 cells. Figure 5.4B shows a confocal image of 
two a actinin-stained cells, one of which has been microinjected with a mixture of 2 pM 
siRNA and FITC dextran. There is no detectable staining in the FITC-positive, injected 
cell, confirming that the siRNA reduce a-Actinin expression. Incidentally, I later 
found that FITC dextran inhibits cell motility; therefore in all subsequent siRNA 
microinjection studies, siRNA-positive cells were identified by directly labelling the 
siRNA with Cy3.
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Figure 5.4: Reduction of a-Actinin expression by RNAi.
Short interfering RNA (siRNA) oligonucleotides directed against alpha actin in mRNA were 
transfected into A297 cells at concentrations of 0, 100 and 150 nM. After 48 hours, cells 
were harvested and immunoblotted. The immunoblot (A) shows that treatment with 100nM 
and 150nM siRNA for 48 hours is sufficient to achieve a reduction in the level of a-Actinin. 
For microinjection studies, siRNA mixed with FITC-dextran were microinjected at 2 pM, 
and the cells fixed after 48 hours and stained for a-Actinin. In (B), the FITC-negative cell 
has not been injected. a-Actinin can be seen in the ruffles and focal adhesions. The 
green cell has been injected with the mixture of FITC and siRNA. In this cell, a-Actinin 
staining is almost undetectable, due to the depletion of the protein by RNAi.
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5.1.3.2 Migration o f A297 cells with reduced a-Actinin
Figure 5.5 shows the speeds of cells microinjected with control siRNA or siRNA 
against actn. The cells migrated at speeds of 13.7 ± 0.7 pm/hour and 16.6 ± 1.9 
pm/hour respectively. The speeds are not significantly different, suggesting that 
reduction of a actinin-1 expression by RNAi has no effect on cell migration.
Figure 5.5: Migration ofA297 cells with reduced a-Actinin.
Cy3-labelled control siRNA or Cy3-labelled 
siRNA to actn were microinjected into 
A297 cells growing on coverslips. After 48 
hours the coverslips were assembled into 
random walk chambers, and cell migration 
recorded by low light level digital 
microscopy. A297 cells microinjected with 
control siRNA migrated at
13.7 ±0.7  pm/hour. Cells microinjected 
with siRNA to a actinin migrated at 
16.6 ± 1.9pm/hour; the speeds are not 
significantly different. The bar chart represents the trajectories of cells obtained from three 
movies, and error bars indicate the SEM.
control s*RNA actinjn sfRNA
StRNA
Since this experiment and the complementary experiment of overexpression in K2 cells 
had no effect on migration, I concluded that a-Actinin is not responsible for the 
differences in cell speed. Having decided by this point to focus on genes from the 
extended microarray experiment, I stopped investigating a-Actinin. I did not have time 
to investigate its effect on cell morphology or the F-actin cytoskeleton, although 
preliminary data suggested that neither overexpression of a-Actinin in K2 nor its 
reduction in A297 had any effect on the cells.
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5.2 Brain and Kidney Protein (BK)
BK protein is so-called because it was originally thought to be selectively expressed in 
brain and kidney. It is now known to be expressed more widely. It contains two 
calcium-binding motifs (C2 domains) at its C-terminus and belongs to the family of 
tandem C2 domain-containing proteins. Like other C2 domain-containing proteins such 
as synaptotagmin and rabphilin-3A, BK is tightly bound to the membrane fraction. It 
lacks a recognisable transmembrane region, and may target the membrane via its 
N-terminal cysteine cluster (Fukuda and Mikoshiba, 2001). The function of BK 
remains unknown, and it was therefore thought to be a potentially interesting candidate 
gene.
5.2.1 Expression o f GFP-BK in non-metastatic K2 cells
As no antibody recognising BK was available, its protein expression in the sarcoma 
cells could not be confirmed by immunoblotting, and so its localisation was investigated 
using a GFP-BK cDNA construct. Figure 5.6 shows the localisation of GFP-BK in 
HeLa cells. GFP-BK is expressed throughout the cytoplasm and accumulates in the 
nucleus. Its wide expression gives the appearance of colocalisation, and it does not 
colocalise exclusively with F-actin. I would expect it to be localised to the membrane, 
as it is reported to be tightly bound to the membrane fraction (Fukuda and Mikoshiba, 
2001). However, it is not significantly enriched at the membrane. This suggested that 
GFP-BK might not be correctly expressed or folded in the cells, or that the GFP tag 
interfered with its localisation. Therefore an untagged BK was used in subsequent 
studies.
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Figure 5.6: Expression of GFP-BK in HeLa cells.
Hela cells expressing GFP-BK were fixed and stained with rhodamine phalloidin. 
GFP-BK is expressed throughout the cell and is concentrated in the nucleus. Its 
ubiquitous expression gives the appearance of colocalisation with actin (see merged 
image in bottom panel). GFP-BK is not enriched at particular areas of the cell with the 
exception of the nucleus. Single confocal images are shown. Scale bar = 20 \im.
118
GFP-BK Rhodamine phalloidin Merged
Figure 5.6: Expression of GFP-BK in HeLa cells.
Hela cells expressing GFP-BK were fixed and stained with rhodamine phalloidin. 
GFP-BK is expressed throughout the cell and is concentrated in the nucleus. Its 
ubiquitous expression gives the appearance of colocalisation with actin (see merged 
image in bottom panel). GFP-BK is not enriched at particular areas of the cell with the 
exception of the nucleus. Single confocal images are shown. Scale bar = 20 pm.
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5.2.2 Effect o f BK on K2 cell motility
The speed of K2 cells microinjected with a mixture of BK cDNA/GFP cDNA, or GFP 
cDNA alone, is shown in the bar chart in Figure 5.7. Both groups of cells migrated at 
approximately 13.5 pm/hour, indicating that the expression of BK in K2 cells has no 
effect on cell migration.
Figure 5.7: Effect of BK expression on K2 cell migration.
A mixture of BK cDNA/GFP cDNA, or
GFP cDNA alone, was microinjected 
into K2 cells growing on coverslips. 
After 4 hours the coverslips were 
assembled into random walk chambers, 
and cell migration was recorded by low 
light level digital microscopy. K2 cells 
expressing BK and GFP migrated at
13.5 ±1.9 pm/hour. Cells
microinjected with GFP only migrated 
at 13.5 ± 0.9 pm/hour; the speeds are 
not significantly different. This bar chart represents the trajectories of 35 cells recorded in 3 
movies and error bars indicate the SEM.
Some tools necessary for the investigation of BK were lacking. Firstly, no antibody 
was available, making it impossible to confirm the protein expression of BK in the 
sarcoma cells. Secondly, there was uncertainty that the cDNA construct of BK was 
functioning correctly; moreover, if it were functioning correctly, the experiment shown 
in Figure 5.7 had already proved that its expression has no effect on motility, which was 
one of my main interests. Therefore, it was thought prudent to stop investigating BK.
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5.3 Calcium /Calm odulin Serine K inase
Calcium/calmodulin serine kinase (CASK) is expressed in a wide range of tissues and 
cell lines. It shares domains with both CaM Kinases and intercellular junction proteins 
(Hata et al., 1996) and therefore probably transduces calcium signals to the membrane. 
Indeed Cohen et al. (1998) showed that it can bind to syndecan-2 and the actin-binding 
protein 4.1, possibly linking the extracellular matrix and the actin cytoskeleton. In this 
model, it is overexpressed in the non-metastatic K2 cells, and therefore represented an 
interesting candidate gene.
5.3.1 Expression o f CASK in the sarcoma cells
Differential expression of CASK at the protein level was checked by immunoblotting 
(Figure 5.8). The blot shows that CASK is expressed in K2 cells, but not at detectable 
levels in the metastatic cells, confirming the microarray and RT-PCR data.
Figure 5.8: Expression o f CASK shown by immunoblotting.
Lysates of the four cell populations were resolved by SDS- 
&  $  &  PAGE and transferred to a PVDF membrane. Blots were
CASK (Pffc J fhen probed for CASK and GAPDH according to standard
ECL protocols. This blot shows that CASK is expressed in 
K2 cells but not in the metastatic T15, A297 and A311 cells. 
Actin levels indicate that equal amounts of protein were loaded.
To investigate the cellular localisation of CASK, K2 and A311 cells were fixed and 
stained for CASK antibody and F-actin; confocal images are shown in Figure 5.9.
CASK staining is diffuse throughout the cytoplasm in both cell types, with a little 
colocalisation with F-actin at the lamellipodia. Confusingly, these and all other CASK 
immunocytochemistry images suggested that there is more CASK in A311 cells, whilst 
the microarray data, RT-PCR and immunoblotting indicated that levels of CASK are 
higher in non-metastatic K2 cells.
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Figure 5.9: Immunocytochemistry to examine the cellular localisation of CASK.
Non-metastatic (K2) and metastatic (A311) sarcoma cells were fixed and labelled with 
mouse anti-CASK antibody followed by staining with rhodamine phalloidin andAlexa 488- 
conjugated anti-mouse secondary antibody. CASK staining is diffuse through the 
cytoplasm. There is a little colocalisation of CASK with ruffles in the A311 cells. The 
microarray data, RTPCR and immunoblotting indicate that levels of CASK are higher in K2 
cells than in A311 cells. However, these and all other confocal images taken of cells 
stained with CASK antibody do not support this expression pattern. The images shown 
are 15-slice projections. Scale bar = 20 [im.
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Figure 5.9: Immunocytochemistry to examine the cellular localisation of CASK.
Non-metastatic (K2) and metastatic (A311) sarcoma cells were Fixed and labelled with 
mouse anti-CASK antibody followed by staining with rhodamine phalloidin and Alexa 488- 
conjugated anti-mouse secondary antibody CASK staining is diffuse through the 
cytoplasm. There is a little colocalisation of CASK with ruffles in the A311 cells. The 
microarray data, RTPCR and immunoblotting indicate that levels of CASK are higher in K2 
cells than in A311 cells. However, these and all other confocal images taken of cells 
stained with CASK antibody do not support this expression pattern. The images shown 
are 15-slice projections. Scale bar = 20 \im.
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5.3.2 Expression o f GFP-CASK in metastatic A297 cells
To explore the function of CASK in the sarcoma cells, GFP-CASK was ectopically 
expressed in metastatic A297 cells, which do not endogenously express CASK. CASK 
was detected on an immunoblot of A297 cells transfected with GFP-CASK (Figure 
5.10A), confirming that it was being expressed by the cells. Next, A297 cells 
expressing GFP-CASK were imaged on a confocal microscope. The images in Figure 
5.1 OB show that GFP-CASK is expressed throughout the cell but is excluded from 
vesicles. There is no localisation to the cell membrane or with F-actin. Inspection of a 
number of images did not reveal any differences in cell morphology or the actin 
cytoskeleton in A297 cells expressing GFP-CASK.
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Figure 5.10: Expression of GFP-CASK in A297 cells.
(A) Immunoblot showing CASK ectopically expressed in A297 cells. No CASK is detectable in 
A297 cells transfected with GFP alone. When the cells are transfected with GFP-CASK, a band of 
CASK can be seen.
(B) GFP-CASK was microinjected into A297 cells and the cells were fixed 4 hours later and 
stained with rhodamine phalloidin. Single confocal images are shown. GFP-CASK is expressed 
widely and is excluded from vesicles. Scale bar = 20 pm.
5.3.3 Migration o f cells overexpressing CASK
I investigated the motility of A297 cells expressing CASK. Figure 5.11 shows that 
A297 cells expressing a mixture of CASK/GFP migrate at 15.1 ± 1.2 pm/hour, which is 
not significantly different from the speed of the GFP-expressing control cells (16 ± 1.8 
pm/hr). Therefore expression of CASK in A297 cells does not affect their speed.
Figure 5.11: Effect o f GFP-CASK on A297 cell migration.
2Or
A mixture of CASK cDNA/GFP cDNA, or GFP cDNA alone, was microinjected into A297 cells 
growing on coverslips. After about 4 hours the coverslips were assembled into random walk 
chambers, and cell migration was recorded by low light level digital microscopy. Cells 
expressing a mixture of CASK/GFP migrated at 15.1 ± 1.2 pm/hour, whilst cells microinjected 
with GFP alone migrated at 16 ±1.8 pm/hour. The speeds are not significantly different.
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5.3.4 Effect o f CASK RNAi on the actin cytoskeleton
Having looked at the effect of ectopic expression of CASK in metastatic cells, I then 
performed the converse experiments by reducing the expression of CASK in 
non-metastatic K2 cells by RNAi. To check the efficiency of the siRNA, K2 cells were 
chemically transfected with the siRNA at various concentrations, harvested after 48 
hours, and CASK protein levels were determined by an immunoblot. Figure 5.12 shows 
that CASK expression is reduced 48 hours after transfection with the siRNA.
Figure 5.12 CASK RNAi in K2 cells shown by immunoblotting.
K2 cells were transfected with control or cask
with cask siRNA, most efficiently at 300 nM. 
GAPDH levels indicate that equal amounts of protein were loaded.
To study the effect of reduced CASK expression on the morphology of K2 cells, 
Cy3-labelled cask siRNA was microinjected and the cells were fixed after 48 hours and 
stained with rhodamine phalloidin. Cy3-positive cells were located and imaged on a 
confocal microscope; example images are shown in Figure 5.13. Reduction of CASK 
expression by RNAi does not appear to have any effect on the F-actin cytoskeleton or 
general morphology of K2 cells.
CASK
GAPDH
siRNA for 48 hours. Lysates were produced, and 
proteins resolved by SDS-PAGE and transferred to 
a PVDF membrane. Blots were then probed for 
CASK and GAPDH and processed according to 
standard ECL protocols. The blot shows that 
CASK is expressed in K2 cells treated with control 
siRNA and is reduced when the cells are treated
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Figure 5.13: Effect of CASK RNAi on cell morphology and the 
actin cytoskeleton.
Cy3-labelled control siRNA or Cy3-labelled siRNA to cask were 
microinjected into K2 cells. After 48 hours the cells were fixed and 
stained with rhodamine phalloidin. Cy3-positive cells were identified 
and confocal images acquired. The Cy3 signals are very weak, but 
distinguishable from background. These are single confocal slices 
representative o f several fields acquired from three independent 
experiments. Reduced CASK expression had no effect on the F- 
actin cytoskeleton or general cell morphology. Scale bar = 20 \im.
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5.3.5 Effect o f CASK RNAi on cell migration
Figure 5.14 shows the speeds of K2 cells microinjected with Cy3-labelled control 
siRNA or Cy3-labelled siRNA against cask. The cells migrated at speeds of 
13.8 ± 1 pm/hour and 13.6 ± 1.7 pm/hour respectively. The speeds are not significantly 
different, meaning that the reduction of CASK expression by RNAi has no effect on K2 
cell migration.
Figure 5.14: Effect o f CASK RNAi on cell migration.
Cy3-labelled control siRNA or Cy3-labelled 
siRNA against cask were microinjected into 
K2 cells growing on coverslips. After 48 
hours the coverslips were assembled into 
random walk chambers, and cell migration 
was recorded by low light level digital 
microscopy. Cells microinjected with 
siRNA against cask migrated at
13.6 ± 1.7pm/hour. K2 cells microinjected 
with control siRNA migrated at 13.8 ± 1 pm/hour. The speeds are not significantly different. 
This graph represents the analysis of 24 cells; error bars represent the SEM.
cask siRNA control siRNA
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5.4 Reversion Induced LIM Protein
Reversion Induced LIM protein (RIL) is upregulated with metastasis in this model 
(Figure 4.4). It was identified as a binding partner of Protein Tyrosine Phosphatase 
(Cuppen et al., 1998) and is thought to be expressed in polarised epithelial cells and to 
play a role in the establishment and maintenance of polarity. It contains a PDZ and a 
LIM domain. It might act as an adaptor, recruiting molecules to the actin cytoskeleton 
via its PDZ domain, and binding kinases via the LIM domain. Vallenius et al. found 
that expression of RIL in osteosarcoma cells caused the continuous assembly and 
collapse of thick irregular actin stress fibres. This is interesting since the expression of 
RIL could relate to the different arrangements of actin in the sarcoma cells.
5.4.1 Expression o f  GFP-RIL in sarcoma cells
As no RIL antibody was available, it was not possible to confirm its expression in the 
sarcoma cells by immunoblotting. The localisation of RIL was investigated by the use 
of a cDNA GFP construct. In non-metastatic K2 cells, GRP-RIL localises to stress 
fibres (Figure 5.15 A). The localisation of the protein is not due to spectral cross-talk 
from the rhodamine phalloidin, since GFP signal is never seen in uninjected cells (see 
left panel of Figure 5.15A). I looked at the effect of ectopic GFP-RIL expression on K2 
and A311 cells in which it is underexpressed and overexpressed respectively. 
Representative images are shown in Figure 5.15B; although GFP-RIL colocalises with 
some stress fibres in K2 and ruffles in A311, it does not provoke any discernible 
alterations in the F-actin cytoskeleton.
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Figure 5.15: Expression of GFP-RIL in sarcoma cells.
GFP-RIL was injected into K2 cells 4 hours prior to fixing and staining of the cells with rhodamine 
phalloidin. Single confocal images are shown; scale bar = 20 pm.
(A) Close-up of the leading edge showing that GFP-RIL localises to actin stress fibres. The left 
panel of images shows an uninjected cell from which no GFP signal is emitted. The images in 
the right panel are of a cell injected with GFP-RIL. GFP-RIL is dotted along the stress fibres.
(B) Images representing a total of three experiments investigating the effect of GFP-RIL on the 
F-actin cytoskeleton. The expression of GFP-RIL in K2 or T15 cells had no effect on the F-actin 
cytoskeleton.
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5.4.2 Effect o f RIL on K2 cell motility
Figure 5.16 shows the speeds of K2 cells microinjected with GFP cDNA or a mixture of 
RIL and GFP cDNA. Cells injected with GFP migrated at 7.48 ± 0.7 pm/hour. Cells 
injected with the mixture of GFP and RIL migrated at a similar speed, of
6.7 ± 0.9 pm/hour. The speeds are not significantly different, meaning that ectopic 
expression of RIL has no effect on K2 cell migration.
Figure 5.16: Effect o f RIL expression on K2 cell migration.
to RIL cDNA or GFP cDNA were microinjected 
into K2 cells growing on coverslips. After 
four hours the coverslips were assembled 
into random walk chambers, and cell 
migration recorded by low light level digital 
microscopy. K2 cells microinjected with GFP 
cDNA migrated at 7.4 ± 0 .7 pm/hour. Cells 
microinjected with RIL cDNA migrated at 
6.7 ±0.9 pm/hour. The speeds are not 
significantly different.
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Chapter Six
The role of 4. IB in cell 
motility and the cytoskeleton
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Microarray analysis showed that the gene epb4H3 was significantly down-regulated in 
metastatic rat sarcoma cell lines and tumours. Epb41l3 was originally isolated as the 
cDNA DAL-1 from a screen of lung adenocarcinomas (Tran et al., 1999), which was 
later found to be a fragment of full length epb41l3. Its protein product, 4. IB, has an 
N-terminal FERM (4.1, Ezrin, Radixin, Moesin) domain, a spectrin binding domain, a 
C-terminal domain, and three unique domains, U l, U2 and U3. 4.IB is thought to be a 
tumour suppressor, as it is lost in about 60% of lung adenocarcinomas (Tran et al.,
1999) and meningiomas (Gutmann et al., 2001). I decided to focus on 4.IB since it was 
emerging as a tumour suppressor, but had not been related to the development of 
metastasis. I performed functional studies on 4. IB to investigate the potential 
relationship between loss of 4. IB and increase in migration, and change in actin 
arrangement.
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6.1 Protein 4. IB is underexpressed in the metastatic cells
6.1.1 Expression o f epb41l3 and its protein product 4. IB
Expression of the epb4H3 gene, which encodes the protein 4. IB, is 36 times lower in 
the metastatic sarcoma cells than in the non-metastatic cells (see Figure 4.4). The 
expression pattern suggested by the microarray was confirmed by RT-PCR (see Figure 
4.5). Immunoblotting was performed to examine the expression of protein 4. IB in the 
four cell populations. Figure 6.1 shows that 4.IB is expressed in non-metastatic K2 
cells, and that very little is expressed in the T15, A297 and A311 cells. This indicates 
that the protein levels correlate with the levels of gene expression for 4. IB.
Figure 6.1: Expression of 4.1 B protein shown by immunoblotting.
Whole cell lysates of the four cell populations were 
prepared and proteins resolved by SDS-PAGE and 
transferred to a PVDF membrane. Blots were then 
probed with antibodies against 4.1 B and actin, and 
processed according to standard ECL protocols. The 
blot shows that 4.1 B is expressed in K2 cells, and that very little 4.1 B is detectable in the 
metastatic T15, A297 and A311 cells. Actin levels indicate that equal amounts of protein were 
loaded.
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6.2 Investigation o f rat epb41l3 splice variants
6.2.1 RT-PCR to identify epb41l3 isoform
There are two previously reported isoforms of rat epb41l3, the minor isoform (Genbank 
Accession Number AB032828), and the major isoform (NM 053927). Both isoforms 
can hybridise to the Affymetrix probe set for epb41l3. To establish which isoform of 
epb41l3 is expressed in the sarcoma cells, I designed PCR primers to flank a region that 
diverged between the minor and major isoforms. The primers were complementary to 
both the major and the minor isoform, but would yield PCR products of different length; 
660 base pairs for the minor isoform, and 1096 base pairs for the major isoform. RT- 
PCR was performed and the products were visualized on an agarose gel (Figure 6.2). A 
band of between 500 and 786 base pairs in length was observed. This suggested that the 
minor isoform was being expressed in the cells. Since no product was visible at -1095 
base pairs, even with permissive PCR conditions and high exposures, it is likely that the 
major isoform is not expressed in the cells.
Figure 6.2: Investigation o f epb41!3 isoforms in the sarcoma cells.
After cloning epb41l3 from the sarcoma cells, it became apparent that the isoform in the 
sarcoma cells was not the minor isoform, but a third splice variant of epb41l3.
Since a major and a minor isoform o f epb4113 have been 
reported in rat, it was necessary to establish which isoform was 
present in the sarcoma cells. An RT-PCR approach was used, 
where primers were designed to anneal to both isoforms of 
epb41l3, flanking a divergent region. A PCR product of 
approximately 660 base pairs in length suggested that the minor 
isoform was being expressed in the cells.
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Figure 6.3: Schematic comparing the three splice variants of 4. IB.
In this figure the three variants have been aligned and regions of divergence greater 
than 10 base pairs in length have been indicated. The variants are largely 
homologous but diverge between base pairs 1500 and 2500 of the NM_053927 
isoform. This region is shown in greater detail in the following figure.
6.2.2 Sequence of the new splice variant
The full length epb4H3 gene was obtained by RT-PCR using RNA from the sarcoma 
cells. Once it had been cloned into the pEGFP-C3 vector, its sequence was checked and 
found to diverge from the sequences of the previously reported rat epb4H3 isoforms. 
The sequence of the new splice variant of epb41l3 was submitted to GenBank and 
assigned the Accession Number DQ462202. To investigate the common features of the 
three variants of rat epb41l3, DQ462202 was aligned with the sequence of the major 
isoform, NM_053927, using the Clustal W multiple sequence alignment program 
(Chenna et al., 2003). The sequence of DQ462202 diverges from the sequence of 
NM_053927 at bases 1569-2115, 2169-2204 and 2398-2521. The multiple sequence 
alignment covering the non-homologous regions is shown in Figure 6.4A. The 
chromatogram of the DQ462202 sequence covering these regions is shown in Figure 
6.4B.
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Figure 6.4: A new epb41l3 splice variant
A third splice variant of epb4113 was identified. The sequence of the new variant; GenBank Accession Number DQ462202, was aligned with the sequence of the 
major isoform NM_053927 using the Clustal W multiple sequence alignment program (Chenna et al., 2003).
(A) The multiple sequence alignment of the non-homologous regions is shown; base numbers correspond to NMJ053927. The sequence of DQ462202 diverges 
from the sequence ofNMJ053927 at bases 1569-2115, 2169-2204 and 2398-2521.
(B) The chromatogram of the DQ462202 sequence covering these regions; the sequence numbers of the chromatogram correspond to DQ462202.
CLUSTAL W (1.83) multiple sequence alignment of novel Epb41l3 splice variant DQ462202 and major Epb41l3 isoform NM_053927
DQ462202 GAGGGAAAG------------------------------------------------------------------------------------------------ 1569
NM_0 53927 GAGGGAAAGTCACCAGGGCATGGCTCTGACTCATGTCCCCTGTCACCTCCATCAGCCCAT 1620*********
DQ462202 --------------------------------------------------------------------------------------------------------------
NM_053927 CTTGACCCTCCCTCTCCCACAGAGCTCCGTAGGAGGTGCAAGGAGAAAGAAAGGGCCTCT 1680
DQ462202 --------------------------------------------------------------------------------------------------------------
NM_053927 CCAGGTTCTGCTGTGCCTAGAGCAGAGCTGTCCTCGGAGTCTGATGCCCAGGGGAAGGCC 1740
DQ462202 --------------------------------------------------------------------------------------------------------------
NM_053927 TACCTAGGGGACCAAGATGTGGCATTTAGTTACAGGCAGCCGGCTGGCAAAGGAACCACA 1800
DQ462202 --------------------------------------------------------------------------------------------------------------
NM_0 53927 CTGTTTTCCTTCTCCTTGCAGCTCCCAGAGTCATTCCCCTCGCTCCTAGATGAAGACGGG 1860
DQ462202 -------------------------------- -----------------------------------------------------------------------------
NM_0 53927 TACCTCTCTTTCCCCAACCTGTCTGAAACCAACCTCCTGCCCCAGAGTTGGCAGCATTTC 1920
DQ462202
NM_053927 TTGCCCATCCGCTCGCCCTCCCTCCTTCCCTGCTTCCTCTTCATCTTCTTCTTCCTGCTG 1980
DQ462202
NWL.053927 TCTGCCTCCTTCTCAGTACCATACGCCCTCACTCTCTCCTTCCCTCTGGCTCTGTGCCTC 2040
DQ462202 --------------------------------------------------------------------------------------------------------------
NM_053927 TGCTTCCTGGAGCCCAAGGCGGCCTCCTTGAGCGCCTCCCTAGACAATGACCCGAGTGAC 2100
DQ462202 ----------------------------ACTGACAGTGAGCGGACAGACACTGCGGCTGATGGAGAGACCAGT 1614
NWLO 53927 AGTTCAGAGGAAGAGACTGACAGTGAGCGGACAGACACTGCGGCTGATGGAGAGACCAGT 2160
• k ' k i c k ' k i e ' k i c ' k i c ' k ' k ' k ' k ' k ' k i c ' k ' k i t i c ' k ' k ' k ' k ' k i c i c i c ' k l e i t ' k i t ' k ' k i c i e ' k ' k ' k ' k ' k ' k ' k
DQ462202 GCCACAGAG GAGCTAGATAAAACT 1638
NM_0 53927 GCCACAGAGTCGGACCAGGAGGAAGACGCAGAGCTCAAGGCACAGGAGCTAGATAAAACT 2220
* * * * * * * * *  * * * * * * * * * * * * * * *
DQ462202 CAAGATGAGCTGGTGAAACACCAAACCAATATTAGCGAACTGAAAAGAACCTTCTTAGAA 1698
NM_053927 CAAGATGAGCTGGTGAAACACCAAACCAATATTAGCGAACTGAAAAGAACCTTCTTAGAA 2280
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
DQ4 6 2 2 0 2 ACCTCTACAGAAACTGCCTTAACAAACGAATGGGAAAAGAGGCTCTCCACATCCCCCGTG 1758
NM_053927 ACCTCTACAGAAACTGCCTTAACAAACGAATGGGAAAAGAGGCTCTCCACATCCCCCGTG 2340
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
DQ4 6 2 2 0 2 CGGCTGGCTGCCAGGCAGGAGGATGCGCCCATGATTGAGCCACTTGTACCTGAGGAGA--  1816
NM_0 53927 CGGCTGGCTGCCAGGCAGGAGGATGCGCCCATGATTGAGCCACTTGTACCTGAGGAGACT 2400
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
DQ462202 --------------------------------------------------------------------------------------------------------------
NM_053927 AAACAATCTTCTGGGGAGAAGCTCATGGATGGCTCGGAGATCCTCAGTCTATTAGAGTCT 2460
DQ462202 ---------------------------------------------------------------------------------------------------------------
NM_0 53927 GCGAGGAAACCCACAGAGTTCATAGGAGGGGTTTCATCTACTACCCAGAGCTGGGTGCAGA 2521
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To check the domain organisation of the new splice variant, the DNA sequence of the 
new variant was translated into the amino acid sequence and searched for protein 
domains and motifs using Pfam. This showed that the FERM, SAB and CTD domains 
of rat 4.1B are conserved in the new splice variant (Figure 6.5). This splice variant was 
used in all experiments where 4.IB cDNA was expressed.
Figure 6.5: Protein domains in the DQ462202 splice variant o f 4.1 B.
1 MTTESGSDSE SKPDQEAEPQ EAAGPQEQAG 
31 AQAAPEPAGG NVEEQPGLEQ FPEAAAHSTP 
61 VKREVSDKDR DFAAAAAKQL EYQQFEDDKL 
91 SQKSSSSKLS RSPLKIVKRP KSMQCKVTLL 
121 DGSEYGCDVD KRSRGQVLFD KVCEHLNLLE 
151 KDYFGLTYRD AENQKNWLDP AKEIKKQIRS 
181 GAWHFSFNVK FYPPDPAQLS EDITRYYLCL 
211 QLRDDIVSGR LPCSFVTLAL LGSYTVQSEL 
241 GDYDPDECGN DYISEFRFAP NHTKELEDKV 
271 IELHKSHRGM TPAEAEMHFL ENAKKLSMYG 
301 VDLHHAKDSE GVEIMLGVCA SGLLIYRDRL 
331 RINRFAWPKV LKISYKRNNF YIKIRPGEFE 
361 QFESTIGFKL PNHRAAKRLW KVCVEHHTFF 
391 RLLLPEAPPK KFLTLGSKFR YSGRTQAQTR 
421 RASALIDRPA PYFERSSSKR YTMSRSLDGA 
451 SVNENHEIYM KDSMSAAEVG TGQYATTKVI 
481 SQTNLITTVT PEKKAEEEHV EEEDRRKKAE 
511 EATPVAALRH EGKTDSERTD TAADGETSAT 
541 EELDKTQDEL VKHQTNISEL KRTFLETSTE 
571 TALTNEWEKR LSTSPVRLAA RQEDAPMIEP 
601 LVPEEKLETK TETIETEVEP TPHPQPLSTE 
631 KVLQETVLVE ERHVMNVHAS GDASHTARDD 
661 VDATESAPAD RHSGNGKEGS SVTEAAKEQR 
691 GEEADKSAPE QEQPATVSQE EDQVSAIHSS 
721 EGLEQKSHFE SSTVKVESIS VGSVSPGGVK 
751 LETSTKEVPV VHTETKTITY ESSQVDPGAD 
781 LEPGVLMSAQ TITSETTSTT TTTHITKTVK 
811 GGISETRIEK RIVITGDADI DHDQALAQAI 
841 KEAKEQHPDM SVTKVWHKE TEITPEDGED
The protein translation of the splice variant DNA sequence was submitted to the Pfam database 
and searched for protein domains. This protein sequence shows the regions of the three main
4.1 B domains. The FERM domain is in red, the spectrin/actin binding domain in blue and the
4.1 family C-terminal domain in green. These three domains are conserved between the three 
known 4.1 B isoforms, and amongst the 4.1 superfamily.
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6.3 A role for 4. IB in actin organisation
6.3.1 Expression o f GFP-4. IB
6.3.1.1 Cellular localisation of GFP-4. IB
As the 4. IB antibody used for immunoblotting does not work in immunocytochemistry,
I examined the localisation of 4. IB in the sarcoma cells by expressing N- and 
C-terminally tagged GFP fusions of 4 .IB cDNA. The ectopically-expressed GFP-4.IB 
can be expressed by the cells as it is detectable by immunoblotting (Figure 6.8A). The 
images in Figure 6.6 show that N-terminally GFP-tagged 4 .IB is expressed in the 
cytoplasm of the sarcoma cells and not in the nucleus. There is some colocalisation 
with F-actin in lamellipodia and filopodia (indicated by the arrowhead). Expression of 
a C-terminally tagged 4. IB (Figure 6.7) revealed a similar pattern but with little or no 
colocalisation between F-actin and 4.IB.
To inspect a large number of cells, HeLa cells were tranfected with 4.1B-GFP, since 
they can easily be transfected with Effectene (Qiagen) and do not require labour- 
intensive microinjection. Images of N-terminally tagged GFP-4. lB-expressing HeLa 
cells are shown in Figure 6.8B. GFP-4.IB is expressed in the cytoplasm and localises 
to areas of apparent protrusive activity (indicated by the arrowheads). In some cells, it 
is possible to see membrane localisation of GFP-4. IB (Figure 6.8C).
6.3.1.2 Effect of GFP-4. IB on the actin cytoskeleton
The same images (Figure 6.6, Figure 6.7 and Figure 6.8) were examined for the possible 
effect of GFP-4. IB on the F-actin cytoskeleton. Inspection of the images indicated that 
the expression of GFP-4. IB had no effect on the cytoskeleton.
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Figure 6.6: Expression of GFP-4.1B in sarcoma cells.
N-terminally tagged 4.1B-GFP was microinjected into K2 or A311 cells 
and the cells were fixed 4 hours later and stained with rhodamine 
phalloidin. 4.1B-GFP is expressed in the cytoplasm and not in the 
nucleus. It can colocalise with F-actin in filopodia and lamellipodia, as 
indicated by the arrowheads. These single confocal images are 
representative of three independent experiments. Scale bar = 20 \im.
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Figure 6.7: Expression of AcGFP-4.1B in sarcoma cells.
C-terminally tagged 4.1B-AcGFP was microinjected into A297 cells and the cells 
were fixed 4 hours later and stained with rhodamine phalloidin. 4.1B-AcGFP is 
expressed in the cytoplasm and not in the nucleus. There is very little 
colocalisation with F-actin. These single confocal images are representative of 
two independent experiments. Scale bar = 20 \xm.
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Figure 6.8: Expression of GFP-4.1B in HeLa cells.
A ,* -*  y
X GFP-4.1B endogenous 4.1B
B
(A) Immunoblot showing that HeLa cells transfected with 
GFP-4.1B cDNA express 4.1B.
(B) To investigate the localisation of GFP-4.1B, HeLa cells 
were transfected with GFP-4.1B and later fixed and 
stained with rhodamine phalloidin. GFP-4.1B is 
expressed in the cytoplasm and not in the nucleus. There 
is colocalisation with F-actin, especially in areas of ruffling 
and protrusive activity, as indicated by arrowheads in the 
upper panel. There is also an enrichment of GFP-4.1B at 
the membrane (middle and bottom panel). This is clearer 
still in (C) a close-up on a region of one of the cells in B 
(bounded by the yellow box). These are single confocal 
images which are representative of three independent 
experiments. Scale bar = 20 pm.
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6.3.2 Effect o f untagged 4. IB on the actin cytoskeleton ofT15 cells
To ensure that the GFP tag did not affect the function of 4 .IB, experiments were 
performed with an untagged cDNA. T15 cells were transfected with GFP or 4. IB 
cDNA, fixed with FA/PBS the next day and stained with rhodamine phalloidin. Figure 
6.9 shows that there is no apparent difference between the morphology of the GFP and 
4.1B-expressing cells. To be certain about the lack of effect on the actin cytoskeleton, 
the cells were scored according to the presence or absence of stress fibres. This analysis 
revealed no significant difference in actin stress fibres between cells transfected with 
4.IB and those transfected with GFP (Figure 6.10).
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Transfected with GFP Transfected with 4.1 B
Figure 6.8: Effect o f untagged 4.1 B on the actin cytoskeleton of 
metastatic T15 cells.
T15 cells were chemically transfected with 4.1 B or GFP, fixed and 
stained with rhodamine phalloidin. Projections of two confocal slices 
are shown. There is no difference between the actin cytoskeleton of 
the cells transfected with 4.1B and those transfected with GFP Scale 
bar = 20 jam.
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Figure 6.10: Quantification o f the effect o f 4.1 B on the actin cytoskeleton of metastatic 
T15 cells.
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The stacked bar chart shows the percentage of GFP- or 4.1 B-expressing cells exhibiting at least 
one stress fibre, and the percentage of cells with no stress fibres. There is no significant 
difference in stress fibre distribution between cells transfected with 4.1 B o r control cells 
transfected with GFP alone.
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6.3.3 RNAi o f 4. IB disrupts the actin cytoskeleton o f K2 cells
Having looked at the effect of 4 .IB overexpression in metastatic cells, in which it is not 
endogenously expressed, I then performed the converse experiments in K2 cells which 
endogenously express 4 .IB. I microinjected them with Cy3-labelled siRNA to epb41l3 
to reduce the expression of 4 .IB, and after 48 hours, cells were fixed and stained with 
rhodamine phalloidin. Confocal images of the cells are shown in Figure 6.11. K2 cells 
injected with the siRNA to epb41l3 display an altered F-actin cytoskeleton, with fewer 
stress fibres and less F-actin than the control cells.
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Cy3 Rhodamine phalloidin
Figure 6.11: Effect o f 4.1 B RNAi on the F-actin cytoskeleton 
of non-metastatic K2 cells.
K2 cells were injected with 2 pM Cy3-labelled epb41l3 siRNA, 
fixed after 48 hours, stained with rhodamine phalloidin, and imaged 
on a confocal microscope. They display an altered actin 
cytoskeleton, with fewer stress fibres, and less total F-actin. Cells 
injected with control siRNA (top panel) are unchanged. These 
single confocal slices represent four independent experiments. 
Scale bar = 20 pm.
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6.3.4 4. IB RNAi causes a loss o f stress fibres in Hela cells
To quantify the effect of epb41l3 RNAi on the actin cytoskeleton, it was necessary to 
analyse a larger number of cells. This would have been difficult to achieve in the 
sarcoma cells, since they require microinjection, which is a labour-intensive technique. 
Therefore, further experiments were performed in HeLa cells which, unlike the K2 cells, 
are highly amenable to lipofection.
6.3.4.1 RNAi o f  4. IB in Hela cells
4.1B protein is expressed in HeLa cells (see lane 1 of the immunoblot in Figure 6.12).
To check the efficiency of siRNA at reducing 4. IB expression, K2 cells were 
chemically transfected with 100 nM control or epb4H3 siRNA, harvested after 48 
hours, immunoblotted and probed with a 4.IB antibody. The immunoblot in Figure 
6.12 shows that 4 .IB protein expression in HeLa cells can be reduced by three 
independent siRNAs.
Figure 6.12: 4.1 B RNAi in HeLa cells shown by immunoblotting.
He La cells were transfected with 100 nM control or 
epb41l3 siRNA and incubated for 48 hours. Lysates were
. .. ^ A...........^ resolved by SDS-PAGE and transferred to a PVDF
4.1 B ■ -r*-" : membrane. Blots were then probed with antibodies to
4.1 B and GAPDH according to standard ECL protocols.
GAPDH
® The blot shows that 4.1 B is expressed in He La cells
treated with control siRNA, and that expression is reduced when the cells are treated with three 
independent epb41l3 siRNAs. GAPDH levels indicate equal protein loading.
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6.3.4.2 Loss o f  stress fibres in 4. IB RNAi HeLa cells
HeLa cells treated with siRNA to epb41l3 for 48 hours exhibited alterations in the actin 
cytoskeleton (Figure 6.13). Rhodamine phalloidin staining shows that siRNA control 
cells often have stress fibres. However, cells with reduced 4.IB have fewer and finer 
stress fibres. In some cells, actin is restricted to the cortex, or arranged into short 
disordered filaments.
Figure 6.13: 4.1 B RNAi causes a loss o f stress fibres in HeLa cells.
Controi siRNA pb41B siRNA #1
epb4U3 siRNA *2 epb4U3 siRNA #3
HeLa cells were transfected with control or epb41l3 siRNA, and fixed 48 hours later and stained 
with rhodamine phalloidin. The cells transfected with epb41l3 siRNA have fewer and finer 
stress fibres; actin is often restricted to the cortex, or arranged into short filaments. They also 
have less total F-actin than control cells. Scale bar = 20pm.
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6.3.4.3 Quantification of effect of 4. IB RNAi on F-actin cytoskeleton 
Confocal images of rhodamine phalloidin-stained control or 4. IB RNAi cells were 
subjected to a double-blind analysis, where each cell was classified according to the 
arrangement of its F-actin. The categories used were “actin stress fibres”, “disordered 
F-actin” and “cortical F-actin”; examples of which are shown in Figure 6.14A. A total 
of 2044 cells from three independent experiments were scored, and the percentage of 
cells falling into each category was calculated (Figure 6.14B). Figure 6.14C shows that 
actin stress fibre-containing cells typically comprise just over 50% of the population 
when transfected with control siRNA. However, when cells are transfected with 
epb41l3 siRNA, the percentage of actin stress fibre-containing cells decreases to less 
than 20% with an increased percentage of cells exhibiting cortical or disordered actin. 
The difference in distribution of stress fibres is significant (x2 P < 0.005).
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Actin stress fibres Disordered F-actin Cortical F-actin 
Control 51.6 45.6 2.8
siRNA #1 18.5 69.5 12
siRNA #2 16.2 70.2 13.6
siRNA #3 18.5 72.2 9.3
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Figure 6.14: Quantification of the effect o f 4.1 B RNAi on the actin cytoskeleton of 
HeLa cells.
(A) Cells were assigned to one of three categories for quantitative analysis of the effect of 
epb41l3 siRNA on F-actin; "actin stress fibres", where at least one stress fibre could be 
seen, "disordered F-actin", where short actin filaments and puncta could be seen, and 
"cortical F-actin".
(B) The actin category o f each cell was recorded and the percentages of cells falling into 
each category are displayed in the table.
(C) The stacked bar chart shows the percentage of cells in each category. Approximately 
half of the control cells had stress fibres, but this fell to just under 20% when the cells were 
treated with siRNA against epb41l3. The difference in distribution o f stress fibres between 
control and epb41l3 siRNA cells is significant (P < 0.005).
Actin stress fibres Disordered F-actin Cortical F-actin
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6.3.4.4 Recovery of stress fibres achieved by expression of rat 4. IB cDNA 
To be certain that the loss of stress fibres is due to the silencing of epb4113, and not the 
result of an unspecific effect of the siRNA, a rescue experiment was performed. Cells 
were treated with epb41l3 siRNA for 48 hours, then transfected with GFP cDNA or an 
RNAi-resistent 4.IB cDNA, and fixed 24 hours later (72 hours after the first 
transfection). The images of phalloidin-stained cells in Figure 6.15 show firstly that the 
4. IB RNAi phenotype persists as long as 72 hours after the siRNA transfection. 
Secondly, they show that whereas the cells transfected with GFP maintain the phenotype 
of a disrupted F-actin cytoskeleton, the cells transfected with 4. IB cDNA recover their 
typical F-actin morphology. Stress fibres and organised F-actin structures have formed 
in cells. Quantification of the images (Figure 6.16) shows that in the RNAi-rescue cells, 
the percentage of cells with stress fibres is just over 40%, almost the same as that in 
control cells. Note that, although this may appear to be a partial rescue of the RNAi 
phenotype, it is likely to be a full rescue, since the transfection efficiency of the 4. IB 
cDNA was only between 50-70%. This rescue experiment confirmed that the effect on 
the F-actin cytoskeleton is due to the depletion of 4.IB by RNAi.
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Figure 6.15: Recovery of the stress fibre phenotype in 4.1 B RNAi 
cells by expression of an siRNA-resistent 4.1 B cDNA.
HeLa cells were transfected with an siRNA-resistant 4.1B cDNA, or GFP, 
48 hours after transfection with epb41l3 siRNA. After a further 24 hours 
they were fixed and stained with rhodamine phalloidin.
Single confocal images are shown here which are representative of three 
indpendent experiments. Cells transfected with GFP exhibit the 
4.1 B RNAi phenotype; they do not have stress fibres and their F-actin is 
disordered, or restricted entirely to the cortex. In contrast, cells 
transfected with 4.1 B cDNA contain stress fibres and organised F-actin 
structures. This confirms that the siRNAs specifically target epb41l3. 
Scale bar = 20 \im.
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Figure 6.16: Quantification of the 4.1 B RNAi rescue experiment.
The stacked bar chart shows the percentage of cells assigned to the 
three actin categories, which are cortical actin, disordered actin, or actin 
stress fibres. Of HeLa cells transfected with control siRNA, 
approximately 50% contained actin stress fibres. When the cells were 
treated with siRNA to epb41l3, this decreased to about 25% of cells. 
However, when the cells were transfected with an siRNA-resistent 4.1 B 
cDNA, the percentage of cells with stress fibres increased to just over 
40%>. This bar chart represents data from three independent 
experiments, where a total of 1665 cells were scored. The difference in 
stress fibre distributions between the RNAi and RNAi-rescue cells is 
significant (P < 0.005).
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6.3.5 Abrogation of 4. IB RNAi effect by introduction of GFP-V14 Rho
I wished to explore briefly the relationship between 4 .IB and Rho, a G-protein well 
known to be involved in the formation o f  actin stress fibres. I investigated whether the 
4.1B RNAi phenotype o f stress fibre loss could be overcome by expressing a 
constitutively-active mutant o f Rho ( VI 4 Rho) in 4. IB siRNA-treated HeLa cells.
6.3.5.1 Effect o f VI4 Rho on the actin cytoskeleton o f 4. lB-RNAi Hela cells 
The small G-protein Rho has been shown to induce the formation o f stress fibres in 
fibroblasts (Ridley and Hall, 1992). To check that GFP-V14 Rho had the expected 
effect on the HeLa cells (an increase in actin stress fibres), the cells were transfected 
with GFP-V14 Rho cDNA, and fixed and stained with rhodamine phalloidin the next 
day. Figure 6.17 shows that there are more actin stress fibres in cells expressing GFP- 
V14 Rho than in the neighbouring, untransfected cells.
Figure 6.17: Effect of GFP-V14 Rho on the actin cytoskeleton of HeLa cells.
GFP-V14 Rho F-actin MergedDj
Iti&L-r- ' - 10B |11
HeLa cells were chemically transfected with GFP-V14 Rho, and fixed and stained with 
rhodamine phalloidin. Single confocal images are shown. All cells contain actin stress fibres, 
but the two cells expressing GFP-V14 Rho have more stress fibres, which are also thicker 
(inferred from the brighter rhodamine phalloidin signal). Scale bar = 20 pm.
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I next looked at the ability of V14 Rho to form stress fibres in cells depleted of 4.IB. 
Cells were treated with epb4H3 siRNA for 48 hours and then transfected with GFP 
cDNA or GFP-V14 Rho, and fixed and stained the next day. The images of phalloidin- 
stained cells in Figure 6.18 show that actin stress fibres are formed in the cells 
transfected with GFP-V14 Rho, whereas the untransfected cells retain the typical 4.IB 
RNAi phenotype of a disordered F-actin cytoskeleton. To quantify the data, cells were 
classified according to their F-actin arrangement. The percentage of cells falling into 
each group is shown in the stacked bar chart in Figure 6.19. This analysis revealed that 
although stress fibre-containing cells account for less than 20% of the 4. IB RNAi HeLa 
cell population, 96% of cells transfected with V14 Rho have stress fibres. Therefore, 
VI4 Rho can overcome the 4.IB RNAi phenotype.
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Rhodamine phalloidin Merged
Figure 6.18: Formation of actin stress fibres in 4.1 B RNAi HeLa cells expressing 
GFP-V14 Rho.
4.1 B RNAi HeLa cells were transfected with GFP-V14 Rho cDNA, 48 hours after the first 
transfection with epb41l3 siRNA. Cells were fixed 24 hours later and stained with 
rhodamine phalloidin. These are single confocal images. Cells not expressing GFP- 
V14 Rho exhibit the typical 4.1 B RNAi phenotype of F-actin arranged in a disordered or 
cortical manner. Cells expressing GFP-V14 Rho do however contain actin stress fibres. 
Scale bar = 20 pm.
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Stress fibres
Figure 6.19: Quantification of V14 Rho-mediated stress fibre formation in 
4.1 B RNAi cells.
The stacked bar chart represents the percentage of GFP-V14 Rho cells 
exhibiting each of the following actin phenotypes; cortical actin, disordered 
actin, or actin stress fibres. Just under 20% of HeLa cells treated with siRNA 
to epb41l3 contained actin stress fibres. 96% of 4 .1B RNAi cells expressing 
V14 Rho contain stress fibres. This bar chart represents two independent 
experiments, where a total o f 501 GFP-V14 Rho-expressing cells were scored.
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6.4 Role of 4.IB in cell motility
6.4.1 Effect o f  4.IB RNAi on sarcoma cell migration
I investigated the function of 4.IB in cell motility by using siRNA to reduce 4.IB 
expression in the slower migrating, non-metastatic K2 cells. K2 cells growing on 
coverslips were microinjected with Cy3-labelled control or epb41l3 siRNA. 48 hours 
later the coverslips were assembled into random walk chambers. Fields containing 
Cy3-positive cells were located and cell movements recorded by low light level digital 
microscopy. Examples of trajectories of control and epb41l3 siRNA cells are shown in 
Figure 6.20A and Figure 6.20B respectively. The control cells migrated at 11 pm/hour, 
whilst the cells microinjected with epb41l3 siRNA migrated at approximately 25 
pm/hour. Cell speeds were normalised to the speeds of uninjected cells in the same 
experiment. After normalisation it was clear that the epb41l3 siRNA cells migrated at 
twice the speed of the cells injected with control siRNA and this is shown in Figure 
6.20C. The difference in speed is significant (P < 0.05). The same experiment was 
performed in A297 cells, which do not express 4.IB, as a control. There was no effect 
on cell migration (Figure 6.21). A297 cells do not express epb41l3, the target transcript 
of the siRNA, and so are unaffected by the siRNA. The lack of effect is pleasing as it 
confirms the specificity of the siRNA.
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Figure 6.20: Effect of 4.1 B RNAi on non-metastatic K2 cell motility.
Cy3-labelled control siRNA or Cy3-labelled siRNA to epb41l3 were microinjected 
into K2 cells growing on coverslips. After 48 hours the coverslips were 
assembled into random walk chambers, and cell migration recorded by low light 
level digital microscopy. Cell translocations were interactively tracked, and 
speeds evaluated in Mathematica. The cell trajectories represent one movie of 
cells injected with control siRNA (A) and one movie of cells injected with epb41l3 
siRNA (B). K2 cells microinjected with control siRNA migrated at approximately 
11 [im/hour. However, cells microinjected with siRNA to epb41l3 migrated at 
speeds of up to 25 [im/hour. Cell speed doubles when 4.1 B is depleted by siRNA 
treatment (C) and the difference in speed is significant (P < 0.05).
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Figure 6.21: Effect of 4.1 B RNAi on metastatic A297 cells.
Control stRNA epfa4113 siRNA
To exclude the possibility that the effect on 
migration o f 4.1 B RNAi was due to an 
unspecific effect of the siRNA, A297 cells, 
which do not contain the target of ep41l3 
siRNA, were injected with the siRNA and 
their migration analysed 48 hours later. 
Cells injected with control siRNA and those 
injected with epb41!3 siRNA migrated at the 
same speed of 28 pm/hour.
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6.4.2 Effect o f 4. IB expression on sarcoma cell migration
Having seen an increase in cell speed in 4.IB-depleted K2 cells, I performed the 
complementary experiment by overexpressing 4.IB cDNA in T15 cells, which do not 
endogenously express detectable amounts of 4. IB protein. Cells were microinjected 
with GFP alone or a mixture of GFP/ 4. IB cDNA and their movements recorded by low 
light level digital microscopy. Cell movements were interactively tracked and analysis 
revealed differences in speed between cells expressing 4.1B/GFP and cells expressing 
GFP alone. Figure 6.22 shows that the expression of 4.IB in T15 cells causes a 
reduction in cell motility; cells injected with GFP migrated at approximately twice the 
speed of those injected with 4.1B/GFP. T15 cells microinjected with only GFP 
migrated at a speed not significantly different to uninjected cells.
Figure 6.22: Effect of 4.1 B expression on metastatic T15 cell motility.
4,1 S+GFP
GFP cDNA, or a mixture of GFP and 4 .1B 
cDNA, was microinjected into T15 ceils 
growing on coverslips. After five hours the 
coverslips were assembled into random walk 
chambers, and cell migration recorded by 
low light level digital microscopy. Cell 
translocations were interactively tracked, and 
speeds evaluated in Mathematical. Cells 
microinjected with both GFP and 4.1 B 
migrated more slowly, and cell speed was 
reduced to approximately half that of the
GFP-injected cells. The difference is significant (P < 0.05).
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Chapter Seven
Discussion
The aim of this project was to improve our understanding of the gene expression 
underlying metastasis by conducting a gene expression microarray analysis of a rat 
sarcoma model of metastasis. The results, approaches, and challenges encountered 
during my research are discussed below, together with the experiments that time did not 
allow, and future directions this research could take.
7 .1 The rat sarcoma model o f metastasis
7.1.1 Suitability o f  the rat sarcoma model fo r microarray analysis
Microarray analysis is now a relatively commonly used approach to investigate 
metastasis. This thesis attempts to deliver an incremental improvement to this 
technique, principally through the use of a panel of four cell lines which originate from 
a common, spontaneous transformation, and which have different abilities to cause 
metastases. Previous microarray studies of metastasis have relied upon samples from 
cancer patients, or animal models with genetic heterogeneity between samples and 
between subjects. The model of metastasis used in this thesis was developed in inbred 
rats, thus providing a uniform genetic background for the experiments. This helped to 
reduce the noise in the microarray data and increased the likelihood that the genetic 
differences that were observed were due to the different abilities of the cells to produce 
metastases.
The rat sarcoma model was suitable for microarray analysis for other reasons. Most 
importantly, the cells exhibited differences in metastatic potential. Secondly, the model 
does not use mice which lack an immune system, such as nude mice, thus allowing the 
effects of the immune system to be taken into account during metastasis assays. This is 
important since the immune system is known to play a role in metastasis, for example 
via the activity of tumour associated macrophages. Finally, the sarcoma cells exhibit in 
vitro behaviours which could be related to their in vivo metastatic potential, and these 
offered opportunities for assaying the effects of genes revealed by the microarray.
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7.1.2 In vitro behaviours o f  the cells and their likely relationships to 
metastasis
7.1.2.1 Chemotaxis
To begin with, I looked at the chemotactic responses of the cells to the growth factors 
PDGF and IGF. These growth facters were chosen because the T 15s had already been 
shown to chemotax towards them (Monypenny, 2003). Furthermore, PDGF and IGF 
may be important in metastasis, since metastatic cells are thought to exploit the homing 
pathways other cells use to move through the body, and these may include PDGF and 
IGF. Also, PDGF is present in the smooth muscle cells of blood vessels, and cell 
migration towards blood vessels is important for the initial intravasation of the 
metastatic cascade.
The analysis of chemotaxis only involved cells that had migrated further than 70 pm. 
This restriction removed non-motile cells, improving the reliability of chemotaxis 
detection since it is only defined for motile cells. I found that the metastatic cells have a 
significantly stronger chemotactic response to PDGF/IGF than the non-metastatic cells. 
The persistence of the cells was also checked, and it was found that none of the 
treatments applied in this thesis had any effect on persistence. A reason for the 
difference in chemotaxis may be that there is differential expression of the PDGF 
receptor or IGF receptor amongst the cell populations. For example, the K2 cells would 
be unable to chemotax if they express fewer receptors for PDGF/IGF. However, the 
microarray analysis did not indicate any differential expression of the receptors, so this 
is unlikely to be the cause of the difference in chemotaxis. It is possible that differences 
in intracellular signalling pathways cause the K2 cells to respond less well to the growth 
factors, although this needs to be explored further. It has also been proposed that the 
lack of chemotaxis in the K2 cells is the result of their inability to release an autocrine 
factor which is involved in chemotaxis (Zicha and Dunn, 1995).
What are the implications of enhanced chemotaxis? A role for chemotaxis in 
intravasation is supported by a report from (Wyckoff et al., 2000) who observed that 
metastatic cells can orient themselves towards blood vessels in vivo. This relates to 
chemotaxis since polarisation is the first stage of chemotaxis. There is also evidence 
that the growth factors employed in this study are specifically involved in some types of 
metastasis. For example, PDGF receptor autocrine signalling is thought to promote
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metastasis in some types of mammary carcinoma (Jechlinger et al., 2006). There is 
evidence that IGF is involved in invasion of melanoma cells (Gimita et al., 2006), and 
IGF was also one of the genes in the Amsterdam signature of poor prognosis (van ft 
Veer et al., 2002). It seems possible in the light of this and other evidence that the poor 
performance of the K2 cells in the chemotaxis assay contributes to their inability to 
metastasise.
7.1.2.2 Speed of migration
Differences in speed between the cells were also observed. The K2 cells migrate at 
approximately 11 pm/hour whereas the metastatic T15 and A297 cells migrate 
significantly faster, at 17 and 19 pm/hour. Since there is no significant difference in 
speed between the K2 cells and the A311 cells, which possess the lowest and highest 
metastatic potential of the model, so there seems not to be an association between speed 
and malignancy in this model. We had expected that there would be an association, 
since increased speed is thought to be associated with malignant cells. For example, by 
performing intra-vital imaging of the tumour cells, Sahai et al. (2005) found that 
metastatic cells had an enhanced speed compared to non-metastatic cells. It is possible 
that the cells investigated in this thesis might migrate differently in three dimensions; 
the cell migration studies described here were performed in an essentially artificial, 
two-dimensional environment. Future work on this model of metastasis would feature 
three-dimensional studies in vitro and in vivo.
It has been suggested that subpopulations of cells from tumours become metastatic, i.e. 
that not all tumour cells have metastatic potential (Fidler and Hart, 1982). Therefore, 
we conducted a detailed analysis of the distribution of speeds within the cell 
populations. This showed that the metastatic cells contain a significantly greater 
fraction of fast-migrating cells than the non-metastatic cells. It is possible that the 
increased speed of these subpopulations can contribute to the metastatic potentials 
observed in the T15, A297 and A311 cells, but this aspect of the study requires further 
investigation.
7.1.2.3 Actin organisation and dynamics
There are also differences in F-actin organisation between the non-metastatic K2 cells 
and the metastatic T15, A297 and A311 cells. The K2 cells typically contain stress 
fibres, while the majority of the metastatic cells in this model do not exhibit stress 
fibres, but rather have their F-actin arranged into a diffuse network of short filaments or
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concentrated into a lamellipodium. Quantification of the images revealed that 68% of 
K2 cells contain at least one stress fibre compared to only 7.5-10% of the metastatic 
populations. How do the observed actin arrangements relate to the situation in vivo? 
Motile responses can be made more efficiently from actin that exists as monomers or 
short oligomers, compared to actin that is largely arranged into stress fibres. This is 
because stress fibres need to be depolymerised before they can be remodelled into other 
actin-based structures. The ability to remodel actin has advantages for the metastatic 
cell. Actin remodelling is known to be an important feature in migration and invasion 
(Rao and Li, 2004) both of which are essential for metastasis. For example, cortical 
actin contraction, formation of a lamellipodium, and tail retraction would probably all 
have to be carried out by an invading cell, and all of these activities are the result of 
actin remodelling.
How do the observed differences in stress fibres relate to cell adhesion? If there are 
fewer focal adhesions, the number of stress fibres will be reduced since stress fibres are 
anchored in focal adhesions. Therefore, it is possible to interpret the loss of stress fibres 
as a loss of focal adhesions. This would result in an increased ability of the cell to 
migrate, since focal adhesions do not have to be turned over. This possibility 
compliments data that has already been obtained on the K2 and T15 cells; namely that 
K2 cells have thick stress fibres and large focal adhesions, and that T15 cells have 
thinner actin fibres and smaller focal adhesions (Pokoma et al., 1994). Had there been 
more time for this project, I would have investigated focal adhesions in detail, since 
they are likely to be central to the functional effect of 4. IB.
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Table 7 summarises the characterisation of the cells and the way in which the 
behaviours of the metastatic cells might contribute to their metastatic potential.
Table 7: Behaviours of the metastatic cells and the ways in which these might contribute 
to metastatic potential.
Relationship to in vivo situation
Enhanced chemotaxis to
Enhanced migration.
Polarisation and chemotaxis towards blood < 
are required for intravasation,
Nicking of physiological homing pathways is thought 
to increase metastasis.
Paster and more efficient completion of the metastatic 
cascade.
Fewer actin stress « w .  Actin can be remodelled and cells are
primed for motile responses.
Xsrzsrr’'"”""*"
The cell may be less firmly attached to the substrate, 
meaning that «t can migrate more quickly.
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7.2 Investigation of the gene expression underlying the
differences observed between the cells
The rationale for the microarray experiment was that the differences described above 
were the result of differential gene expression. The microarray analysis began with the 
analysis of two cell populations and their responses to growth factors, and was then 
extended to include a further two cell populations plus primary tumours generated after 
subcutaneous injection of the cell populations into inbred rats.
Three replicates were performed for each sample, to improve the precision of the 
estimates of gene expression. The statistical significance of each expression ratio was 
determined by a t-test. The P-value was corrected using the Benjamini-Hochberg 
algorithm (Benjamini and Hochberg, 1995) which was necessary to avoid the excess 
false-positive calls which occur in multiple testing. This helped to produce a final 
dataset whose reliability was verified in two ways. Firstly, RT-PCR of a sample of 
candidate genes replicated the expression patterns found by the microarray analysis. 
Secondly, some of the genes that were identified, for example, cspg and neol, have 
been implicated in metastasis by other groups (Faassen et al., 1993; Kiewe et al., 2006; 
Lee et al., 2005).
7.2.1.1 Microarray analysis of K2 and A297 cells
The initial microarray experiment, comparing the non-metastatic K2 and 90% 
metastatic A297 cell populations, and their responses to the growth factors PDGF/IGF, 
found that 294 genes were differentially expressed between the two cell populations. 
This is fewer than are typically obtained from similar studies. For example, Gildea et 
al. (2002) used a human bladder cancer cell line and its isogenic variant to investigate 
the gene expression of metastasis, and found that 2368 out of the approximately 33000 
genes probed were differentially expressed, i.e. 7.2% of genes. In my study, however, 
only 1.9% of the genes were shown to be differentially expressed. Similarly, my 
microarray analysis revealed fewer differentially expressed genes than patient-based 
studies. For example, in the seminal paper by van’t Veer et al. describing gene 
expression associated with poor prognosis, 20% of the transcripts probed by the 
microarrays were found to be differentially expressed (van't Veer et al., 2002), almost 
10 times the percentage of differentially expressed genes reported here. The reasons 
that a small number of differentially expressed genes is considered positive are that it is
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easier to work on a limited number of genes and that the chances of finding a 
biologically relevant gene are increased. The small proportion of differentially- 
expressed genes strongly supports the fitness of the inbred rat sarcoma model for 
microarray analysis.
7.2.1.2 Effect of PDGF/IGF on sarcoma cell gene expression
A growth factor treatment had been included in the microarray experiment since, in this 
model, the progression to the invasive phenotype correlated with enhanced chemotaxis 
in response to a gradient of PDGF/IGF, and I was interested in the transcriptional 
activity that occurred during this response. However, the microarray unexpectedly 
revealed very few significant gene expression differences resulting from up to three 
hours treatment with growth factors. Even when permissive candidate gene criteria 
were applied, very few genes were seen to be changed in response to growth factors, as 
expressed in Figure 4.1. There are two possible explanations for this. Firstly, a short, 
single treatment of PDGF/IGF may not be sufficient to alter gene expression, and may 
instead exert its effect via molecular switches, such as G-proteins, whose activation 
state cannot be determined by microarray analysis. Secondly, in the microarray 
experiment, the cells were exposed to a uniform concentration of growth factors. Cells 
exposed to the uniform growth factor environment might respond differently compared 
to cells experiencing a concentration gradient such as that in the Dunn chemotaxis 
chamber. They may also not respond at all.
An alternative way to explore the effect of PDGF/IGF on gene expression would be to 
expose cells to a concentration gradient in the Dunn chamber, harvest the cells, amplify 
the mRNA and perform gene expression analysis. Gene expression analysis on a small 
number of cells has been carried out successfully by other groups (Wang et al., 2003). 
However, this is unlikely to be as useful as the exploration of the data already obtained. 
Firstly, because growth factors probably exert an effect via intracellular signalling 
leading to the activation of proteins through, for example, phosphorylation events rather 
than a transcriptional change. Secondly, because other growth factors, for example, 
EGF, now appear to be more critical in vivo and perhaps merit investigation more than 
PDGF/IGF. For example, the EGF receptor (EGFR) is often expressed in cancer and is 
associated with a poor prognosis (Klijn et al., 1994).
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7.2.1.3 Extension of the experiment
The microarray experiment was extended to include the 40% metastatic T15 cells and 
100% metastatic A311 cells, enabling us to look for correlations across a panel of four 
cell lines from the same model. There were no changes in gene expression in response 
to the growth factors, as before. We took advantage of this by averaging the mean 
expression values for the three growth factor treatments. We are certain that it did not 
distort the results, since our data had shown that there was no differential gene 
expression following growth factor treatment. Averaging the growth factor treatments 
improved the quality of the data, because the number of replicates used to obtain the 
gene expression values was increased. This is borne out by the fact that in the first 
experiment, one of three genes tested did not have the same expression profile in 
RT-PCR, whilst in the extended experiment, in which the growth factor-treated samples 
were pooled, the RT-PCR and microarray data indicated the same expression patterns.
Another improved aspect of the extended microarray experiment is the analysis of 
primary tumours, which were generated by subcutaneously implanting the cells into the 
rats. The tumours were subjected to microarray analysis in order to assess whether the 
gene expression patterns in the cultured cells were due solely to the influence of cell 
culture conditions. The correlation between the gene expression patterns shows that the 
gene expression of the cultured cells is an acceptable reflection of the gene expression 
patterns in vivo (see graphs displayed in Figure 4.4 and Appendix 4).
For the primary tumour analysis, a whole section of tumour tissue was sampled. This 
section would contain blood vessels and stromal cells including any number and type of 
immune cells. It is possible that these interstitial cells may mask gene expression in the 
tumour cells themselves. Other groups use techniques such as microneedle collection or 
laser capture microdissection to avoid this problem (Wang et al., 2003; Yang et al., 
2006). Unfortunately such techniques were not within the scope of this project.
The gene expression patterns in the tumours were the same as those in the cultured 
cells. Therefore it seems that the gene expression of the stromal cells did not 
appreciably mask the gene expression of metastasis, so I would regard the use of 
unpurified sections as satisfactory. However, it would still be interesting to see whether 
certain genes were differentially expressed at the periphery of the tumour compared to 
the main tumour mass, and whether in fact there are distinct subpopulations of cells
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within the tumour, since particular subpopulations of cells may be critical to the 
behaviour of the tumour (Fidler, 2002).
7.2.1.4 Selection of candidate genes
The rat genome is relatively poorly characterised, meaning that many genes on the array 
were unannotated. In the final candidate gene list, nine out of the twenty-three genes 
were unannotated. Therefore, the choice of candidate genes was influenced by the 
limited availability of reliable sequence data and gene annotation in the rat. It would be 
interesting to investigate the unannotated candidate genes when more information is 
available about them.
The annotated genes were associated with a number of GO terms (see Table 6 for the 
three main biological process GO terms) ranging from embryonic patterning to 
proteolysis. Some of the genes, for example adamtsl, which is assigned the GO terms 
proteolysis, integrin signalling and cell proliferation, have easily imaginable roles in 
metastasis, which lends support to the microarray data and the approach used here, 
whilst for other genes, for example, cask, whose GO terms are protein complex 
assembly, protein phosphorylation, and transport, a role in metastasis is not immediately 
obvious.
Another way to assess the potential relevance of candidate genes is to look at them in the 
context of their interacting partners or in the context of a gene network (Brazhnik et al.,
2002). We coupled the microarray data with a specially developed protein interaction 
database to identify protein communities associated with metastasis (Jonsson et al., 
2006). We found that the majority of communities had already been associated with 
metastatic behaviour to some degree; for example, MMPs, TGF-P and actinin. This 
work still has to be validated experimentally, for example, by testing whether the 
expression or depletion of communities or their regulators has an effect on the behaviour 
of the cells. Nevertheless the methodology developed may be useful in future for the 
analysis of microarray data.
7.2.1.5 Comparison of candidate genes with those proposed by other studies
First I will compare my microarray data with that of others, before going on to speculate 
on the potential relationship of my candidate genes to metastasis. I looked at candidate 
gene lists obtained from other microarray studies of metastasis to check the universality 
of the results. Manual inspection of thirteen other microarray-based analyses of
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metastasis revealed very little overlap between candidate genes, and this is summarised 
in Table 8. Of the thirteen studies inspected, only four contained genes overlapping 
with the genes reported here; in all, five overlapped; actn, epb41l3, greml, RAR and 
tpml. The small overlap between the datasets is disappointing, but perhaps to be 
expected given that lack of correlation between data-sets is an emerging feature and 
challenge of gene expression studies of metastasis (Ein-Dor et al., 2006).
Why is there so little overlap between the studies? Microarray analyses on cohorts of 
patients have been shown to have a lack of transferability to other data-sets (Michiels et 
al., 2005). These problems have been attributed principally to the use of too few 
samples given that the majority of samples come from hosts with heterogeneous genetic 
backgrounds. Similarly, genetic heterogeneity within animal models might mean that a 
high proportion of candidate metastasis genes are actually unconnected with metastasis. 
Additionally, the genetic background of the model, whether heterogeneous or not, will 
have a certain bearing on the candidate genes resulting from the study. Therefore, the 
lack of overlap between my and other studies is disappointing but not overly surprising. 
The implications are that the relevance of the data can only really be ascertained by 
functional studies. As more and improved microarray datasets become available, the 
genes frequently occurring in candidate gene lists might be reliably considered to be 
important players in metastasis.
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Table 8: Comparison of microarray data with other studies on the gene
expression of metastasis.
Study 
Clark et al.
Approach Overlapping genes
Nude mouse model of metastasis. a-Actinin up in
metastasis.
Gildea et al. Comparison of human bladder 
cancer cell lines.
None.
Goswami et al. Profiling of chemotactic cells 
isolated from tumours.
Adamts up in 
metastasis.*
Hao et al. Comparison of primary breast 
carcinomas and their lymph node 
metastases.
None.
Khanna et al. Mouse model of osteosarcoma Ankyrin down in 
metastasis.*
Liu et al. Nude rat model of metastasis. epb41l3 down in 
metastasis.
Minn et al. Nude mouse model of metastasis. None.
Pawitan et al. Analysis of 159 primary breast 
carcinomas.
None.
Ramaswamy et al. Comparison of primary/secondary 
human adenocarcinomas.
Gremlin and RAR 
down in metastasis.
van't Veer et al. Analysis of 117 primary breast 
carcinomas.
None.
Wang et al. (2002) Rat model of metastasis. None.
Wang et al. (2004) Analysis of chemotactic breast
cancer cells.
Tropomyosin and 
a-Actinin up in 
metastasis.
Yanagawa et al. Comparison of primary colorectal None.
tumours with liver metastases.
r indicates that the expression pattern reported is the opposite of that found in this thesis
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7.2.1.6 Potential roles of the candidate genes in metastasis
The candidate genes bk, cask, epb4H3 and ril will be discussed in the next section since 
they were subjected to functional studies. Here I speculate upon the relevance of some 
of the other candidate genes.
Greml, coding for Gremlin (also called DRM), was found to be downregulated with 
metastasis both by this study and by Ramaswamy et al. (2003). Greml was found to be 
repressed in transformed rat embryonic fibroblasts and its exogenous expression therein 
causes apoptosis (Topol et al., 1997). Therefore, its expression in the K2 cells may 
prevent their successful growth in a new site and account for their inability to cause 
metastases. Gremlin also functions as a negative regulator of monocyte chemotaxis 
(Chen et al., 2004). The expression of a negative regulator of chemotaxis in the non­
metastatic cells may explain their poor chemotactic responses to PDGF/IGF.
Adamtsl, encoding the metalloprotease ADAMTS-1, is downregulated with metastasis 
in this model. Our data agree with that of Kuno et al. (2004) who report that 
overexpression of ADAMTS-1 in CHO cells causes inhibition of tumour growth and 
metastasis. It is counter-intuitive that a metalloprotease would be downregulated with 
metastasis, since degradation of ECM is known to be important in cancer, however, 
tumour cell migration may also occur in a non-proteolytic manner (Friedl and Wolf,
2003) meaning that proteases would not necessarily have to be expressed. RNase 4 is 
also downregulated with metastasis. Although there is currently no clear role for RNase 
4 in cancer, unusual levels of RNase have been detected in cancer patients (Peracaula et 
al., 2000) and RNase 4, has been implicated in prostate cancer (Silverman, 2003). Neol 
(Neogenin) is also downregulated in metastasis in this model. Its expression has been 
found to be inversely correlated with mammary carcinogenicity (Lee et al., 2005) which 
would agree with my data.
Cspg4, which encodes the proteoglycan NG2, is overexpressed approximately 65-fold 
in metastatic cells, and 14-fold in metastatic tumours. This agrees with data from Burg 
et al. (1998) who reported that expression of NG2 enhanced the metastatic properties of 
melanoma cells. NG2 is a proteoglycan involved in cell adhesion and its increased 
expression is likely to confer an advantage on cells during the metastatic cascade, by, 
for example, enhancing their ability to adhere to the vessel wall during extravasation. 
Ankyrin 3 is upregulated approximately 19-fold in the metastatic cells and tumours.
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Ankynns link the cell membrane to the spectrin-based cytoskeleton and are thought to 
be involved in migration. Bourguignon et al. (2000) report that the interaction of 
Ankyrin with Tiaml promotes migration in mouse breast tumour cells. The function of 
Tiaml is likely to be affected by an increased availability of Ankyrin. Therefore, an 
increase in Ankyrin expression, as occurred in the metastatic cells of this model, could 
lead to enhanced invasion, which is important for metastasis. It is also possible that the 
increase in Ankyrin expression accounts in part for the enhanced speed of the T15 and 
A297 cells of this model.
7.3 Functional studies o f  selected candidate genes
Here I will discuss the functional studies carried out on candidate genes actn, bk, cask 
and ril. Epb41l3 will be discussed separately in Section 7.4, since many implications 
arose from the experiments on epb41l3.
7.3.1 a-Actinin
My results, showing that a-Actinin is upregulated in metastatic A297 cells, are similar 
to those obtained in a microarray analysis of pulmonary metastases against parental cell 
line grown as subcutaneous tumours, where a-Actinin was enhanced between 3.3-7.3 
times in metastases compared to their corresponding primary tumours (Clark et al.,
2000). The cellular localisation of a-Actinin was investigated by immunocytochemistry 
and colocalisation was seen with actin in both cell types, as expected. There was 
slightly less a-Actinin staining in K2 cells which supported the expression pattern seen 
in the microarray data. Neither metastatic cells overexpressing a-Actinin nor non­
metastatic cells with artificially depeleted a-Actinin displayed any difference in 
motility. This is understandable in view of the fact that a-Actinin is not on the final 
gene list; the expression ratio and statistical significance were not particularly high in 
comparison to some candidate genes, and in view of the extended dataset, may not 
represent significant expression changes but rather random or redundant fluctuations in 
gene expression. In view of this new information, a-Actinin was not explored further, 
although it served as a useful pilot study for how the functional studies would take 
place.
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7.3.2 BK
The gene bk was upregulated in metastatic cells in this model. Its protein product BK 
belongs to a family of C2 domain-containing proteins, other members of which are 
synaptotagmin and rabphilin 3A (Fukuda and Mikoshiba, 2001; Kwon et al., 1996). Its 
name derives from the fact that it was initially thought to be expressed selectively in the 
brain and kidney, although it is now known to be expressed elsewhere (Fukuda and 
Mikoshiba, 2001). It has been shown to target to the membrane via an N-terminal 
cysteine cluster, and Fukuda and Mikoshiba (2001) speculate that this motif may allow 
it to localise to the golgi apparatus. The function of BK is unknown.
There are no antibodies against BK available. This meant that firstly, I was unable to 
confirm the protein expression by immunoblot. Although I have ascertained the 
expression of the Bk gene by both microarray and RT-PCR, it is possible, though 
somewhat unlikely, that the transcriptional activity does not mirror the translational 
activity in the cells, as the mRNA may be preferentially translated in different tissues or 
at different stages. Secondly, I had to rely upon cDNA constructs of BK to investigate 
its localisation in the cells.
I cloned and expressed GFP-BK in the sarcoma cells. The BK protein was C-terminally 
tagged since I did not wish to place the GFP tag at the N-terminus and risk disrupting 
the membrane targeting which is believed to occur via the N-terminal cysteine cluster. 
When GFP-BK was expressed in Hela cells, it had a wide cellular distribution with a 
slight accumulation in the nucleus, and was not significantly enriched at the membrane, 
although it is reported to be tightly bound to the membrane fraction (Fukuda and 
Mikoshiba, 2001). This raised the possibility that the BK protein may not have been 
correctly expressed or folded by the cells, or that the GFP tag interfered with the 
membrane localisation and activity of BK. I therefore removed the GFP tag from BK 
for the subsequent motility studies.
I found no significant difference between the motility of cells injected with GFP and 
cells injected with the mixture of BK/GFP. This indicated that BK has no effect on 
motility in the sarcoma cells. However, without a functional antibody, it was not 
possible to assess whether BK was being expressed and localised correctly in the cells. 
Similarly, without an antibody to check RNAi efficiency, I was unable to perform the
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complimentary motility experiments in the metastatic A297 cells, which are believed to 
overexpress BK.
In summary, technical limitations opened these functional studies to uncertainty. For 
example, I could not check the possibility of a discrepancy between the mRNA and 
protein expression, nor could I check the cellular localisation of the endogenous or 
ectopic protein. Therefore I decided to abandon the experiments on BK. If time had 
allowed, I would have generated an antibody against BK in order to resolve the issues 
mentioned above, before beginning overexpression and knock-down studies. An 
alternative way to check the correct targeting of the BK construct would be to fuse it to 
a FLAG or similarly small tag. FLAG tag technology consists of tagging a protein with 
an eight amino acid motif, which is very likely too small to interfere with protein 
function. The protein is then expressed by the cells and the cells are fixed and probed 
with an anti-FLAG antibody, to check the expression and localisation.
7.3.3 CASK
The gene cask and its protein product are upregulated in K2 cells compared to the three 
metastatic cell populations. CASK was identified as a neurexin-interacting protein 
(Hata et al., 1996) and is composed of a CaM Kinase domain, a DHR domain, PDZ 
domain, SH3 domain and a guanylate kinase domain. The structure suggests that 
CASK is an adaptor protein, presumably localising to the membrane via its SH3 domain 
and possibly mediating calcium signalling events via its CaM kinase domain. CASK 
has also been shown to bind to protein 4.1, which suggests a role in linking the ECM 
and the cytoskeleton (Cohen et al., 1998).
The protein expression was confirmed by immunoblotting, and the cellular localisation 
was investigated in fixed cells using the same antibody. The staining pattern of the 
CASK antibody was diffuse throughout the cytoplasm and there was no increase in 
CASK staining in the K2 cells. In fact, it was possible to see a slight increase in CASK 
staining in the metastatic cells which is the opposite of what would be expected given 
the expression patterns revealed by the microarray, RT-PCR and immunoblot. Since 
the antibody had worked well in immunoblotting (i.e. without recognising non-specific 
proteins) it seems reasonable to conclude that the antibody simply does not work well 
for immunocytochemistry and can only be relied upon for immunoblotting. This is 
likely due to the manner in which the antibody was generated. For example, if a peptide
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was used to make an antibody, it is possible that the peptide site was exposed by the 
procedures for immunoblotting but not by the procedures for immunocytochemistry.
The amount of CASK probably appeared to be greater in the A297 with 
immunocytochemistry because of cross-hybridisation.
I went on to investigate the effect of overexpression of GFP-CASK on the sarcoma 
cells. The GFP was tagged to the N-terminus of the protein so as to not interfere with 
the putative membrane binding. GFP-CASK could be detected on an immunoblot by 
the anti-CASK antibody, which indicated that CASK was expressed correctly by the 
cells. Expression of GFP-CASK in A297 cells was seen throughout the cytoplasm and 
nucleus and there was no colocalisation with F-actin and no enrichment at the 
membrane. It is possible that this is the correct localisation of CASK, and that it only 
binds the membrane when the correct calcium signals are received and transduced by 
the CaM kinase domain. If more time had been available, I would have improved the 
investigation of CASK by observing the behaviour of the cells in response to activation 
of the CaM kinase cascade (Soderling, 1999). This might reveal an effect on cell 
behaviour which is not evident in basal conditions.
Again, it is difficult to be sure that the GFP tag (which was beside the CaM kinase 
domain) did not interfere with the function of CASK, and if I had more time to 
investigate this aspect, I would use a FLAG-tagging strategy to try and establish its 
cellular localisation. For the motility studies, untagged CASK was used. I found no 
difference in speed between A297 cells injected with GFP/CASK and those injected 
with GFP alone. I then performed the complimentary experiment in K2 cells by 
reducing CASK expression by RNAi. Again, there was no difference in speed between 
cells expressing different levels of CASK, nor was there any difference in cell 
morphology or actin cytoskeleton in CASK RNAi A297 cells. Since these 
complementary approaches had no effect on the cells it is clear that CASK alone cannot 
be responsible for the differences in cell motility and cytoskeleton.
Although I have not been able to show experimentally that CASK has a role in 
metastasis or any associated behaviours, work by others suggests that CASK may be 
involved in metastasis. For example, Al-Lamki et al. (2005) investigated the genes 
associated with relapse in paediatric acute lymphoblastic leukaemia and found that 
overexpression of CASK was common in non-relapsed patients. It has also been
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reported that CASK was upregulated in 87% of human oesophageal carcinomas tested 
by Northern analysis (Wang et al., 2002a). This would agree with my data that shows 
that CASK is overexpressed in non-metastatic sarcoma cells.
7.3.4 R1L
Reversion-induced LIM protein (RIL) is overexpressed with metastasis in this model.
RIL contains a PDZ and an LIM domain, and was found to be upregulated in 
Jun-transformed cells (Fu et al., 2000). RIL may be a regulator of actin stress fibre 
turnover, since the expression of RIL causes the rapid formation of new stress fibres and 
frequent collapse of thick stress fibres (Vallenius et al., 2004). As RIL is upregulated in 
metastatic cells which do not have thick stress fibres, one might speculate that the 
presence of RIL contributes to the turnover of filaments and the phenotype of reduced 
actin stress fibres. Similarly, the upregulation of RIL in the metastatic cells would 
account for the faster actin dynamics in T15 cells.
I used a GFP-fusion protein of RIL to investigate its cellular localisation. The 
colocalisation of RIL with actin stress fibres demonstrated that the protein was expressed 
correctly and had actin-binding function. The lack of effect on actin stress fibres in K2 
cells, which typically do not express RIL, was surprising, as was the absence of a change 
in speed when the cells were injected with RIL. This indicates that RIL is unable to 
affect stress fibres on its own. The function of RIL in stress fibre turnover does not seem 
to affect these cells, although this aspect would be better investigated in live cells, for 
example by FRAP (fluorescence recovery after photobleaching).
Since RIL contains a PDZ and LIM domain it may act in synergy with a-Actinin, which 
is a PDZ containing protein. If the two proteins were co-expressed, they may have some 
effect on the cells and this is something that regretfully I was unable to explore.
Vallenius et al. report that RIL can enhance the association of a-Actinin with F-actin. If 
time had allowed, I would have investigated whether the coordinate deregulation of these 
two proteins is able to elicit a change in the cells.
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7.4 Is there a role for 4. IB in metastasis?
The candidate gene epb41l3 is significantly down-regulated in metastasising sarcoma 
cells. The similarity of expression patterns in the primary tumours and the cultured 
cells, shown in Figure 4.4, excluded the possibility that the expression pattern of 
epb41J3 was solely a result of cell culture conditions. Immunoblotting showed that the 
protein product 4.IB was also downregulated in the metastatic cells.
7.4.1 4. IB as a tumour suppressor
The tumour suppressor activity of 4. IB has been demonstrated in lung, meningioma 
and breast cancer cell lines (Charboneau et al., 2002; Gutmann et al., 2001; Tran et al., 
1999). 4.1B is lost in about 60% of lung adenocarcinomas (Tran et al., 1999), 
meningiomas (Gutmann et al., 2001) and renal clear cell carcinomas (Kikuchi et al., 
2006). However, Yi et al. (2005) recently developed a 4. IB deficient mouse and found 
it to be indistinguishable from wild-type mice in terms of development and tissue 
morphology. Furthermore, the 4. IB7' mice had no change in cellular proliferation and 
no predisposition to cancer, under the conditions tested. This raised the possibility that 
4. IB loss occurs in association with, rather than as a cause of cancer (Yi et al., 2005). 
However, the lack of apparent difference in cancer predisposition in 4. IB7" mice does 
not rule out a causal role in cancer, as other factors, such as genetic background and 
functional compensation, must also be considered. The effect of 4. IB loss would be 
dependent upon the genetic background of the model system or of the patient, just as the 
effect of any other alteration is influenced by the genetic background in which it occurs. 
Furthermore, the absence of 4. IB in this mouse may be compensated for by other 
proteins, such as other members of the 4.1 superfamily or splice variants of 4. IB. 
Finally, 4. IB may be more important in the progression of cancer rather than its 
initiation.
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7.4.2 A new epb4H3 splice variant
I found that the epb4H3 transcript in the sarcoma cells is a variant of the 4. IB minor 
isoform type II, which represents a third splice variant of epb41l3. This variant was 
submitted to GenBank and assigned the Accession Number DQ462202. By checking 
the predicted protein sequence of the new isoform, I confirmed that the protein domains 
that characterise 4. IB were conserved. The discovery of a third splice variant 
underscores the importance of alternative splicing in the effects of 4. IB and the 4.1 
superfamily. Different splice variants of epb41l3 are thought to contribute to its tissue 
specificity (Gascard et al., 2004). As yet the function of the new splice variant is not 
known.
7.4.3 What is the cellular localisation o f  4. IB?
DAL-1 had been localised to cell-cell contacts (Tran et al., 1999) and to the plasma 
membrane (Charboneau et al., 2002). Although the 4. IB antibody worked satisfactorily 
for immunoblotting, it did not work in immunocytochemistry, in a range of different 
fixation and staining conditions. Therefore, the only way to localise the protein was 
with the use of genetic fusions. Constructs encoding a 4. IB protein tagged at the N- or 
C-terminus with GFP were generated and expressed. Co-staining with rhodamine 
phalloidin was performed, since 4.IB contains an SAB domain, known to bind actin, 
and I wished to check whether GFP-4.1B would colocalise. Expression of GFP-4.1B 
was diffuse in the cytoplasm with no expression in the nucleus. Some colocalisation 
with actin was observed, as indicated by arrow heads in Figure 6.6. There were areas of 
higher expression at the edge of the cell, as indicated by the arrowheads in Figure 6.8B 
and the high magnification image in Figure 6.8C. This agrees with an observation by 
Tran et al. who reported minor punctuate staining at the cell edges, and Charboneau et 
al., who observed an enrichment of 4.IB at the cell membrane. To avoid the potential 
problem of the GFP interfering with the protein function, an untagged version of 4. IB 
was used in the subsequent functional studies. Incidentally, the problems associated 
with tagging FERM domain-containing proteins have been commented on before 
(Chambers and Bretscher, 2005). Had more time been available, I would have 
employed a FLAG-tagging strategy, or preferably generated another antibody to 4. IB, 
to check more rigorously the localisation of the protein.
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7.4.4 Does 4. IB regulate cell motility and the actin cytoskeleton?
The effect of depleting expression of 4. IB in K2 cells, in which it is endogenously 
overexpressed, was assessed. K2 cells microinjected with siRNA against epb4H3 
displayed an altered F-actin cytoskeleton, with fewer stress fibres and less total F-actin 
than cells microinjected with control siRNA. Similar results were obtained in HeLa 
cells, illustrating that 4. IB loss can cause an effect in more than one cell type. The 
stress fibre phenotype could be restored by expressing siRNA-resistant epb41l3 in the 
cells. This was achieved by the use of an untagged rat epb4H3; the siRNA used for the 
HeLa cells was targeted against sequences specific to human epb4H3 and not conserved 
in rat epb41l3. The recovery of stress fibres is important since it indicates that all three 
siRNA were correctly targetting the epb41l3 sequence and that the loss of stress fibres 
is a specific result of 4. IB loss. The specificity of the siRNA was further backed up by 
experiments in which siRNA against epb4H3 was shown to elicit a phenotypic change 
in the K2 cells and not the A297 cells, the reason being that the A297 do not express 
epb41l3, the target transcript of the siRNA.
Metastatic cells in this model contain fewer stress fibres and less 4.IB than the 
non-metastatic cells. Similarly, cells made to express less 4. IB exhibit fewer stress 
fibres. Taken together, these observations suggest that the loss of 4.IB in the metastatic 
cells is partly responsible for their lack of stress fibres. Interestingly, a reduction in 
stress fibres accompanying the metastatic phenotype has been observed by others 
(Khanna et al., 2001).
The relationship between 4. IB and the actin cytoskeleton was further explored by 
expressing 4.IB in the metastatic cells. The ectopic expression of 4.IB in metastatic 
T15 cells, which do not endogenously express 4.IB, had no apparent effect on the 
arrangement of F-actin. There are a number of reasons that can account for the 
non-appearance of stress fibres in T15 cells overexpressing 4. IB. As seen from the 
microarray, a wide range of genes are differentially expressed between the 
non-metastatic and metastatic cells. These additional proteins may be required by the 
metastatic cells in order to form a significant number of stress fibres. Since 7-10% of 
the metastatic cells do contain stress fibres there must be other stress fibre-forming 
factors at work besides 4. IB. One of the differentially-expressed proteins may be a key 
binding partner of 4.IB, meaning that overexpressed 4. IB would have no opportunity to 
affect the cytoskeleton. Alternatively, 4.IB may have no effect on the actin
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cytoskeleton because, for example, its signalling partners are being used by another 
protein. The third and perhaps most likely possibility is that the method that I used to 
detect the stress fibres is not sensitive enough to detect 4.IB-induced differences in the 
T15 cells; I used a binary classification where cells were scored as having stress fibres 
or no stress fibres. Automatic quantification of the cells on the basis of their rhodamine 
phalloidin signal might reveal differences between cells expressing 4. IB and control 
cells, although the natural heterogeneity of the sarcoma cells renders such a strategy 
very difficult.
As 4.IB RNAi disrupted the actin cytoskeleton of K2 cells, its effect on cell migration 
was also tested. K2 cells were microinjected with control or epb4H3 siRNA and their 
migration recorded 48 hours later. Reduction of 4. IB expression by siRNA treatment 
caused cell speed to double. Although 4. IB expression did not induce the formation of 
stress fibres in the metastatic T15 cells, it reduced their speed by half. The fact that 
overexpression of 4.IB as well as its depletion can lead to changes in speed in different 
cell types, strongly supports the possibility that 4. IB is important for cell migration in 
this model.
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7.4.5 How does 4. IB affect stress fibres and speed?
The 4. IB RNAi-induced loss of stress fibres and increase in cell speed is striking 
because these two phenotypes also occur in the metastatic cells, which do not 
endogenously express 4. IB. Furthermore, actin rearrangements accompanying changes 
in speed have been observed by others. For example, Clark et al. (2000) reported that 
metastatic cells migrate more and have more filopodial protrusions than cells from the 
primary tumours. The link between loss of stress fibres and increase in speed may be 
that cells in which actin is not polymerised into stress fibres are primed for migration 
since their largely monomeric actin can be more easily remodelled into the structures 
required for motility, as mentioned in Section 7.1.
Since stress fibres are localised at focal adhesions (Parsons et al., 2000) the presence of 
4. IB in focal adhesions might explain its affect on the actin cytoskeleton. Perhaps a 
clustering of 4. IB within the focal complexes provides an anchor for actin filaments and 
helps them to remain organised in stress fibres. There is some evidence to suggest that 
4.IB is involved in focal adhesions. Firstly, 4.IB has been shown to colocalise with the 
focal adhesion protein Paxillin in cultured astrocytes (McCarty et al., 2005). Secondly, 
4.IB is thought to affect cell adhesion. It has been observed that 
DAL-l/4.1B-expressing breast carcinoma cells were better able to adhere to Fibronectin 
or Matrigel™ than DAL-1/4. IB non-expressing cells (Charboneau et al., 2002), and 
Gutmann et al. (2001) observed spreading defects in RT4 schwannoma cells 
overexpressing DAL-1. Thirdly, 4.IB can interact with proteins that are known to be 
involved in adhesion, such as integrin avp8 (McCarty et al., 2005) and TSLC-1 (Yageta 
et al., 2002). Together these reports would support the idea that loss of 4.IB might 
disrupt the focal adhesions. If 4. IB is involved in maintaining focal adhesions, it may 
be the effect on these, rather than a direct effect on stress fibres, that causes the 
phenotype reported in this study.
The regulation of focal adhesions can also affect cell speed. For example, 
FAK-deficient mice, which have increased focal adhesions, also display reduced 
motility (Ilic et al., 1995). Therefore, disruption of focal adhesions by perturbation of 
4.IB levels could account for the increase and decrease in cell speed that occurs upon 
4.IB depletion and overexpression respectively. For example, overexpressed 4.IB
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arranged into focal complexes might hinder the de-adhesion that is an essential part of 
cell migration. Similarly, the reduced amount of 4.IB in focal adhesions might cause 
the adhesions to be slightly less stable and increase the speed with which they can be 
turned over by the cell and consequently increase the speed of cell migration. These 
ideas are summarised in Figure 7.1.
Of the three main domains on protein 4. IB, it is most likely that the observations 
reported here are mediated by the FERM domain, which has been shown to link the 
cytoskeleton to the ECM (Chishti et al., 1998). Therefore, reduced availability of the 
FERM domain of 4.IB may mean that the cell/ECM linkage is lost. This would mean 
that cells can move in a faster and uncontrolled way. In comparison, cells that 
overexpress the 4.IB protein move more slowly, since there are more interactions 
between the cell and the substrate, meaning that adhesion is too high and cell migration 
is impeded.
Had more time been available, I would have tested the effects of different truncation 
mutants of 4.IB in order to postitively identify the domain interactions responsible for 
the changes in cell motility. Given more time I would also characterise the focal 
adhesions in cells with altered levels of 4.IB. It has however already been shown that 
the K2 cells (which overexpress 4.IB) have larger focal adhesions than the 4. IB non­
expressing T15 cells (Pokoma et al., 1994) and so a correlation if not a direct link 
between 4.IB and focal adhesions has been shown.
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Figure 7.1: What are the consequences for the cell if 4.1 B is involved in focal adhesions?
A focal adhesion containing various proteins including 4.1 B.
STRESS
FIBRE cytosol
plasma
membrane
■ ECM
FOCAL ADHESION formed from a variety 
of proteins, including 4.1 B.
Focal adhesion turnover is slow 
and speed is moderate.
A focal adhesion without 4.1B.
STRESS________
FIBRE ------cytosol
becomes finer plasma
or membrane
disassembles fill i\
 ECM
FOCAL ADHESION becomes weaker.
Focal adhesions are weaker and 
stress fibres are rarer.
Focal adhesion turnover is rapid 
and speed increases.
The possibility that 4.1B is involved in focal adhesions can explain some the data presented in this thesis.
Upper panel: 4.1 B contributes to the focal contacts into which stress fibres are embedded. Stress fibres can be seen in rhodamine phalloidin-stained cells. The speed of 
the 4.1B-containing sarcoma cells is approximately 11 \.im/hour:
Lower panel: The absence of 4.1 B from the cells, either in metaststic cells or in non-metastatic cells treated wtih RNAi, may result in a destabilisation of the focal 
contacts which in turn means that fewer stress fibres are present. The weakness of the focal contacts means that they are rapidly turned over by the cell and migration 
increases.
Focal adhesions are strong and 
stress fibres form.
7.4.6 What are the other mechanisms by which 4. IB might affect cell 
motility and the cytoskeleton?
4.IB could affect cell motility and the cytoskeleton in other ways besides contributing 
to focal adhesions. 4.IB has recently been shown to modulate the methylation activity 
of other proteins and this ability may affect cell motility and the cytoskeleton. 4. IB 
interacts with N-methyltransferase 3 (PRMT3) (Singh et al., 2004) and PRMT5 (Jiang 
et al., 2005), although 4.IB does not become methylated by PRMT3 or PRMT5 in vitro, 
but rather modifies their ability to methylate other protein substrates in the cell. If 4. IB 
is able to modulate the activity of a PRMT, it may be able to affect the cell in many 
ways, since methylation of proteins can influence signal transduction and transcriptional 
activation (McBride and Silver, 2001). The interaction of 4.IB with PRMT3 and 
PRMT5 may be a mechanism through which 4.IB regulates tumour suppression.
Indeed, in MCF-1 breast cancer cells, artificial protein methylation and 4.IB were 
shown to enhance apoptosis (Jiang and Newsham, 2006).
The mechanism by which 4. IB may stabilise or contribute to the formation of stress 
fibres is most likely via the GTPase Rho, as Rho controls both stress fibre formation 
and focal adhesion formation (Ridley and Hall, 1992). Moreover, other ERM proteins 
have been shown to be required for Rho function (Mackay et al., 1997) so it would 
seem reasonable to suppose that 4. IB might also affect Rho function. I therefore 
performed an experiment with constitutively active (VI4) Rho in an attempt to 
determine the signaling involved. If 4. IB were an effector of Rho, VI4 Rho would not 
be expected to form stress fibres in a 4.IB RNAi background (see Figure 7.2A). VI4 
Rho was found to recover stress fibres in 4.IB RNAi K2 cells. The observation that 
V14 Rho can make stress fibres independently of 4.IB could be explained by Rho being 
downstream of 4. IB (see Figure 7.2B). This would mean that the depletion of stress 
fibres in 4. IB RNAi cells occurs because Rho does not become activated by 4. IB.
This hypothesis conflicts with a recent report (Gerber et al., 2006) that 4.IB has no 
effect on the activity of Rho. An alternative explanation for the ability of V14 Rho to 
form stress fibres in a 4.IB RNAi background is that 4.IB and Rho operate through 
different signaling pathways. Alternatively, the depletion of 4.IB by siRNA treatment 
may have been insufficient, meaning that 4.IB was still available to be activated by V14 
Rho. This aspect of 4.IB action needs to be explored in further detail by, for example,
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the performance of Rho pull-down experiments and by testing whether 4. IB is able to 
form stress fibres in cells expressing the dominant negative N 17 Rho.
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Figure 7.2: Schematic illustrating the possible interplay between 4.1 B and Rho.
Hypothesis: Rho activates 4.1B.
Wild-type situation 4.1B RNAi
V14
RhoRho
4.1B
Hypothesis: 4.1B activates Rho.
Wild-type situation 4.1 B RNAi
4.1B
V14
Rho
Rho
Experiments were performed in a 4.1 B RNAi background to explore the possible
interplay between 4.1 B and the small GTPase Rho. In hypothesis A, activation of 4.1 B 
results in the formation of stress fibres. In a 4.1 B RNAi background therefore, 
constitutively active V14 Rho will not form stress fibres. Hypothesis B is that 4.1 B 
activates Rho. If this is the case, V14 Rho will be able to form stress fibres in the 
absence of 4.1 B.
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7.4.7 Other evidence for a role for 4. IB in metastasis
A range of studies suggest that 4. IB is a tumour suppressor (Charboneau et al., 2002; 
Gutmann et al., 2000; Tran et al., 1999). My data suggest that 4.IB may also function 
as a metastasis suppressor as its loss supports the enhanced cell motility which is 
required for metastasis (Ahmad and Hart, 1997) and a concomitant reorganisation of the 
actin cytoskeleton. Had more time been available, stable cell lines with depleted or 
overexpressed 4.IB would have been generated to test whether the metastatic potentials 
of the K2 and T15/A297/A311 cells could be reversed. As metastasis assays have not 
yet been performed, I cannot say with certainty that 4. IB can act as a metastasis 
suppressor in vivo. There is however some evidence to suggest that 4.IB loss is 
associated specifically with a tendency to metastasise. For example, loss of 
heterozygosity of the region of chromosome 18 where 4. IB is localized has been 
observed in more than 55% of invasive DCIS (ductal carcinoma in situ) tumours 
(Kittiniyom et al., 2001). Also, in a microarray analysis of cancer cell lines, Liu et al.
(2004) found that 4. IB is downregulated in metastatic variants of the H460SM lung 
cancer cell line. Loss of 4.IB via epigenetic inactivation is also associated with 
metastasis in human cancers. The epigenetic inactivation of 4.IB by promoter 
methylation was found to be an indicator of poor prognosis in patients with lung 
adenocarcinoma, as it is associated with a shorter survival (Kikuchi et al., 2005). 
Preferential methylation of 4. IB in lung adenocarcinomas with invasion to the 
surrounding tissues, lymph nodes (often the first step in metastatic disease) and pleura 
was also observed. Similarly, epigenetic inactivation of 4.IB by promoter methylation 
was also found to correlate with a shorter recurrence-free survival in patients with renal 
clear cell carcinoma (Kikuchi et al., 2006). These observations support the data I have 
shown to suggest that loss of 4.IB can enhance cell behaviours which are associated 
with metastatic potential.
7.4.8 Summary
To summarise this section, 4.IB was found to be downregulated in metatastic cells. 
Fucntional assays of 4.IB by both siRNA treatment and cDNA expression strongly 
suggest that 4. IB has a role in both cell motility and the cytoskeleton. The mechanism 
through which 4. IB exerts its effects remains unknown but a role in metastasis seems 
likely, as loss or epigenetic inactivation of 4.IB has been associated with invasive 
cancer and a shorter survival time in cancer patients.
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7.5 Conclusion
In this thesis I have described the use of gene expression microarray technology to 
search for genes that relate to the development of metastasis. The model of metastasis 
used for the microarray was chosen because of its uniform genetic background and 
correlation between cell behaviour in vitro with metastatic potential in vivo. The 
success of the microarray experiment is demonstrated by the fact that the data are 
reproducible in other assays, and that some of the candidate genes have already been 
identified in metastasis. Furthermore, one of the candidate genes, epb41l3, has a 
functional effect in the cells.
Epb41l3, encoding the protein 4. IB, is downregulated in metastatic cells and its 
reintroduction reduced the speed of the cells by half. Conversely, the depletion of 4. IB 
from non-metastatic cells resulted in an increase in cell speed and concomitant loss of 
stress fibres. This is important because both cell migration and the regulation of the 
actin cytoskeleton are known to be involved in metastasis.
I conclude that the loss of 4. IB in the metastatic cells causes a remodelling of the actin 
cytoskeleton together with an increase in speed that may promote the ability of the cell 
to metastasise. Others have associated 4.IB with cancer (Charboneau et al., 2002; 
Gutmann et al., 2000; Tran et al., 1999) and specifically with human cancers that are 
invasive or likely to invade (Kikuchi et al., 2006; Kikuchi et al., 2005; Kittiniyom et al.,
2001). The clinical implications of this are that 4. IB could be a useful prognostic 
marker for cancers since its loss may be indicative of metastasis.
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7.6 Reflections on the approaches used in this thesis
Since completing the research for this thesis I have reflected on the approaches used. 
The central approach was the use of a gene expression microarray to shed light on some 
of the gene expression controlling metastasis. A possible criticism of this work could 
be that, as 4. IB is thought to be a tumour suppressor, an investigation into its role in 
metastasis might have been initiated without the use of microarray technology, which is 
costly and was at the time rather difficult. Whilst this is true, I believe that the 
microarray analysis that was conducted was a sensible, rigourous approach, and that it 
cannot be undermined by the fact that the main gene investigated, 4. IB, was already 
known to be involved in cancer. Secondly, the use of the microarray can be justified by 
the fact that my data validates other data, which is a valuable contribution in itself. 
Thirdly, the microarray data has not yet been fully exploited, and it is likely that 
investigation of other candidate genes may reveal entirely novel, useful information.
With regard to the model that I chose, it has now come to light (Ein-Dor et al., 2006) 
that many thousands of samples are needed to generate a robust gene expression 
signature for patients. This is due to the fact that the variation between patients 
interferes with the collection of reliable data. This information supports my reasons for 
using the model of metastasis that I did; a model in which the subjects are genetically 
related, thus supplying little heterogeneity between samples.
The ideal project would have been to collect tissue samples from hundreds of patients 
and conduct a tissue microarray. However, at the time that my project began, tissue 
microarrays were not yet particularly reliable. Similarly, the number of samples needed 
to produce reliable data was simply not known. In terms of the scope of my project and 
the constraints of time, budget and labour, I think that my approach is justified and 
provided useful information.
Were I to continue with my research, I would try to exploit my microarray data fully, 
and compare it to emerging patient data in order to assess the relevance of the genes, 
before moving on to careful and thorough functional studies.
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Appendix l: Algorithms used for the processing of cell tracks.
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SPECIFY DIRECTORY WITH *.cel (Kinetic Imaging) or Mog (Universal Imaging) FILES AND GROUPS
Files grouped in subdirectories 01 jgroupl, 02_jgroup2,... also optionally containing *.txt files
Optional *.txt files can provide following parameters:
xyResolution = {1.27,1.27} (*in pm/pi)el or pixels/Cm (default)*)
resol utjonUnit="pm/pixBr
image\Mdth=640
imageHeight=512
lapselnterval = 5 (*min*)
rotationAigle = 0 (‘degrees*)
Universal Imaging log tiles from automatic tracking have format. "Object #","Frame tf'/’XVY "Distance" with log column titles ON
dirPath = ;
= EUaNmea["*.oel", diifiatii, Infinity]; 
grcxpFLlenanas = S£lit[allFilea, dtutfetrii]; 
graptferaes = Tabla[StringTate[graipFilenmBS[ [ i , 1] ] ,
{StringPositicn[gEoipEllenanes[[i, 1]], " \\" ][[-2 ,1]] +4,
Stringftasiticnlgroipri lnrwms[ [1, 1]], "\\"] [[-1, 1]] -1 }], ( i ,  Length[groipFilenagBs])] ;
TViblBFhTm[I>biLe[(grrxpNamfts[[i]] ,  Igngth[grenpFiIenanBS[[i]]]), { i ,  Tnnijth[grrii'|tlriirn]]]. Tnhlnllmrllngn i [nrrtrmrHr {"Group", "N"})]
Group N
1 niceA297ribFilm 1
Mathematica® 
routine for the 
evaluation of cell 
motility
This reproduction of a 
Mathematica® Notebook shows the 
routines used for evaluation of cell 
motility, from import of the cell 
tracks to generation of trajectories 
and production of circular 
histograms
SELECTING SUBSET OF GROUPS: False or True If True type in the groups that you'd like to include in the 
selectGroupSubset = False
Ecilse
groupelncluded = Range] Length[groipFilenMnas] ] (*default to a ll  data*)
{1}
Tf gmywTnr.l'rWi = {3, « i]; TthlaEtarm[Tahle[{grouftfetnee [ [groupsInc1urted[ [i] ] ] ] , Length[groupgLlenanBS[ [gpcq?sIncUrinti[ [i] ] ] ] ] ) ,  {1, Length [gnxpelnrhriwri]) ] ,
TablcHoadingrj -> (Automtic , {"Gnxp", "N"}}]
Group N
1 nioeA297nbFllm 1
208
LOAD TRACK DATA (OPTIONALLY SEPARATE DATAfor CNT and TRE with pathological FLAG: False or True)
separatePathologicalCells = False
F alse
■ OPTIONAL CHOICE OF pathological-> True or False (‘replace Ail*)
I f  [ I separataftithcil ogjcalOnlls,
trackData = Tahlg[]narfTYacto[graq?FilgnanBa[[gre^yslncludad[ [grxxplndax]]]] [ [novialndex]] , patixxLogiaal-»A ll], {gnxplndax, L*rgth[graj?sInclLidad]},
{movielndsoc, Length [graipFil«nane8[ [grcnyalncludad[ [grxxplndax] ]]]]} ];
Ednansicns /o trackData]
Z:\chaTDtaxis_groups\16_nioeA297nbFilm\030814c.oel: xyFtesolution = 7874.02 7874.02 jm /p ixe l la p se In te rv a l = 5 
{{1, 2764, 3}}
trad'DataQn: = IWbl«[IoadCradcs[gcot()FilaraRB8[[grotpsIncludad[[grotplndax]]]] [ [novialndsx]] , pattological-» Eslaa] , {gratpliri«x, length[gnxpalnr.Uried] },
{ncvialndeoc, largth[grotffilonanas[[gcoqpalKluted[ [gixxpIndK]]]]]} ];  
tradOataTPE = Tiabla[lcatffiradca[grxriiy)FilenaraBS[[groupaIncludBd[[grotplndax]]]] [ [novieEndeK]] , patinlogiaal-*Ttue], (gnxpIndeK, Iangth[gixxj?elhcludad]},
{RDvxalndax, Length[graupKLLenanBe[ [groqpeInclu3ed[ [grotpIndeK] ]]]]} ]; trac*Data= JccLn[trac*DataCNr, trat*Data35E] ; 
grotyNagnea = Join[StrlngOam[ #, "_COT"] &/ograqcNames, StringJ6in[ #, "jn®"] S/egrot$f6nB8] ;
grcnyFilenanas = Jain[groipFilerime8, groqnPtl enamas]; Tibleebm[Tabl«[{groi5NarBS[[gEctpoIncludad[[i]]]], Iangth[gisqpgiIanamBB[ [grotysTncl )rinri[ [ i] ] ]] ]} , { i, Lengtji[groLysTnr'.hriBri]}], 
TafcvLoffrwtinjg -> {Autocratic, ("Gccq?", "N"})]]
■ RECI BOSE GROUPS WITH M XTURE OF COVTROL (CNT) AND TREATED (PATHOLOGICAL - TRE) CELLS
selectSeparatedGroupSifeset=False
I f  [changeFtaraRange, 
ndriFEamMuifcer * 1; 
naxEYanaNUriber = 1000;
<rmrtcn»ha [grotylndax. movielndeK] ] ,  (c_, f_, {x_, y_, h_J} /;  nrixiFrareNiiTtoer <= f  <= maxFrameNufaar], {gnxplndax, Langth[gix>.ysTncludBd]},
{mcvielridax, Length [grotpFilenaiBSl [ grcgysTncl irieri[ [gnxplndeoc] ]]]]>];
Dimensicns /e  trackData
]
False
i, groupslncluded = Range[Length[gnxpEilensras] ] ]
&& aalectSeparatBdRrotySubset, grxxyslnrhrtari = {1, 2 , 3 j]
CHOOSE RANGE OF FRAMES INCLUDED IN CALCULATIONS
change Frame Range = False
F alse
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TRACK PLOTS 1
Do[loczdjOella = part±ticriEyR iii8[Sart[trackD ata[ {grotyTnriax, movialrriax] ] ] ] ;
Shoir[Gka|*iic8[{IdnB/o (localCBIU / .  {cJDitagar, f_ ,  { ix _ , iy _ , h_)) -* { ix , i y } ) , FQB0Olar[0,1 , 0 ] ,  R x intS iza[.02],
(£ td n t/» 'M a»[# l, 1] 6) / •  (looalO alls / .  {c ln b a g a r , f_ ,  { ix _ , iy _ , h j ) - »  { ix ,  i y ) ) , H 2C olor[l, 0 , 0 ] ,  JtadntSiaal .0 2 ],
(B aint/*M B #[#1, -1 ] t )  / •  (localO aU a/ .  { c lr r to ^ r ,  f_ ,  { ix _ , iy _ , h J )  - .{ ix ,  i y ) ) } ] , AapactSatio-> A itcr a t ic , Axae->Trua, RLotBanga-*All,
P lo tla b a l-♦ gnxjM maa[ [grrey «Tnrlnriy1[[gnxglndw ] ] ]]< > "  "o n m y P L U n m .;  [arr.r «T^i,>uH[ , r » ^ T .y i« r ]] " "<> H >String[Ixngth[localOalla] ] <> " o a l ls " ] ,
{gcaqplndax, Ixngtti{grtxi3eXnclud»d]} , {movixlndax, Lengthtgrorpfilanxoae { [groupeIiKiudbd[ [groupIndBic] ] ] ] ] } ]
niceA2 97nbPilm Z ;\chemotaxis_groups\16iceA297nbFilm\03 0 8 l.toel 2 0 cells
300 400 500 600 700
TRACK PLOTS 2
tradcBEiarDrigin = T aaL a[gatnadanxnC rigin[tgadcData[ [grcuplndax, moviolndmc] ] ] ,  {grcufilixiax, Ifirgthtgra^JelncluJad]} ,  {iruvialndBX, L n gth[gE cqS ilx ia iB S[ [gron»Includ*d[ [groi*>IndeK] ] ] ] ] } ] ;  
Length / •  tracksEraiOcLgiji
{1}
aamcriPlotSanga = { {Mm[tradtaFtcnOrigin ] , Mhx[txadcsEixiiOcigin]}, {Mm[trackaFraiOrigin], Eta[txactaFtatC cigin])}
{{-74.93, 214.63), {-74.93, 214.63})
specifyCommonPlot Range =Trua
True
I£[apad^axiracnPLot£angB, oatnonPlotSanga = {{-230, 250), {-£50, £50}]]
{{-250, 250), {-250, 250))
210
Dot
P ti]  =
Show[
Gta$hics[{TBKt[grGCFNanBs[ [grwyslncludedt [i] ] ] ] <> " (N = ,'<>'ItoSta±ng[Iangth[Elatten[tracicsEiatCe±gin[[i]] ,1 ]]] <>")", {0, 275),
TaxtStyla-»{EbntEfendly-*"Arial", ElontSlae-* 16, FantSfei i^t-* "Bold"}], PointSi2»[.02],
Llna/« mtt»[tradcsEixnCteLg±n[[i]], 1], Baint[#[[-1]] ] 6 / •  Elatten[tradcsE'rarOribgin[ [i] ] , 1]}], AspectRatio -♦ Autxnatic, Frzraa ->Trua, PlotRange-»ocnncnElatSangB, 
GbdjdLlnao-»{{0}, {0}}, TeKtStylB-♦ {EbntElsnily-* "Arial", EtntSiza-»16, Ebnttfeicfrit-»"Plain"}, ELotttagicn-* {{0, 1}, {0,0.90})], { i, LwgtiitgnixpetocludKfl}]
200
100
100
-200
0 100 200-100-200
SE C T IO N  6: R U N = A L W A Y S
SPEED ANALYSIS
IMPORTANT: If lapse Interval not specified in Protocol.txt file, it will default to 1 min
lapselnbarval
5
specifyLapselnterval = False
F alse
I f  [spac±fyTqpseIntarval, lapaelnterval = 1]
numberOfLapselntervalsForSpeedCalculation <1{2|3j4j5..> AND 
speedUnits < >  m/hour”j'V* mfe“> AND runLength
sp—dData .  TahLa[rwlHilatirffraad[tiadd)Bta[ [grapflndaac, oovialndaK] ] ,  nu*«ia£Up8eInbervalaEbrS£eecl>lculaticn-«l, apaadUhita -> ’W h o u r" , ow cLap-»IU aa, t im»9taBpa-»Trua], 
{groipIndBx, Lmgth[gro<^ MlnelirlBd]) ,  {npviaTnrtof., Langthtgrmpfilanamaal [groipeIrclixJad[ [gnxplixtac] ] ] ] ] } ] ;  
len gth /a  apaaJ e t a
{1}
Group speed plots
ranncnSpeadPlotKancp■ {0 .0 , tte[apaacData/.dataBatbam -»d]}
{0 ., 274.743}
specHyGommonSpeedPlotRange = False
False
I f  [^peci^OamaiStDeadPlotRangB, i i nin i /frawrtPlotBmgB ■ C0f 1000}]
Do[Hi1 tiplttT.1stPlot[aplitDataF»
S£dLit[Sart[
Elattai[Elattan[flpasd3Bta[[gcoiplhdeK]] ,1] *
13/.<fetaS*tt*m *<t,d}] ,#1[ [1] ]==#2[[1] ]fi] ; 
pIotData^Dable[dataFTranflpoo<[flplitData [ [ i3 ] ] ;
{{Man[drta[ [1] ] ] ,MMn[dsta[ [2] ] } ) ,
EetoiSm: [St«rtanffinraEQCSanpl*Maan[data[ [23 ] ] ] ) ,  { i,I« g th [a p litD a ta ]}] ,PlotRang^>ocxm^ <frftwlPlo^ 
gp gig ltm s [ [gEtxpaTnrhriari[ [grotplrriax] 3 3 ] 0 ” " O  
apeadttiit], {groifaindeK,I«ngth[9cotfslixduclad]}]
nic«A297nbFi lrqum/hour
2;
2 i
1.
H
12.5 152 . 5 7 . 55 10
Individual *.cel file speed plots
Do [M jltipleLiatPlot [^ilitDat®- 
S p ilt  [Sort [
F latten [speecEata [ [grcuplniax.novielndax] ] ,  
l]/.c te ta i« * a n v .{ t,d }]  ,# l[ [ l ] l~ # 2 [ t l] ]S ]  ; 
plotDataFTdsLe [datapTcansposa [splitData [ [ i]  ] ];
{{Maan[data[ [1] ] ] ,Maan[data[ [2] ] ]},
EtrarBar [StardanErrarQESanpiafean [data [ [2] ] ] ] } ,  ( i ,Length [aplitData ]}] ,FlotRange->canncn^»8dELotRangB,PlotIabal-> 
grcxpNmea [ [gnxpalncluiedl [grtxplndm] ] ] ] 0 "  "O
grotpRJenmea [ [graupalncludedt [gropxlndex] ] .tnovielnctex] ] 0 ” "O  
speedjh it], {grctpInda)c,Length[grotpsIhc1i.rt?d] }, {movielndax,
IflngtfalgroqpKlananBS t tg ton»IndLudBd[ [grapxinim] ] ] ] ] } ]
lm Z: \chejnotaxi8_gtoup8\lfiiceA297nbPilm\0308
2.5 5 7 . 5 10 12.5 15
K>t—*U>
SPEED SUMMARY
analyseDataSiteet=Faise
False
I f [analyseDataSubSSt, nagativsOxiditicnEbaiticns = Roaithon[«paacData, dataEtotbam/;d< 0.005]; 
dataflifrinat  = DelatelapaacCBta, nagativsOcndLticnBositicns] ; 
enptyBos = Ibeiticn[dataSifcoet, {}] ;
dataSi&set = Delate [dataSubaet, snptyftja], dataStbsat = apaacData] ;
Dimensions [dataSubeafc]
(1, 1, 20)
paramtmCata = dataflitx a t  / .  datafttfaam -»d;
Diinensicns[pajarafearData]
(1, 1- 20)
rafiaranoaGfcon> = 1
Length/ •  paranatazData
(1)
If[MarbarQ[Langth/oparsraterData, 1 ] ,  Do[Print[grotfMagBB[ [grnnpaTnr1nrtari[[re f erenoeGroup])] ] , " v s . ", <pnxfNras[ [groipelnclu iid t [ i]  ] ] ] ] ; 
anovaRasults[i] = shoctMCMi[(paiMua LmData[ [rafaretxaQrcny, 1 ] ] ,  paranafaazData)[i, 1 ] ] } ] ,  { i ,  1 , Iangth[grocpaIiKitudad]} ] ,
Do[PriMt[groiptfcPB8[ [g ra p elnc ltidbd[[DeferenoeGrag] ] ]] , " v s . ", gron*hm aa[lgre*palncluded[[i]] ) ] ] ;  anoeaReaultsti] = ahartBNCTflV[(paraPBtaiPatat[PBfierm oeGDap]] ,  panm atatO ata[[i]] )]  
( i ,  1 , Langthtgrotpolncludad])]]
niceA297nbFilm vs. niceA297nbFilm
Var DoFl DoF2 F -ratio  P-value Signif
L2 -4.88975 1 37.0888 0. n .s .
LI 76.9331 38 5448. 14.3733 <0.00001 .**
L0 781.083 5448
anovaRasults [safazsnoeGcotp] = { { } , {'"’))
{{)/ {))
meanData = Tablet Mean/o F la tten [parameteiDBta[ [grc*plndax] ] ,  1 ] ,  {grotplndeoc, IangthtgzoipsIncUriBd]}] ;
Dimenaicns [ meanData]
{1, 20)
i 005 ooo \ Sncnn
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□RATIONALITY ANALYSIS
CHOICE OF % OF CELLS TO REACH HORIZON OR HORKON
anglesDyAndSqdist = Table [data = traclcsFrarOrigin[ [grouplndex, novielndex] ] ;  (*horizon=findlforizcn[data,50] * ); horizon = 70; 
getAnglesDyAndSqdist[d a ta , horizon], {grcupLndex, Length[groupslncluded] >,
{movielndex, Length[groupFilenainest [groupsIncludBd[ [grouplndex] ] ] ] ] } ] ;
Length /© anglesDyAndSqdist [ [1] ]
{12}
BaaLtimlangleeDyAndSqdist, {}]
{}
anglaaDyflndSqdiat = DalatB[angLesOyAndSgdist, Pfaai-him[angliMnyftnriRryHat- {}]];
TableForm [Table [data ■ Mean /®angle8l>yXndSqdi8t[ [i] ] /. {theta_Real, dy_, aqdist }^ : > dy/Sqrt[sqdiat] ;
{groupNamea[[group«Included([i] ]]], Naan [data], StandardXrrorOfSamplaMean[data]}, {i, Langth [groupalndudad]} ] ]
niceA297nbFilm 0.53687 0
refeeenaeGacotp = 1
1
angl8EDyftndScjiist[ [1] ]
{{{0.153945, 73.66, 5556.44}, {1.92957, -26.67, 5769.34}, {-0.104877, 72.39, 5298.38}, {0.206683, 78.74, 6472.57}, {-0.495133, 63.5, 5208.05}, {-0.551655, 66.04, 6012.89},
{0.0535203, 71.12, 5072.57}, {0 ., 71.12, 5058.05}, {1.35213, 15.24, 4935.47}, {-0.977794, 39.37, 4962.89}, {2.30496, -46.99, 4919.35}, {-1.66146, -6.35, 4919.35}}}
{angled)gAndScjjist[ [referenoeGnxp] ] , angleapy*ndSqdist[ [2] ]} / .  {thetajteal, dg_, aqdistj -*dy/Sqrt[«jiLst.]
{{{0.988174, -0.351123, 0.994505, 0.978717, 0.879905, 0.851658, 0.998568, 1 ., 0.21693, 0.558853, -0.669965, -0.0905357}},
{{{0.988174, -0.351123, 0.994505, 0.978717, 0.879905, 0.851658, 0.998568, 1 ., 0.21693, 0.558853, -0.669965, -0.0905357}}}[2]}
Do[Print[groupNames[ [groupslnd uded[ [referenoeGroup]] ]] , " vs. ", groupKames[[grotpsIncluded[[i] ]] ] ] ;  
anovaResultsl [i] =
shortANOVA[ F la tte n [ {anglesDyAndSqdist[ [referenoeGroup] ] ,  anglesDyAndSqdist[ [i] ]} / .  {theta_R eal, dy_, sqdist_} -» dy / S qrt[sqd ist] ] ,  1] 
{ i, 1, Length [groupslnduded]} ]
niceA297nbFilm vs. niceA297nbFilm
Var DoFl DoF2 F-ratio  P-value Siqnif
L0 0.347269 23
anovaResultsl[3] * {{}, {""}}
{{}, {}}
Do [angles = F la t te n [anglesDyAndSqdist [ [i] ] / .  (th e ta_ , dy_, sqdist_} -> theta] ;
taxisR eport [groupNames[ [groupsIncluded[ [i] ] ] ] , angles, len g th [F latten[tracksFrcnO rigin[ [i] ] ,  1] ] ] ; 
b in s l = BinCounts[ang les, {N [-E i], N[Pi] , N [P i/ 10]}] ;
P [ i ]  -  
Show[
{Graphics[{Text[groupNames[ [groupsIncluded[[i]] ] ] ,  {0, 20}, T extS ty le-» {FantFamily-> "A ria l" , FantSize-* 22, FontJfei^it-» "Bold"}], 
Text[anovaR esultsl[i] { [2 , - i]]  <> " (N = "<> ToString[Length[angles] ]<>")", {0, -12} ,
TextStyle -> {FontFamily -> "A ria l" , FontSize -> 18, FantWeight -> "Bold"}]}] , taxisQ[angles] , c im ila rH is to g ram [b in s l]}, 
AspectRatio-> Automatic, PlotRange-»{{-15, 15}, (-10 , 20}}, PlotRegion-► {{0, 1}, {0.1, 0.90}}], { i, 1, Iength[groupsIncluded]}] ;
Treatment niceA297nbFilm
Ntot ( to ta l c e l l  tracks) = 20
N (ce ll tracks reaching horizon) = 12
Mean D irection = 1.24265 degrees
95% Confidence In terval = -38.5006 to  40.9858 degrees
p robab ility  o f uniform directions = 0.0308839
kappa = 3.36782
iiuriim
ROUTINES
«  "V:\\dan\\nprog\\speedflndChenDtaxisAnalysi£Master.m"
Appendix 2: Algorithms used for the processing of microarray data.
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Mathematica® routine 
for the analysis of 
microarray data
This reproduction of a Mathematica® 
Notebook shows the routines used for 
the microarray analysis, from import of 
the data to generation of a candidate 
gene list to production of graphs of gene 
expression.
a n n o t=  I m p o r t [ " D : \ \m ic rQ A rra y \\P M 2 3 Q A _ a n n o t .c s v " ,  "CSV"] ; 
D im e n sio n s  [a n n o t]
{15924, 42}
h l a s t x s  I irp o rt["D :\\ra iL c rQ A rra y \\R A E 2 3 C IA _ b la s tx .c sv '', "C SV "]; 
D im e n s io n s  [ h l a s t x ]
{56559, 6}
h cm o lo g u es  = I n p o r t [ "D : \ \m ic r c A r r a y \V ta n o ta t io n _ 1 0 4 2 .c s v " , "C SV "]; 
D im e n sio n s  [hcm o logues]
{2223, 7}
fp O a ta  = G e t[  "V : \\d an \\tan ia ra \\fp D a ta2 0 0 4 m R N D W A .d a t" ]  ;
D im e n sio n s  [ fp D a ta ]
{11859, 11}
■ Import and join unsealed data
d a t a l  = I n p o r t [ "D : \ \ m i c r o A r r a y \ \ u n s c a l e d .c s v " , "CSV"] ;
D ime n s io n s [ d a t a l ]
{15924, 47}
d a t a 2 =  I n p o r t [ "D : \ \m ic r o A r r a y \ \u n s c a 1 e d 2 n d .c s v " , "CSV"] ; 
D im e n s io n s [d a ta 2 ]
{15924, 11}
d a ta 3 =  Im p o r t [ " D : \ \m ic 3 X iA r r ^ \ \u n s c a lQ d 3 rd .  c s v " , "C S V '] ; 
D im e n s io n s  [d a ta 2 ]
{15924, 11}
D im e n sio n s  [D ro p  [ d a t a l ,  1 ] ]
{15923, 47}
D im e n sio n s  [ D rop  [ d a t a 2 , 1 ] ]
{15923, 11}
D im e n sio n s  [ D r o p [ d a ta 3 ,  1 ]]
{15923, 92}
T ra n s p o s e  [D rop  [ d a t a l ,  1] ] [ [1] ] == T ra n s p o s e  [ D rop  [ d a t a 2 ,  1] ] [ [1] ]
True
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T r a n s p o s e [ D r c p  [ d a t a l ,  1] ] [ [1 ] ] == T r a n s p o s e [ D r c p [ d a t a 3 ,  1 ] ]  [ [1 ] ]
True
d a t a =  T r a n s p o s e [ J b i n [ D r c p [ T r a n s p o s e [ D r c p [ d a t a l ,  1 ] ] ,  - 1 ] ,  D ix p [ D R ^ [ X c a n a p o s e [ D r c p [ d a t a 2 ,  1] ] ,  1 ] ,  - 1 ] ,  D r c p [ T r a n s p o s e [ D r q p [ d a ta 3 ,  1 ] ] ,  1 ] ] ] ;
D im e n s io n s  [ d a t a ]
{15923, 146} 
d a t a l [ [ l ] ]
{ ,  0803_DZ2_uR_A297Nb_5_rl_Signal, 0803_DZ2_uR_A297Nb_5_rl_Detection, 0803_DZ2_uR_A297Nb_5_rl_Detection p -v a lu e , 0803_DZ3_uR_A297Nb_9_rl_Signal, 
0803_DZ3_uR_A297Nb_9_rl_Detection, 0803_DZ3_uR_A297Nb_9_rl_Detection p -v a lu e , 0803_DZ4_uR_K2_l_rl_Signal, 0803_DZ4_uR_K2_l_rl_Detection,
0803JDZ4_uR_K2_l_rl_Detection p -v a lu e , 0803_DZ5_uR_K2_5_rl_Signal, 0803_DZ5_uR_K2_5_rl_Detection, 0803_DZ5_uR_K2_5_rl_Detection p -v a lu e , 0803_DZ6_uR_K2_9_rl_Signal, 
0803_DZ6_uR_K2_9_rl_Detection, 0803_DZ6_uR_K2_9_rl_Detection p -v a lu e , 0903_DZ7 uR A297Nb 2 r2 S ig n a l, 0903_DZ7_uR_A297Nb_2_r2_Detection, 
0903_DZ7_uR_A297Nb_2_r2_Detection p -v a lu e , 0903_DZ8_uR_A297Nb_7_r2_Signal, 0903_DZ8_uR_A297Nb_7_r2_Detection, 0903_DZ8_uR_A297Nb_7_r2_Detection p -v a lu e , 
0903_DZ9_uR_A297Nb_10_r2_Signal, 0903_DZ9_uR_A297Nb_10_r2_Detection, 0903_DZ9_uR_A297Nb_10_r2_Detection p -v a lu e , 0903_DZ10_uR_K2_2_r2_Signal, 
0903_DZ10_uR_K2_2_r2_Detection, 0903_DZ10_uR_K2_2_r2_Detection p -v a lu e , 0803 DZ11 uR K2 6 r2  S ig n a l, 0803_DZll_uR_K2_6_r2_Detection,
0803_DZll_uR_K2_6_r2_Detection p -v a lu e , 0803_DZ12_uR_K2_10_r2_Signal, 0803_DZ12 uR_K2_10_r2_Detection, 0803_DZ12_uR_K2_10_r2_Detection p -v a lu e , 
0903_DZ13_uR_A297Nb_l_rl_Signal, 0903_DZ13_uR_A297Nb_l_rl_Detection, 0903_DZ13_uR_A297Nb_l_rl_Detection p -v a lu e , 0903_DZ14_uR_K2_3_r3_Signal, 
0903_DZ14_uR_K2_3_r3_Detection, 0903_DZ14_uR_K2_3_r3_Detection p -v a lu e , 0903_DZ15_uR_K2_7_r3_Signal, 0903_DZ15_uR_K2_7_r3_Detection,
0903_DZ15_uR_K2_7_r3_Detection p -v a lu e , 0903_DZ16_uR_K2_ll_r3_Signal, 0903_DZ16_uR_K2_ll_r3_Detection, 0903_DZ16_uR_K2_ll_r3_Detection p -v a lu e , D escrip tio n s}
■ Derive data pattern: 1-4 quiescent, 5-8 early, 9-12 late
oo lunriN am as = S t r i n g D r c p [ # ,  S t r i n g P o s i t i o n [ # ,  [ [ 3 ,  1 ] ] ]  & / © D r o p [ D r c p [ d a t a l [ [ l ] ] ,  - 1 ] ,  1 ] ;
d a t a P a t t e m l  =
S t r i n g f e p l a o e t # ,  { "A 297N b"-> " a " ,  "K 2" ->  " k " ,  " _ 1 _ "  ->  " c " ,  " _ 2 _ "  ->  " c " ,  " _ 3 _ "  ->  " c " ,  " _ 4 _ "  ->  " c " ,  " _ 5 _ "  ->  " e " ,  " _ 6 _ "  ->  " e " ,  " _ 7 _ "  ->  " e " ,
" _ 8 _ "  ->  " e " ,  " _ 9 _ "  ->  " 1 " ,  " _ 1 0 _ "  ->  " 1 " ,  ->  " 1 " ,  " _ 1 2 _ "  ->  " 1 " ,  " r "  ->  " _ S ig n a l "  ->  " s _ " ,  " _ D e t e c t i c n  p - v a l u e "  ->  " p _ " ,  " _ D e t e c t i c n "  ->  " d _ " } ]  &/©
cxxlixm N am es;
d a t a P a t t e m l  = T b E sq o re ss ic n t P r e p e n d  [ d a t a P a t t e m l ,  " i d e n t i f i e r _ " ]  ]
{ id e n t i f ie r _ ,  a e ls _ , a e ld _ , a e lp _ , a l ls _ ,  a l ld _ ,  a l lp _ ,  k c ls _ , k c ld _ , kc lp _ , k e ls _ , k e ld _ , ke lp _ , k l ls _ ,  k l ld _ ,  k l lp _ ,  ac2s_, ac2d_, ac2p_, ae2s_, ae2d_, ae2p_, a l2 s _ ,  
a l2 d _ , a l2 p _ , kc2s_, kc2d_, kc2p_, ke2s_, ke2d_, ke2p_, k l2 s _ , k l2d_ , k l2p_ , a c ls _ , a c ld _ , a c lp _ , kc3s_, kc3d_, kc3p_, ke3s_, ke3d_, ke3p_, k l3 s _ , k l3 d _ , k l3p_}
c o lu n r iN a n e s  = S t r in g D c c p [ # ,  S t r i n g P o s i t i c n [ # ,  [ [ 3 ,  1 ] ] ]  & /© D < r c p [ D r c p [ d a t a 2 [ [ l ] ] ,  - 1 ] ,  1] ;
d a t a P a t t e m 2  =
S t r i n g R e p l a c e [ # ,  ("A 297N b"-»  " a " ,  "K 2" ->  " k " ,  " _ 1 3 _ "  ->  " c " ,  " _ 1 5 _ "  ->  " e " ,  " _ 1 8 _ "  ->  " 1 " ,  " r "  ->  " J S i g n a l "  ->  " s _ " ,  " _ D e te e t io n  p - v a l u e "  ->  " p _ " ,
" _ D e t e c t i c n "  ->  " d _ " } ]  & / e  ooluconN am es; 
d a t a P a t t e m 2  = T c E x p re s s ic c i  [ d a t a P a t t e m 2  ]
{ac3s_, ac3d_, ac3p_, ae3s_, ae3d_, ae3p_, a l3 s _ , a l3 d _ , a l3p_}
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ra lu n n N a m e s  = S t r in c p E c p [ # ,  S t r i n g P o s i t i o n [ # ,  [ [ 3 ,  1 ] ] ]  & / e D r c p [ D E c p [ d a t a 3 [ [ l ] ] , - 1 ] ,  1] ; 
d a t a P a t t e m 3  =
S t r in g R e p la oe [ # ,  { "T 1 5 "-»  " t " ,  "C" ->  " c " ,  " _ r "  ->  " _ S ig n a l "  ->  " s _ " ,  " _ D e t e c t i o n  p - v a l u e "  ->  " p _ " ,  " _ D e ta c t io n "  ->  " d _ " ,  "A 311" ->  " m " , " L "  ->  " 1 " ,
"K 2" ->  " k " ,  "A 297rib" ->  " a " ,  "T " ->  " t " ,  " E "  ->  " e " ,  " 1 _ 2 "  ->  " 1 " } ]  &/© co lix m N m n es ; 
d a t a P a t t e m 3  = T o E x p r e s s i c n  [ a p p e n d  [ d a t a P a t t e m 3 , " d e s c r i p t i o n j '  ] ]
{ t c ls  , tc ld _ , tc lp _ , m l2s_, ml2d_, ml2p_, k t ls _ ,  k t ld _ , k t lp _ , t t l s _ ,  t t ld _ ,  t t lp _ ,  a t ls _ ,  a t ld _ , a t lp _ , m tls _ , m tld_ , m tlp_ , tc 3s _ , tc3d _ , tc3p _ , te 3s _ , te3d _, te3p _,
t l2 s _ ,  t l2 d _ , t l2 p _ , t l3 s _ ,  t l3 d _ , t l3 p _ , mc2s_, mc2d_, mc2p_, tc 2s _ , tc2d _, tc2p _, mc3s_, mc3d_, mc3p_, me3s_, me3d_, me3p_, m l3s_, ml3d_, ml3p_, k t2s _ , k t2d_,
kt2p _, k t3s _ , k t3d _, k t3p _, t t2 s _ , t t2 d _ , t t2 p _ , t t3 s _ , t t3 d _ , t t3 p _ , a t2s _ , a t2d _ , a t2p _ , a t3s _ , a t3d _ , a t3p _ , mt2s_, mt2d_, mt2p_, te ls _ ,  te ld _ , te lp _ , mt3s_,
mt3d_, mt3p_, te 2s _ , te2d _, te2p _, t l l s _ ,  t l l d _ ,  t l l p _ ,  m cls_, mcld_, mclp_, m els_, meld_, melp_, me2s_, me2d_, me2p_, m lls _ , m lld _ , m llp _ , d e s c rip tio n _ }
T a b le P o n n [
S o r t [
T r a n s p o s e [
{ S t r in g R e p l a o e [ # ,  { "T 1 5 "-»  " t " ,  "C " ->  " c " ,  " _ r "  ->  " J S i g n a l "  ->  " s _ " ,  " _ D e t e c t i c n  p - v a l u e "  ->  " p _ " ,  " _ D e te c t io n "  ->  " d _ " , "A 311" ->  " m " ,
"L "  ->  " 1 " ,  "K 2" ->  " k " ,  "A 297rib" ->  " a " ,  "T " ->  " t " ,  "E "  ->  " e " ,  " 1 _ 2 "  ->  " 1 " } ]  &/e c a l ix tn N a m a s ,  D r o p [ d a ta 3 [  [1 ] ] ,  - 1 ] ) ] ] ] ;
d a t a P a t t e m  = J o i n  [ d a t a P a t t e m l , d a t a P a t t a m 2 ,  d a t a P a t t e m 3 ]
{ id e n t i f ie r  , a e ls  , a e ld  , a e lp  , a l l s  , a l ld  , a l lp  , k c ls  , k c ld  , k e lp  , ke ls  , k e ld  , k e lp  , k l ls  , k l ld  , k l lp _ , ac2s_, ac2d_, ac2p_, ae2s_, ae2d_,
kc3s_, kc3d_, kc3p_, ke3s_, ke3d_, 
m l2s_, ml2d_, ml2p_, k t ls _ ,  k t ld _ ,  
t l2 s _ ,  t l2 d _ , t l2 p _ , t l3 s _ ,  t l3 d _ ,  
k t2s_ , k t2d_, k t2p_, k t3s _ , k t3d_, 
te ls _ ,  te ld _ , te lp _ , mt3s_, mt3d_, 
m lls _ , m lld _ , m llp _ , d e s c rip tio n _ }
L e n g th  [ d a t a P a t t e m ]
146
■ Reject control initial lines
d a t a  = D ro p  [ d a t a ,  5 7 ] ;  D im e n s io n s  [ d a t a ]
[15866, 146}
■ Reject absents (keep genes with at least 1 present value)
d a t a  = C a s e s  [ d a t a ,  x _ / ; L e n g th  [C a s e s  [ x ,  " P " ] ]  > 0 ] ;
D im e n s io n s  [ d a t a ]
[11859, 146}
ae2p_, a l2 s _ , a l2 d _ , a l2p_, 
ke3p_, k l3 s _ , k l3d_ , kl3p_, 
k t lp _ , t t l s _ ,  t t ld _ ,  t t lp _ ,  
t l3 p _ , mc2s_, mc2d_, mc2p_, 
kt3p _, t t2 s _ , tt2 d _ , tt2 p _ , 
mt3p_, te 2s _ , te2d _, te2p_.
kc2s_, kc2d_, kc2p , ke2s ,
ac3s , ac3d , ac3p_, ae3s_,
a t ls _ , a t ld _ , a t lp  , m tls_,
tc2s_ , tc2d  , tc2p  , mc3s_,
t t3 s _ , tt3 d _ , t t3 p _ , a t2s  ,
t i l s _, t l l d _ , t l l p  , mcls ,
ke2d_, ke2p , k l2 s _ , kl2d_,
ae3d , ae3p , a l3 s  , a l3 d _ (
m tld  , m tlp  , tc3s  , tc3d_,
mc3d_, mc3p , me3s_, me3d ,
a t2d  , a t2p  , a t3s  , a t3d
mcld_, mclp_, mels , meld_(
k l2p_ , a c ls _ , a c ld _ , ac lp _ , 
a l3 p _ , tc ls _ ,  tc ld _ , tc lp _ ,  
tc3p _, te3s_ , te3d _, te3p_, 
me3p_, m l3s_, ml3d_, ml3p_, 
at3p _ , mt2s_, mt2d_, mt2p_, 
melp_, me2s_, me2d_, me2p_,
T a b le [m 0d [ i ]  = M a d i a n [ d a t a [ [ A l l ,  i ] ] ] , { i ,  2 ,  L e n g t h [ d a t a [ [ 1 ] ] ]  - 2 ,  3}]
{3 5 1 .5 , 3 50 .2 , 4 11 .4 , 4 6 5 .4 , 2 6 9 .6 , 4 6 9 ., 4 95 .9 , 4 80 .5 , 4 56 .8 , 4 4 5 .1 , 4 39 .8 , 5 58 .8 , 4 47 .8 , 3 4 7 .9 , 4 9 7 .5 , 481 .7 , 3 36 .1 , 3 88 .4 , 3 2 7 .1 , 2 5 5 .3 , 2 7 9 .6 , 2 8 1 .9 , 2 6 0 .5 , 3 1 5 .3 , 2 88 .3 , 
2 5 5 .5 , 2 4 2 .5 , 2 9 3 .3 , 3 11 .4 , 2 1 0 ., 3 13 .5 , 3 78 .1 , 3 09 .8 , 3 18 .8 , 2 2 4 .5 , 3 1 8 .4 , 2 6 0 .2 , 173 .8 , 3 5 1 .8 , 2 8 1 .4 , 2 3 3 .8 , 3 3 5 .1 , 2 7 5 .3 , 2 6 5 .5 , 2 2 7 .2 , 1 7 6 ., 2 4 6 .1 , 285 .3}
T a k e  [ d a t a  [ [1 ]  ] ,  2 ]
{1398749_at, 7844 .7}
D o [ D o [ d a t a [ [ j ,  i ] ]  = d a t a [ [ j ,  i ] ]  / n e d [ i ] ,  ( i ,  2 ,  L e n g th [ d a t a [  [1 ] ] ] - 2 ,  3 } ] ,  { j ,  L e n g th  [ d a t a ] } ] ;
T a k e [ d a t a [ [1 ] ] ,  2 ]
{1398749_at, 22.3178}  
f o l d l = 2 . 5
2 .5
£ o ld 2  a 2 . 5
2 .5
p V a l l = 0 .0 5
0 .05
p V a l2 = 0 .0 5
0 .05
■iripftl-i f i  grS iihT .i f i t  =
C a s e s [ f p D a ta ,
{i d e n t i f i e r _ S t r i n g , d a t a  } 
i d e n t i f i e r  / ;
( ( ( C a s e s [ T a k e [ S o r t [ T a k e [ { d a t a ) , 6 ] ] ,  5 ] ,  { x _ B e a l , y_} / ; x > p V a l l  11 y <  f o l d l ]  «  {}) &&
(C a s e s  [T a k e  [ S o r t [ T a k e [  { d a t a } , 6 ] ] ,  { 6 , 6 } ] ,  { x J R e a l ,  y _ )  /  ; x  > p V a l2  11 y <  f o l d l ]  == {}) && (M in [C a s e s  [T a k e  [ { d a t a } , 6 ] ,  ( x _ ,  y_) / ;  x < p V a l l - » y ] ]  > 1 ) )  11
( { C a s e s [ T a k e [ S o r t [ T a k e [ { d a ta } , 6 ] ] ,  5 ] ,  { x _ R e a l , y_} / ; x > p V a l l  11 y *  1 / f o l d l ]  == {}) &&
( C a s e s [ T a k e [ S o r t [ T a k e [ { d a t a } , 6 ] ] ,  ( 6 ,  6 } ] ,  { x _ R e a l ,  y_} /  ; x  > p V a l2  11 y  ^ 1 / f o l d l ]  «  {}) && (^ fe x [C a s e s [ T a k e [ { d a ta } , 6 ] ,  { x _ , y_J /  ; x <  p V a l l -> y ] ] < 1 ) )}  &&
(M in [ ( T a k e [ { d a ta } , - 4 ]  / .  { x _ , y_J - » x )  ] > p V a l l )  ] ;
L e a g t h [ i d a n t i  f i e r S u b L i s t ]
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c l = c l u s t e r A n a l y s i s [c l u s t e i D a t a ] ;
d a t a S u b S e t=  i d e n t i f 1e r S i i b T . i s t / .  i d _ S t r i n g »  ( C a s e s [ f p D a ta ,  { i d ,  } ] )  [ [ 1 ] ]  ;
D im e n s io n s  [d a ta S u b S e t]
o o l o u r O f f s e t  = - 0 . 7 ;  o o lo u r G a in =  1 . 6 ;
T a b le P o im [  
s u b S e tT a b le  =
Brepend[
F l a t t e n  [
{ E L r s t t # ] ,
( S ty l e E to m [ T o S t r in g [ ( # [ [ 2 ] ]  * 1 0 / /  R ound) / 1 0  / / N ]  <> W i i d i [ # [  [1 ] ] < 0 .0 1 ,  " * * * " ,  # [ [ 1 ] ]  < 0 . 0 5 ,  " * * " ,  # [ [ 1 ] ]  < 0 . 1 ,  T r u e ,  " " ] ,  E ta n tW e ic h t->  " B o ld " ,  
E b n tF a n d ly - >  " A r i e l " ,  E T o n tC o lo r - » h a l l lW [ ( # [ [ 2 ] ]  + o o lo u r O f f  s e t )  * o o lo u r G a in ]  ] )  & / e R e s t [ # ] , s h o r t A r a x > t [ F i r s t [ # ] ] } ]  & / «  d a t a S u b S e t ,
{ " id e n t i f i e r " , " t /k " ,  "a /k" ', "EB/k",, " fc t/k t" ', " a t /k t " , "mfc/kt1", " k tJk " t t / t " ,  " a t /a " ,  "H it/Hi", "a n o tta tJ jo n ")], T a b le S p a c i n g ->  {1 , 1 )]
. i d e n t i f i e r T./k a / k nvk tt./ kt a t/' k t icc1 k t kt.) k t t . / t a*. / a mt/rn anot/tatior!
1377375_at 9.2** 16.8** 28.8*** 33.8** 113.9#*# 59.#* 0.1* 0.4** 0.7 0 2 * * S im ila r  to  am inoadipate-sem ialdehyde synthase (LOC296925), mRNA
1368685_at 54.*** 76.6*** 84.9*** 12.8*#* 14.6**# 15.3*** 6.2 1.5 1.5 Cspg4 membrane-spanning pro teog lycan  NG2
1370477_at 24,8*** 49,6*** 86.2*** 3.9*# 9.9** 6.8*## 4.4*# 0.7* 0.9 0.5** Ocm oncomodulin
1371132_a_at 18.1*** 17.3*** 21.3*** 13.8*# 21.7#* 24,1** 1 5 1.8 1.6 Ank3 a n k y rin  3 (G)
1389353_at 0.1*** 0.1** 0.1*** 0.1** 0.1** 0.1*** 15.8** 13.1* 1 1 5 * 15.2*
1368512_a_at 0.*** 0.1*** 0.*** 0.** 0.*** 0.** 11.9** 30.# 2.5** Enpep aminopeptidase A
1373727_at 0.1*** 0.1** 0.1 •* • 0.1 * •• 0.** 0.** 16.2* 19.8*** 4.8 4,1* BLASTx H yp o th e tic a l p ro te in  HEMBA1007053
1373748_at 0.*** 0.*** 0.*** 0.1*** 0.1 •** 0.1** 1 8 * 13,9*** 9.1 8.*#
1367581_a_at 7.2*#* 5.2*** 5 .8*** 3.2*#* 3.*# 2 ,8*** 3.3** 1.5 1.9* 1.5* Sppl secre ted  phosphoprotein 1
1390474_at 2 .9*** 2 .9*** 3.2*** 3.6** 2.8#*# 3.5*## 1.4 1.3 S im ila r  to  RIKEN cDNA 9330161F08 (LOC362898), mRNA
1373642_at 5 .7*** 3 .7*** 8,1 * ** 3.8*# 4,3### 4,1** 8.8 1.4* 0.8 S im ila r  to  h y p o th e tic a l p ro te in  (LOC310628), mRNA
1387153_at 4 .1*** 4 ,5*** 4.9*#* 3.1** 3.5#* 3.9** 1.4 R i l  rev e rs io n  induced LIM gene
1370418_s_at 3 .8*** 4 .2*** 5 .9*** 3,5*** 4.7##* 4,8*#* 1 4 * 1,3 1.5* Bk B/K p ro te in
1368223_at 0.2** 0.3** 0.2** 0.3** 0.1*** 0.1** 8.# 7.5 2. 4,7* Adamtsl a d is in t e g r in - l ik e  and m eta llopro tease  (re p ro ly s in  type) w ith  thrombo
1369044_a_at 0.2** 0.1** 0.1 • • 0.1 • • 0.1*** 0.1** 19,2** 3,5 5.2 3.7 Pde4b phosphodiesterase 4B
1374157_at 0.1*** 0.1*** 0.1*** 0.1*** 0.1*** 0.*** 9.9* 5.3* 3.6*# 3,3**
1391428_at 0.1*** 0.3** 0.4** 0.1** 0.1** 0.1** 10.2* 7,* 3.3 3 2
1372101_at 0.4** 0.1** 0.2** 0.2*** 0.1** 0.1** 9.1 * * * 3.9 1 12 7.1* Ppap2b ER transmembrane p ro te in  D r i 42
1372615_at 0.2** 0.2** 0.2** 0.2** 0.2** 0.2** 8.** 10. 9.6 6.
1375267_at 0.*** 0.2*** 0.2*** 0.2** 0.4** 0.2** 10.8* 1.5** S im ila r  to  Chain A, C y c lo p h ilin  C Complexed W ith C yclosporin  A (LOC291463), m
1374081_at 0.2*** 0.*** 0.1*** 0.1** 0.** 0.*** 2.9*# 1 3.5 2.2
1374474_at 0.4** 0.1*** 0.1*** 0.2** 0.1*** 0.1*** 3.** 1.5 4.3 2.7
1398823_at 0.3** 0.1** 0.1 *** 0.4*** 0.4*** 0.3** 0.8 3.7 2. Tsnax t ra n s lin -a s s o c ia te d  fa c to r  X
1398387_at 0.3** 0.1*** 0.3** 0.2*** 0.2*** 0.2** 2.2 1 4 3.8** MGC72614 Unknown (p ro te in  fo r  MGC:72614)
1R6 RR 6R =>* 0  3** n ? . . 0  3** 6 4 . . 0  4 . . . 6  3** 1 3 1 4 * . 7 f t * 1 3 c i l r l a ^  c o I i t F o  r a r r i o r  •Farrn 1 \t 1 / r r l i a l  h i r f h  p 'f ’f i  n i r r l  t - r a n c r v i r F o r ^  m
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{ L o g T ii.s tP lo t[
( C a s e s [ d a t a ,  {i d e n ti .f ie .i rS u K Ij.s t[  [8] ] ,
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M aa n [M a a n /e  { { a c l s ,  a c 2 s ,  a c 3 s } ,  { a e l s ,  a e 2 s ,  a e 3 s } ,  { a l l s ,  a l 2 s ,  a l 3 s } } ] , M a a n [M e a n /e { { m c ls ,  xnc2s, m c 3 s} , { n e l s ,  m e 2 s , m e 3 s> , { m i l s ,  m L 2s, m l3 s } } ] }) [ [1] ] ,  
P lo t J o in e d - *  T r u e ,  D is p la y E lm c t ic n - »  I d e n t i t y ] ,
LogT.istPlot[
( C a s e s [ d a t a ,  { i< te jta f ie rS t& L .iff it{  [8] j , __ }] / .
d a t a P a t t e m - >  { M a a n [ { k t ls ,  k t 2 s ,  k t 3 s } ] , M e a n [ { t t l s ,  t t 2 s ,  t t 3 s } ] , M e a n [ { a t l s ,  a t 2 s ,  a t 3 s } ] , M e a n [{ m tls ,  m t2 s ,  m t3 s } ]} )  [ [ 1 ] ] ,  P lo t J o in e d - »  T r u e ,
DisplayEUncticn-* Identity]}, PlotBange-* All, Displa^Vmction-» $Display£\inction]
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Appendix 3: First microarray experiment: Genes differentially expressed between
non-metastasising and metastasising cells.
In this table, the Affymetrix Identifiers, expression ratios and symbols for each differentially 
expressed transcript are displayed. The Affymetrix Identifier is the unique identification for each 
transcript that is probed by the array. Not all transcripts are yet characterised, which is why only 
some of the Affymetrix Identifiers in this table have accompanying gene symbols. Full details of 
the genes in the following list can be accessed by entering the Affymetrix ID into the NetAffx™ 
Analysis Center at htto://www. affymetrix. com/analvsis/index. affx. Each column describes the 
expression ratio (ER) of two experimental groups, where ac = control A297 cells; ae = early (30 
minute) response to PDGF/IGF of A297 cells; al = late response (3 hours) of A297 cells; 
kc = control K2 cells; ke = early (30 minute) response to PDGF/IGF of K2 cells; al = late 
response (3 hours) of K2 cells. High expression ratios (ER > 1) indicate that the numerator (the 
upper part of the fraction) is over-expressed in metastatic cells. Low expression ratios (ER < 1) 
indicate that the denominator (lower part of the fraction) is under-expressed in metastatic cells. 
Pseudocolours represent the degree of overexpression of the numerators, with red being high 
overexpression, through orange, yellow, green and blue with black representing 
underexpression of the numerator. Statistical significance is indicated as follows; *P <  0.1,
**P < 0.05, ***P < 0.01.
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Affymetrix ID ae/ac al/ae ke/kc kl/ke ac/kc ae/ke al/kl
1377018 _at 1. 0.8 2.4 0.4 39.$ 16.2 31.$.
1372013 _at 0.9 0.9 1.3 0.5 11. 7.7. 14.$
1372200 _at 1. 1. 0.6 0.9 *$. 12.6 14.8
1377375 _at 1. 0.6 0.9 0.5 16. 17.4. 19.7
1371679 _at 0.7 0.8 1. 0.8 18.6 13, 12-$.
1372447 at 0.9 0.9 1.1 1. 16.$.. 13,. 12-4 Fgfrl
1368103 _at 1.2 0.9 16.1 16.$. 13.$ Abcgl
1388866 _at 0.9 1. 0.8 1.3 18.1 19-4 15,.
1386935 _at 0.3 0.6 18.7 0: 2.9 o.i 0.8 Nr4al
1369067 _at 0.2 1.8 24.$ 0.1. 5.7 0. 0.6 Nr4a3
1373776 _at 0.4 9.4 0.9 0.1.. o, 0.3
1389402 _at 2.5 0.5 5.?. 0.2 1. 0.5 1.
1387766 _a_at 0.4 4.6 1. 0.9 0.1 0. 0-2. Rbp2
1372539 at 0.8 2.8 1.1 1. 0. 0. o: .
1373748 _at 0.7 2.6 1.1 0.9 0: 0. o...
1368311 _at 0.4 3.3 1. 0.9 0. 0. o: . Mgmt
1375729 _at 0.4 3.1 1.1 1. 0.1 o... 0.2
1370503 s at 0.4 3.9 1. 1.1 o: . 0. 0: Epb4 .113
1368515 _at 1. 3.5 1. 1. 0: 0. o.... Epb4 .113
1374318 _at 1.3 3.5 1.1 0.9 0: 0,. 0.
1374816 _at 0.9 0.9 1. 2-$. 0.8 0.7 0-3
1388924 _at 0.9 0.6 1.8 0-2. 0.3 0.2
1376667 _at 0.9 0.8 2.? 0.3 0.4 0.2. Cyp26bl
1373122 _at 1. 0.4 0.8 0.4 0.5 0.1
1368106 _at 2.1 0.6 1.1 o... 0. 0. Plk2
1371517 _at 1.8 0.8 0.9 1. o: . 0: 0;
1370692 _at 1.9 0.5 0.9 1.1 0.1 0.3 0.1.. Illrll
1372006 _at 1.7 0.5 0.9 0.2. 0.4 0.2
1387273 at 1.5 0.7 1. 1.4 0.2 0.3 0.1.. Illrll
1386899 _at 1.6 0.8 1. 0.1 0-2. 0.1
1370362 _at 1.3 0.6 1. 1. o.i. 0.1 0.1 Ptpm
1398823 _at 1.5 0.6 0.9 1. 0.1. 0.1 0.1.. Tsnax
1369484 at 1.5 0.6 0.9 1.1 0.1.. 0-1 0.1 Wisp2
1376105 _at 1.5 1.1 1. 0.5 0: 0.1.. 0.1
1368223 _at 0.7 1.2 1.5 0.8 0.4 0.2 0.$. Adamtsl
1376937 _at 0.8 0.8 1.4 0.5 0-4. 0.3 0.4
1387951 _at 0.6 0.8 1.5 0.8 0.4 0.2 0.2. Daf
1372750 _at 0.7 0.6 1.7 0.8 0.3 0.1 0.1
1367888 _at 1. 1.1 1.1 1.4 0-1. 0.1. 0.1 Pcdh21
1367759 _at 0.7 1. 0.8 0.3 0.3 o.$. HlfO
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Appendix 4:
Expression patterns of candidate genes from the extended 
microarray experiment.
Absolute gene expression values are shown for the cultured cells and primary 
tumours, where the green line represents expression levels in the cultured cells, 
and the red line represents expression levels in the primary tumours. In the 
following graphs, the expression patterns of the cells and tumours are closely 
matched since this was one of the criteria used to obtain the list of candidate 
genes.
Gremlin 1 homolog
0.5
0.1
0.05
- T -
A297 A311K2 T15
Cell Type
230
G
en
e 
E
xp
re
ss
io
n 
Le
ve
l 
G
en
e 
E
xp
re
ss
io
n 
L
ev
el
PAR-related orphan receptor a
0.5
0.2
0.05
0.02
K2 T15 A297 A311
Cell Type
Erythrocyte protein band 4.1-like 3
0.5
0.2
0.05
0.02
A311A297T15K2
Cell Type
231
G
en
e 
E
xp
re
ss
io
n 
L
ev
el
Ca/CaM dependent serine protein kinase
0.5
0.2
0.1
0.05
0.02
T15 A297 A311K2
Cell Type
Hypothetical gene AF152002
10
5
2
1
0.5
A31IA297T15K2
Cell Type
232
Ge
ne
 
Ex
pr
es
si
on
 
Le
ve
l 
G
en
e 
Ex
pr
es
si
on
 
Le
ve
l
EST; Affymetrix Identifier 1376071_at
0.5
0.2
0.1
A311T15 A297K2
Cell Type
Polo-like kinase 2
0.5
0.2
0.1
0.05
A311A297T15K2
Cell Type
233
G
en
e 
Ex
pr
es
si
on
 
Le
ve
l 
Ge
ne
 
Ex
pr
es
si
on
 
Le
ve
l
EST; Affymetrix Identifier 1375986_at
0.5
0.2
K2 T15 A297 A311
Cell Type
Rnase A family 4
TJL
2
1
0.5
K2 A297 A311T15
Cell Type
234
Ge
ne
 
Ex
pr
es
si
on
 
Le
ve
l 
Ge
ne
 
Ex
pr
es
si
on
 
Le
ve
l
Similar to CG12279-PA
0.5
0.2
K2 T15 A311A297
Cell Type
Translin-associated factor X
1
0.5
v
0.2
0.1
K2 T15 A297 A311
Cell Type
235
G
en
e 
Ex
pr
es
si
on
 
Le
ve
l 
Ge
ne
 
Ex
pr
es
si
on
 
Le
ve
l
A disintegrin-like and metalloproteinase (Adamtsl)
0.5
0.2
K2 T15 A297 A311
Cell Type
Growth Differentiation Factor 1
0.5
0.2
0.1
0.05
0.02
A311A297T15K2
Cell Type
236
Ge
ne
 
Ex
pr
es
si
on
 
Le
ve
l
EST; Affymetrix Identifier 1391428_at
1
Cl
X
UJ«c
0.1
0.05
T15 A297 A311K2
Cell Type
Neogenin
1
0.5
0.2
A311A297T15K2
Cell Type
237
Ge
ne
 
Ex
pr
es
si
on
 
Le
ve
l 
Ge
ne
 
Ex
pr
es
si
on
 
Le
ve
l
Similar to RIKEN cDNA 9330161F08
0.5
1/
K2 T15 A297 A311
Cell Type
Reversion-induced LIM gene (Ril)
2
1
K2 T15 A297 A311
Cell Type
238
Ge
ne
 
Ex
pr
es
si
on
 
Le
ve
l 
Ge
ne
 
Ex
pr
es
si
on
 
Le
ve
l
Brain and Kidney Protein
0.5
K2 T15 A297 A311
Cell Type
EST; Affymetrix Identifier 1373642_at
0.5
0.2
A311A297T15K2
Cell Type
239
EST; Affymetrix Identifier 1377065_at
0.5
0.2
0.1
0.05
0.02
K2 T15 A297 A311
Cell Type
Similar to Synaptopodin-2
1
I  0.5
0.2
K2 T15 A297 A311
Cell Type
240
Ge
ne
 
Ex
pr
es
si
on
 
Le
ve
l 
Ge
ne
 
Ex
pr
es
si
on
 
Le
ve
l
Ankyrin 3, epithelial isoform g
0.5
0.2
0.1
0.05
0.02
K2 T15 A297 A311
Cell Type
Chondroitin sulfate proteoglycan 4
0.5
0.2
0.1
0.05
0.02
A311A297T15K2
Cell Type
241
Appendix 5: Author publication- Cluster analysis of networks generated through 
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Abstract
Background: Protein-protein interactions have traditionally been studied on a small scale, using classical biochemical 
methods to investigate the proteins of interest. More recently large-scale methods, such as two-hybrid screens, have 
been utilised to survey extensive portions of genomes. Current high-throughput approaches have a relatively high rate 
of errors, whereas in-depth biochemical studies are too  expensive and time-consuming to be practical for extensive 
studies. As a result, there are gaps in our knowledge of many key biological networks, for which computational 
approaches are particularly suitable.
Results: W e constructed networks, or 'interactomes', of putative protein-protein interactions in the rat proteome -  
the rat being an organism extensively used for cancer studies. This was achieved by integrating experimental protein- 
protein interaction data from many species and translating this data into the reference frame of the rat. The putative rat 
protein interactions were given confidence scores based on their homology to proteins that have been experimentally 
observed to interact. The confidence score was furthermore weighted according to  the extent of the experimental 
evidence, giving a higher weight to  more frequently observed interactions. The scoring function was subsequently 
validated and networks constructed around key proteins, identified as being highly up- or down-regulated in rat cell lines 
of high metastatic potential. Using clustering methods on the networks, we have identified key protein communities 
involved in cancer metastasis.
Conclusion: The protein network generation and subsequent network analysis used here, were shown to be useful for 
highlighting key proteins involved in metastasis. This approach, in conjunction with microarray expression data, can be 
extended to other species, thereby suggesting possible pathways around proteins of interest.
Background
Microarray experiments provide information about gene 
expression within the cells under study.
Expression patterns can be uncovered from large-scale 
microarray data by systematically grouping genes with the
help of clustering methods. Co-clustering of genes can 
indicate that the genes in question have a similar function 
or that they participate in the same cellular process [1,2]. 
Nevertheless, microarray experiments typically yield hun­
dreds of significandy differentially-expressed genes, mak­
ing it difficult to draw biological conclusions.
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Furthermore, although microarray experiments can show 
correlations between the expression of genes, they do not 
reveal the exact protein interaction mechanism.
Protein network analysis is dependent on a reliable 
assignment of protein-protein interactions. Protein-pro­
tein interactions are commonly studied using biochemi­
cal methods, and several different experimental methods 
are currently in use. Two-hybrid screens have, to date, 
yielded the bulk of available data [3,4]; however their 
level of accuracy is not particularly high and should be 
supported by additional evidence [5,6]. Advances in other 
techniques, such as tandem-affinity purification and mass 
spectroscopy, have also made large-scale studies increas­
ingly feasible [7,8],
A number of computational methods, either based on 
sequence or structural features, have been developed to 
complement experimental approaches to predicting pro­
tein-protein interactions [9,10]. An increasing emphasis 
has been on deducing and exploring the protein-protein 
interaction networks that are reflected in expression data; 
gene networks have been inferred from gene expression 
data using mathematical analysis such as Bayesian regres­
sion [11-14]. Moreover, networks have been derived by 
complementing gene expression data with data from dif­
ferent sources, such as gene ontologies, phenotypic profil­
ing and functional similarities [15-18].
Alternative techniques to network construction have also 
been taken, see e.g. Cabusora et al. [19], where a protein 
interaction map was created based upon the principle that 
interacting protein modules in one organism may be 
fused into a single chain in another, and Calvano et al.
[20] who constructed the network by literature searches 
for information pertaining to interacting protein pairs 
from closely related organisms. These methods do not uti­
lise gene expression explicitly in the network generation, 
rather the expression data is used as a tool to focus on the 
network.
Previous studies have mapped expression data of different 
systems onto experimentally-based networks. Ideker et al.
[21] used gene expression changes in response to pertur­
bation to highlight clusters within a yeast network, and 
Sohler et al. [22] made use of statistical analysis to high­
light significant sub-dusters, also within a yeast network. 
Moreover, the dynamic aspect of yeast networks have 
been highlighted by de Lichtenberg and coworkers [23], 
who combined temporal cell cycle expression data with 
protein-protein interaction networks.
Here we have taken an extensive multi-genome approach, 
utilising a homology-based method for predicting inter­
acting proteins [24] and further extended it by developing
a scoring function, based upon sequence similarity and 
the amount of experimental data supporting each interac­
tion. This scoring function has subsequently been exten­
sively validated. In contrast to the above methodologies 
we go beyond data integration by considering ortholo- 
gous relationships and are therefore able to create a more 
extensive protein interaction network -  or 'interactome' -  
for a higher eukaryote, the rat.
In order to demonstrate the utility of our predicted inter­
actions, expression data on tumour progression resulting 
in rat sarcomas with high metastatic potential were 
mapped onto our interactome, creating protein networks 
around key proteins involved in the metastatic process.
Results and Discussion
Networks of interacting proteins were constructed auto­
matically for the entire rat (Rattus norvegicus) genome 
using the approach described in the methods section and 
summarised in Figure 1. The number of individual inter­
actions was reduced from 325,087 to 151,049, when a 
scoring function was applied to filter out low-quality data, 
and was further cut down by a clustering method aimed at 
identifying key interconnected network nodes. The inter­
actome data is available though the PIP (Potential Interac­
tions of Proteins) web server [25].
Validation o f  the scoring function
The protein networks are composed of predicted individ­
ual interactions, each of which is assigned a score which 
indicates the strength of the prediction. Before examining 
the networks in detail it is necessary to assess the quality 
of the predictions and to validate the method.
Selection o f cut-off value for the scoring function 
Our method of constructing networks is based on homol­
ogy to known interactions. It is therefore imperative to 
ascertain the minimum level of homology whereby the 
structural and functional similarity of the interacting pro­
teins is retained. Russell et al. [26] have previously exam­
ined the relationship between sequence and structural 
divergence of interacting proteins. They found that pairs 
of interacting proteins can be considered structurally sim­
ilar if their sequence identity is no lower than 30%. As we 
utilise BLAST bitscores as components for our scoring 
function, we tested the relationship between bitscores and 
sequence identity. At the 30% sequence identity level, the 
bitscore ranges linearly from 86-177 (see Figure 2) which, 
according to Equation 1, yields minimum interaction 
scores ranging from 9 to 10. We chose to set the minimum 
score for interactions at 10, to minimise possibilities of 
false positive results due to low homology.
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Figure I
Inferring in teractions by hom ology. Each interaction is inferred from homology to  experimentally observed interactions. 
In this schematic, proteins a ( and b ( have been shown experimentally to  interact in one organism, here labelled 'species X', and 
protein a2 and b2 in another, 'species Y'. Lists of homologues are generated for each of the proteins, ranked by their bit score 
( s a. , 5j,. , etc.). A protein from one list may interact with a protein from the o ther (shown by the red arrow) and potential
pairwise interactions are scored according to  Equation I, based on homology to  the proteins involved in the known interac­
tion. Furthermore, interactions receive a higher score if they are derived from multiple experimental sources (n > I). The 
score is additive, for instance, in the example here, the blue and green sequences are predicted to  interact based on the inter­
actions in 'species X' and 'species V  and the overall score is the sum of both pairwise scores. This additive process continues 
over all experimentally determined protein pairs, N, (e.g. through 'species Z'), for which the rat sequences, labelled blue and 
green, are present.
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Figure 2
The distribution of bit scores as a function of 
sequence identity. The sequence identity and bit score of 
each hit when proteins in the interaction data were queried 
against the rat genome. The solid red line shows the best lin­
ear fit to the data and shown in dotted red is a line, starting 
at the origin, which contains 97% of the data in the area 
below it. Reading from these lines at 30% sequence identity 
gives bitscores of 86 and 177, respectively, yielding interac­
tion scores of 9 and 10 when inserted into Equation I. To 
ensure a stringent criteria for the minimum interaction score 
the higher value was selected as a cutoff score.
Identification o f  highly reliable interactions 
Many methods for detecting protein-protein interactions 
can yield either false positive or false negative results, but 
X-ray crystal structures of complexed proteins can be con­
sidered to be a gold standard for proof. To examine the 
validity of our scoring function we looked at the interac­
tion scores of rat proteins that have either been crystal­
lised together in a complex or have a very high homology 
to one that has been. These scores were then compared to 
ones without any crystallographic evidence, i.e. those that 
do not interact or have not been proven to do so by crys­
tallography.
We found that highly reliable interactions, identified by 
X-ray crystallography, score higher than those without 
crystallographic evidence, with median scores 128 and 16 
respectively. This difference was significant according to a 
^2-test (p «  0.0001), indicating that true interactions 
score higher than those whose association has not been 
confirmed by crystallography.
T able I: D istribution o f  protein-protein  interaction  scores. 
Interaction sco res o f X -ray crystal structures (n = 377) com pared  
to  th e  scores o f  all (g en om e-w id e) predicted interactions.
Percentage of interactions
Interaction s Interaction
core 0 -  10 score > 10
X-ray crystal structures 6.4 93.6
Genome-wide 43.2 56.8
Moreover, as shown in Table 1, about 94% of the interac­
tions confirmed by X-ray crystallography score above 10, 
reaffirming the choice of the cutoff score, whereas just 
under half of all genome-wide predicted interactions score 
10 and lower.
Com m unity participation and cellular localisation 
Another way of estimating the quality of the scoring func­
tion is to look at proteins participating in the same cellu­
lar process and compare them with proteins that are not 
thought to interact directly in a pathway. We used a clique 
percolation method to identify 'communities' within the 
network that show high interconnectivity. This yielded 37 
communities of tightly interconnected proteins that will 
be described later. One can assume that interactions 
within communities are more likely to be true than inter­
actions between communities, i.e. higher scores would be 
expected for intra-community interactions [27]. We found 
this to be true; the average score for interactions within a 
community was 26.2 (n = 2038) and the average score for 
interactions between communities was 13.5 (n = 502). 
This is significant at a 95% confidence level (p = 3.1 x 10- 
30).
Lasdy, the protein interaction scores were examined in the 
context of cellular localisation. We assume that for true 
interactions, interacting proteins would co-localise in the 
same cellular compartment, at least during the time of 
interaction, and thus would expect predicted interactions 
between proteins in separate cellular compartments to be 
less reliable and receive a lower score. Localisation data 
from the Gene Ontology Consortium [28] were used, 
where available, for proteins within the thirty-seven pro­
tein communities. Of the protein interactions predicted, 
681 (94%) were considered co-localised, with an average 
score of 25.8 and 41 (6%) were annotated as not sharing 
cellular localisation, with an average score of 13.1. The 
score difference is statistically significant (p = 0.001 at a 
95% confidence level).
M etastatic network communities identified by cluster 
analysis
Metastasis is a key event that is associated with a poor 
prognosis in cancer patients. Metastasising cancer cells
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Figure 3
Identifying protein com m u n ities by cluster analysis. The communities identified by k-dique analysis performed on the 
predicted genome-wide rat protein network. The communities are distinguished by different colours and labelled by the overall 
function or the dominating protein class. N ote that proteins, particularly at community edges, can belong to  more than two 
communities, although this is not shown. A complete list of protein names is included as supplementary material [see Addi­
tional file I]. The graph was created by Graphviz [6 1].
have the ability to break away from the primary tumour 
and move to different organs, making the cancer more dif­
ficult to treat. Much is unknown about the molecular biol­
ogy of metastasis, but it culminates in the cancerous cells
acquiring several properties, such as increased motility 
and invasiveness. This involves a network of cascading 
protein-protein interactions which have to be unravelled 
if an effective treatment is to be developed.
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Table 2: Domain frequency within the clustered communities. The table shows the most frequently observed domains in the 
metastasis-related cluster communities (observed frequencies) alongside the expected domain frequencies, based on the domain 
composition of the whole rat genome. The n-fold difference was calculated from the frequency percentages (numbers within 
parentheses).
Domain O bserved frequency (%) Expected frequency (%) n-fold difference
Spectrin repeat 56 (6.9) 6 (0.7) 8.3
IQ calmodulin-binding m otif 54 (6.6) 2 (0.2) 26.5
EGF-like domain 52 (6.4) 16(2 .0) 2.2
Protein kinase domain 4 7  (5.8) 12(1 .4 ) 3.0
SH2 domain 2 7  (3.3) 2 (0.3) 11.7
EF hand 25 (3 .1) 7 (0 .8 ) 2.6
Immunoglobulin domain 2 1 (2.6) 35 (4.3) -0.4
SH3 domain 20 (2.4) 6 (0 .7 ) 2.6
Calponin hom ology (CH) domain 13 (1.6) 2 (0.3) 5.4
Proteasom e A-type and B-type 12 ( 1.5) I (o .i) 20.0
LIM domain II (I.3) 3 (0.4) 2.7
Transforming growth factor /Mike 
domain
10(1 .2) 1 (0.1) 11.2
As a starting point, we used data from a microarray analy­
sis of cell lines with different metastatic potentials (see 
Methods). We took the highest up- and down-regulated 
genes (> 4-fold up- or down-expression), and constructed 
networks around these, extending two generations from 
the starting point, i.e. initially including proteins that 
interact directly with the originating protein and then 
going on to include the proteins that interact with them. 
This subset of the rat interactome contained 10,628 inter­
actions. We then performed a cluster analysis in order to 
highlight areas in the protein networks that are involved 
in the metastatic process. The clustering is based on a 
clique percolation method [29] that seeks to identify 
'communities' of highly interconnected proteins that 
make up the essential structural units of the networks.
The community definition is based on the observation 
that a typical member in a community is linked to many, 
but not necessarily all other nodes in the community. In 
other words, a community can be regarded as a union of 
smaller, complete, fully-connected subgraphs that share 
nodes (see Methods section). Palla et al. [27] have shown 
that clique clustering analysis is a powerful tool to identify 
communities of proteins participating in the same cellular 
processes. Furthermore, it has been shown that subnet­
works of proteins involved in a defined cellular process 
are more heavily interconnected by direct protein interac­
tion than would be expected by chance [16]. Highly con­
nected proteins are also more likely to be essential to 
cellular processes [30].
By applying the clustering method to our rat interactome 
we automatically identified 37 protein communities of
highly interconnected proteins, containing 313 proteins 
involved in 1,094 interactions (Figure 3). The majority of 
the communities have been associated with cancer and 
metastasis. Some show a degree of overlap and are linked, 
the most prominent link running through the centre of 
the figure and containing 17 communities linked in a 
chain-like manner, however others are not linked, for 
example, the transcription regulation, which consists of 
only four proteins.
An initial analysis of the structural- and functional com­
position of the networks was performed using Domain 
Fishing [31], which assigns structural domains to 
sequences based on homology to known domains. When 
comparing the domain composition of the communities 
to domain frequencies of the whole rat genome we 
observed a bias towards classes of domains found in pro­
teins involved in cytoskeletal structures, cell motility and 
cell-signalling (see Table 2). All but one of the most fre­
quent domains are overrepresented when compared to 
the genome-wide distribution; only immunoglobulin 
domains appear less frequently. Spectrin repeat domains, 
which top the table, are found in proteins involved in 
cytoskeletal structure, such as spectrin, a-actinin and dys­
trophin. They are known to bind to calponin homology 
domains, which are found in both cytoskeletal and signal 
transduction proteins. The IQ calmodulin-binding 
domains work as Ca2+ switches for myosin which are 
involved in cell motility and chemotaxis. Furthermore, 
protein kinase domains, SH2 and SH3 domains and pro- 
tein-tyrosine phosphatase participate in signal transduc­
tion and known to interact. These categories of domains,
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Figure 4
A  closer view  of a part o f th e  'intracellular signalling 
cascade'. The figure shows a subsection of the network 
around the intracellular signalling cascade where it extends 
to  the VEGFs and JAK/STAT protein communities. The con­
fidence of the interactions is shown by colour coding based 
on the interaction scores ranging from low-scoring blue (10 
< s < 10.5) to  high-scoring red (s > 40.0). The metastatic cell 
line expression levels are also shown; blue for down-regu­
lated genes and red for up-regulated ones.
and associated functions and interactions, are all of inter­
est in the context of cancer metastasis.
The intracellular signalling cascade
It is not the aim here to explore every member o f each 
community, instead, with the automatic identification of 
metastatic-related protein communities being the primary 
focus, we will illustrate the value o f our approach by 
describing a key section o f the regulation pathway. The 
intracellular signalling cascade constitutes the head of a 
chain o f communities (Figure 3), and as such warrants a 
closer investigation.
Figure 4 shows a detailed view of some of the interactions 
within that community, focused on the intersection with 
the vascular endothelial growth factors (VEGFs) and the 
JAK/STAT group. Many of the interactions in this network 
have been established either in rat or in other species; oth­
ers have not been previously demonstrated and we pro­
pose that these might have a role in the context of the 
surrounding proteins.
Three separate groups o f proteins are distinguishable: vas­
cular endothelial growth factors (Vegfa, Vegfc, Figf) and 
the receptor (Kdr), which play a principle role in tumour 
progression and angiogenesis [32] and which have also 
been associated with tumour metastasis [33]; insulin-like 
growth factors and receptors (Igfl, Igflr and Grb 7/14); 
and JAK/STAT proteins (JAK2, STATSb).
The figure shows the three ligands, Vegfa and Vegfc and 
Figf, at different levels o f expression, all o f which can bind 
to kinase insert domain protein receptor Kdr, a VEGF 
receptor, which in turn induces mitogenesis and differen- 
tation o f vascular endothelial cells [34].
The interaction between Kdr and Socsl, an SH2 domain- 
containing suppressor of cytokine signaling 1, is plausible 
as Kdr has a tyrosine protein kinase domain which in a 
mouse homologue has been shown to interact with Socsl 
[35]. Furthermore, up-regulation of Socsl has been linked 
with the suppression of cytokine signalling and the JAK/ 
STAT inflammatory signalling [36-38], which is shown 
here further down the network; here also, Socsl is up-reg­
ulated and JAK/STAT down-regulated.
The proposed Ptpnll-Lck interaction is based on orthol- 
ogy to an interaction between Ptprc and Lck in mouse. 
P tp n ll and Ptprc both have tyrosine specific protein 
phosphatase activity. P tpnll is phosphorylated by tyro­
sine protein kinases, contains two SH2 domains and 
therefore could be phosphorylated by Lck.
Higher up the network are the insulin-like growth factor 1 
and its receptor (Igfl and Igflr, respectively) which are 
highly implicated in different cancers [39-41]. The insu- 
lin-like growth factors are involved in several cellular 
processes, such as regulation of proliferation, migration, 
survival, size control, and differentiation [42-45]. Igflr is 
overexpressed in most malignant tumours, where it func­
tions as an anti-apoptotic agent by enhancing cell sur­
vival. Igfl has also been shown to enhance adhesion and 
motility o f cancer cells [46,47]; however, the exact role of 
Igflr in the metastatic process has not been established. 
The network shown here suggests a link between the insu- 
lin-like growth factor receptor and the vascular endothe­
lial growth factors through the highly up-regulated 
phospholipase delta 4 (Plcd4) and phospholipase gamma 
1/2 (Plcg 1/2). The Plcg 1/2 and Igflr interaction is based 
on the fact that the phospholipase has been shown to 
interact with insulin receptor, a close homologue of the 
insulin-like receptor.
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Table 3: The connectivity of up- and down-regulated proteins. 
Observed and expected frequencies of pairwise protein 
interactions, categorised by their expression: N-N (non­
expressed protein interacting with non-expressed protein), U-U 
(up-regulated protein interacting with up-regulated protein), D- 
D (down-regulated protein interacting with down-regulated 
protein) and U-D (up-regulated interacting with down- 
regulated). For the purpose of the classification, up-regulated 
proteins are those up-regulated more than 20% and down- 
regulated proteins down-regulated more than 20%. Expected 
values were calculated based on a random distribution of the 
expression data on the network (p < 0.001 for a ^ 2-test).
O bserved Expected n-fold
difference
N -N 8 5 1.5
U-U I2I 109 1.1
D -D 17 41 0.4
U-D 71 67 1.1
Another distinguishing feature in the network is the 
highly down-regulated protein tyrosine phosphatase 
(Ptpnl3). It has been reported that a protein tyrosine 
phosphatase, Ptp61F, negatively regulates the JAK/STAT 
pathway in Drosophila melanogaster [48]. Our networks 
suggest that the signalling protein tyrosine phosphatase, 
Ptpnl3, may act on the JAK/STAT pathway similarly, 
through the dephosphorylation of the growth hormone 
receptor Ghr.
The few examples shown here illustrate the value of the 
approach in terms of revealing potential pathways and 
interactions that play a part in cancer metastasis, but fur­
ther experimental work will be needed to confirm the 
validity of these predictions.
Network view o f gene expression
Extracting meaningful information from microarray 
expression data is often difficult, especially when looking 
at a complex process involving a large number of genes 
and unknown mechanisms. Clustering of genes may be of 
use when trying to find genes in a common pathway and 
genes with related function, but it often has limitations, 
such as in identifying negative feedback loops [49]. Fur­
thermore, even if key proteins are highlighted through 
microarray analysis, the expression data rarely reveals all 
proteins involved in a particular pathway.
Examining the distribution of up- and down-regulated 
proteins in the context of their neighbours, shows that 
this is indeed the case for the protein networks shown in 
Figure 3. The metastatic expression data was mapped onto 
the networks and the frequency of the up-, down- and up­
town-regulated genes interacting was examined. The 
results, in Table 3, indicate that if expression data from the
Table 4: Experimental sources for building the interactome. 
Summary of the experiments used as a foundation for building 
the interactome, from most frequent (top) to least frequent 
(bottom). The percentage of the total is listed after each value.
Method Frequency (%)
Tw o hybrid test 35,759 (69.9)
Immunoprecipitation 6,290 (12.3)
Tandem Affinity Purification (TAP) 3,503 (6.85)
Affinity chromatography 1,070 (2.09)
Copurification 572 (1.12)
Cross-linking 5 18(1 .0 1 )
X-ray crystallography 511 (1.00)
In vitro binding 452 (0.88)
Biochemical/biophysical 327 (0.64)
Gel filtration chromatography 326 (0.64)
In vivo kinase activity assay 185 (0.36)
C om petition binding 185 (0.36)
Immunoblotting 140(0 .27)
C osedim entation 133 (0.26)
Gel retardation assays 106(0 .21)
Native gel electrophoresis 103 (0.20)
O ther 973 (1.90)
network was randomly redistributed, the probability of 
observing two up-regulated proteins interacting with each 
other is about the same as the observed probability. That 
is, up-regulated proteins do not have a trend of directly 
interacting with each other, but are interlinked through 
either neutrally expressed or down-regulated proteins. 
Moreover, down-regulated proteins are much less likely to 
interact with each other than expected, demonstrating the 
benefit of projecting the expression data onto already 
built networks, as clustering similarly expressed genes and 
assigning to the same pathway would not be effective.
Conclusion
Expression data has previously been put into a network 
context, for example by incorporating gene ontology data 
[15] and protein interactions [50], but here we generated 
the networks first, mapped the expression on top, and 
then performed a clustering. This approach allows us to 
bypass some of the obstacles involved in traditional 
microarray analysis, such as clustering of gene expression 
patterns; as demonstrated here, interactions of up-up and 
down-down regulated genes are not necessarily co-local- 
ised. To focus on the parts of the genome-wide interaction 
network relevant to metastasis we first selected subnet­
works around highly up- and down-regulated genes and 
then utilised the clique method, which highlights hubs of 
highly interconnected protein communities. This allows 
us to examine the most complex parts of the network but 
as a result simple linear pathways do not get included.
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Table 5: Gene ontology cellular compartments. A simplified representation of gene ontology cellular compartments. Protein 
accessibility between compartments is represented by ones and zeros: the former indicates the possibility of interaction between 
respective compartments and the latter excludes any interactions.
Extracellular Intracellular Cytoplasm Nucleus Mitochondrion Membrane
Extracellular I 0 0 0 0 1
Intracellular 0 I 1 1 1 1
Cytoplasm 0 I 1 0 0 1
Nucleus 0 I 0 1 0 1
Mitochondrion 0 I 0 0 1 0
Membrane I 1 1 1 0 1
Although we believe the general approach is of value in 
protein network analysis, there remain some shortcom­
ings. Most importantly, transient protein-protein interac­
tions are unlikely to be captured by our approach. This is 
a direct consequence of transient not being as well docu­
mented as non-transient interactions. Moreover, the 
method cannot distinguish between true and false posi­
tives, for which there is limited experimental data -  how­
ever, these problems will be alleviated as more high- 
throughput proteomic studies are completed.
The system-level approach taken here, combining infor­
mation on how proteins interact with each other and how 
genes are expressed, is a particularly appealing way to gain 
understanding of complex biological processes, such as 
metastasis. Although not discussed here in great detail 
several interesting groups of interactions, at the domain 
level, have been highlighted as potentially important 
players in the metastatic process. Further dissection of 
these is the subject of ongoing studies and consequently 
to be confirmed experimentally.
This method of using homologous protein interaction 
data to infer protein-protein information could be partic­
ularly useful for proteins for which there is no definite 
binding partner information. Moreover the relative 
expression levels of neighbouring proteins may prove an 
important consideration, when protein networks are to be 
subsequently modulated in conjunction with disease 
analysis, for example by targeting the expression of a par­
ticular gene by short interfering RNA (siRNA) [51].
The approaches described in this work are readily transfer­
able to other species and cellular processes.
Methods
Protein interaction prediction
In order to identify homologous interaction pairs for 
which there is experimental data, BLAST searches were run 
for the rat genome [52] against all proteins in the DIP [53]
and MIPS Mammalian Protein-Protein Interaction data­
bases [54].
The experimental data arises from several methods -  the 
most frequent are listed in Table 4. The putative interac­
tions were given confidence scores based on two factors: 
the level of homology to proteins found experimentally to 
interact, and the amount of experimental data available 
(see Figure 1 for an illustrationof the approach).
The score, S, was calculated for each putative interaction 
according to the following:
S = X ln (sa.sb.)n, (1)
i=i
where sa. and s^ ,. are sequence similarity bit scores to
proteins a, and bf, respectively, which have experimentally 
been shown to interact; n is the number of experiments 
linking protein a, to protein b,; and N  is the total number 
of instances where the same pair of proteins is identified 
as interacting through different homologues. As men­
tioned in the Introduction, two-hybrid experiments are 
prone to giving false-positive results. Although most of 
the interactions created here are derived through yeast 
two-hybrid links, it has been shown that confidence is 
higher for interactions detected in multiple independent 
yeast two-hybrid experiments [15]. This fact is reflected in 
the additive nature of the score, where a protein interac­
tion that shows up repeatedly in independent two-hybrid 
experiments gets a higher score.
Validation
In order to test the scoring function, we created a subset of 
data from the RCSB Protein Data Bank [55] that specifi­
cally concentrates on stable functional protein interac­
tions, rather than transient. Protein chains with high 
sequence homology to the Norwegian rat were considered
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Table 6: The number of protein communities at different 
clustering threshold values. The number of protein communities 
vary as the k-value for clustering is changed. The table shows the 
total number of separate protein communities for each k-value.
Clustering threshold value Num ber o f protein communities
k = 3 145
k = 4 37
k = 5 12
k = 6 8
k = 7 2
k = 8 I
k = 9 I
k = 10 I
k = 11 I
(e < 1 x 10 10). We distinguished biologically functional 
complexes (where multimeric protein chains are perma­
nently bound and essential for the complex function) 
from transient ones (where protein chains may be bound 
to a complex but may also act as a separate functional pro­
tein on its own), by applying a method proposed by 
Ofran and Rost [56]. This yielded 377 binary chain inter­
actions.
Cellular localisation of proteins was obtained from the 
Gene Ontology Consortium [28]. Each of the proteins 
identified by the cluster analysis was placed in a basic cel­
lular localisation class as per Table 5. Protein pairs pre­
dicted to interact were considered co-localised if they were 
found in compatible cellular compartments.
Creation o f networks around up/down-regulated genes
Rat genes that were overexpressed or underexpressed 
more than four-fold were used as starting points (n = 
100). Networks were expanded two generations out from 
the starting points using protein-protein interactions 
whose S-score value was 10 or higher. The resulting 
10,628 interactions were then analysed using CFinder 
[27], which locates maximal complete subgraphs (k- 
diques) in the networks and then identifies 'communi­
ties' by carrying out standard component analysis of the 
clique-clique overlap. In this context, the variable k is 
defined as the number of nodes in the subgraph and a fe- 
clique community is defined as the union of all fe-diques 
that can be reached from each other through a series of 
adjacent k-cliques, where cliques sharing k - 1 nodes are 
defined as adjacent. Table 6 shows the number of individ­
ual protein communities for different fe-values. Thirty- 
seven communities were identified for k = 4, i.e. setting 
the subgraph size threshold to a minimum of four. Select­
ing the k-value is a balancing act; the higher the k-value, 
the smaller and more internally connected the communi­
ties become, but less connection is observed between
communities. The k-value was selected after observing 
that at k = 4, reasonably large communities were formed. 
Proteins which shared sequence identity higher than 40% 
within each community, were merged together such that 
they appeared as a single nodes on the protein map. These 
merged nodes inherited all the interactions from the indi­
vidual proteins before the merging process. This was done 
to correct for any possible redundancies caused by our 
homology-based method for predicting protein interac­
tions. There was negligible change in the protein networks 
as a result of this.
Microarray expression data for metastatic rat cells
To investigate genes that may be important in the devel­
opment of metastases, we used a rat sarcoma model in 
which the cell populations K2, T15, A297 and A311 have 
0, 40, 90 and 100% incidence of metastasis, respectively. 
We performed Affymetrix microarray analysis on the four 
cell populations and the primary tumours that formed 
when the cells were injected subcutaneously into rats. All 
experiments were performed in triplicate, using Affyme­
trix rat 230A GeneChip oligonucleotide arrays [57]. Total 
RNA was extracted from each sample and used to prepare 
biotinylated target RNA; 10 fj% of RNA was used to gener­
ate first-strand cDNA by using a T7-linked oligo(dT) 
primer. After second-strand synthesis, in vitro transcrip­
tion was performed with biotinylated UTP and CTP (Enzo 
Diagnostics), resulting in approximately 100-fold ampli­
fication of RNA. A complete description of the procedures 
is included in The Paterson Institute's Affymetrix Gene­
Chip systems protocols [58].
The target cRNA generated from each sample was proc­
essed as per the manufacturer's recommendation using an 
Affymetrix GeneChip Instrument System [59]. Briefly, 
spike controls were added to 10 fig fragmented cDNA 
before overnight hybridisation, arrays were washed and 
stained with streptavidin-phycoerythrin, and scanned on 
an Affymetrix GeneChip scanner. The procedure is further 
described in The Paterson Institute's RNA Hybridisation 
protocols [60]. The median fluorescence intensity value of 
each GeneChip was calculated and used to normalise the 
chips. Gene expression was considered in terms of fold- 
changes between non-metastatic and the median of the 
three metastatic samples.
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RMS Proceedings (March 2005, Volume 40/1, p37).
Investigating the gene expression profiles of metastasising sarcoma cells.
Tamara Cavanna1, Eva Pokoma2, Pavel Vesely2 and Daniel Zicha1 
1 Light Microscopy, Cancer Research UK, London Research Institute, Lincoln’s Inn 
Fields Laboratories, 44 Lincoln’s Inn Fields, London WC2A 3PX, UK.
Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 
Flemingovo nam. 2, 166 37 Prague 6, Czech Republic.
Metastasis occurs when cells from a primary tumour migrate to another site in the body 
and form a secondary tumour. The development of metastases is likely to require 
changes in gene expression that promote certain aspects of cell behaviour, for example 
motility and chemotaxis.
To investigate genes that may be important in the development of metastases, we are 
using sarcoma cell populations K2 and A297 derived from inbred rats. K2 sarcoma cells 
are spontaneously in vitro transformed embryonic fibroblasts, and the A297 cell 
population was obtained from the K2 cells by serial tumour progression. When 
subcutaneously injected into the rats, the K2 and A297 cells form primary tumours that 
shed metastases at rates of 0% and 90% respectively. Since these two cell populations 
have such different abilities to metastasise, we examined their behaviour and gene 
expression in vitro.
Cells were placed in the Dunn Chemotaxis Chamber with a gradient of PDGF/IGF, 
and phase-contrast images were acquired every 5 minutes for 16 hours. The films of 
K2 and A297 cells were analysed using interactive tracking software by Kinetic 
Imaging, and the speed and mean direction of the cells evaluated using a 
Mathematica notebook developed in the laboratory. We found that the K2 cells are 
weakly chemotactic to PDGF/IGF, whilst the A297 cells have a strong chemotactic 
response, and that the responses are significantly different (ANOVA p < 0.05). We
255
also found that the K2 cells move at a speed of 11 pm per hour, whereas the A297 
cells move at 17 pm per hour. The difference in speed between the two populations 
is significant (ANOVA P < 0.01).
In order to identify genes that may contribute to the observed in vivo malignancy and 
in vitro motility, we compared the gene expression of the two cell populations using 
the Affymetrix system. We found that 297 genes were significantly differentially 
expressed, and selected 10 of these for further study. We have validated the 
differential expression of some of these genes by RT-PCR and western blotting, and 
are now in the process of investigating their function in cell motility and other 
behaviour that may be relevant to metastasis.
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